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The mechanistic target of rapamycin (mTOR), specifically mTOR complex 1 (mTORC1) is 
believed to be a central regulator of muscle size, however, the upstream mechanisms which 
activate this kinase in response to anabolic stimuli remain to be fully elucidated. This thesis 
therefore aimed to investigate the role of several novel regulators of mTORC1 activity in 
human skeletal muscle. Chapter 3 displays that mTOR translocation to the cell periphery is 
mTORC1-specific and is greater following resistance exercise (RE) and protein-carbohydrate 
(PRO-CHO) feeding compared to feeding alone. In chapter 4 we validate and optimise a 
immunofluorescent staining protocol to visualise L-Type amino acid transporter 1 (LAT1) in 
human skeletal muscle, where it was more greatly expressed in fast twitch fibres and 
localised close to sarcolemma and microvasculature. Chapter 5 investigated the role of 
vacuolar protein sorting 34 (Vps34), a potential nutrient ‘sensor’, in mTORC1 activation in 
skeletal muscle. Here, both in vitro and in vivo experimental designs were utilised to display 
that changes in Vps34 cellular location, rather than kinase activity, may be important for 
nutrient sensing in skeletal muscle. Finally, chapter 6 reports how mTORC1 activation can 
occur without alterations in Vps34 protein content, kinase activity or LAT1 fibre type 
distribution in response to RE and/or PRO-CHO feeding. Overall, this thesis enhanced our 
understanding of the intricate regulation of mTORC1 activity in human skeletal muscle, 
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1.1 – Overview of skeletal muscle 
1.1.1 Importance of skeletal muscle for optimal health 
Skeletal muscle is one of the largest organs in the human body, contributing to ~40% of 
an individual’s body mass (1). Its primary functions of posture maintenance, respiration 
and locomotion display this organs significance in human daily life and healthspan (1). 
In addition, skeletal muscle is an essential metabolic tissue implicated in glucose disposal 
and lipid oxidation as well as providing amino acids (AAs) to be utilised as fuel by other 
organs during fasting (1). The high metabolic capacity of skeletal muscle results in it 
being the principle contributor to basal metabolic rate in humans (2). It has long been 
established that increases in skeletal muscle mass and strength are associated with 
enhanced longevity and improved overall health (3, 4). This is in part due enhanced basal 
metabolic rate, which helps to stave off metabolic disease over a lifetime in addition to 
an enhanced capacity for glucose disposal, which by extension, reduces the risk of 
developing type II diabetes (5, 6). As humans age, a progressive loss of skeletal muscle 
mass is commonly noted (7), a phenomena termed sarcopenia, which imposes a 
significant financial burden on healthcare systems (8). This loss of skeletal muscle mass 
significantly impacts the quality of life of individuals and is therefore detrimental to 
overall healthspan (9). Therefore the ability to complete everyday tasks into later life is 
maintained if an individual has a enhanced muscle mass and strength.  It is these positive 
effects of skeletal muscle on whole body homeostasis and health span which support the 
need for research examining the cellular regulation of skeletal muscle mass, to develop 





1.1.2 Protein balance in skeletal muscle 
Skeletal muscle is a highly plastic tissue, displaying an ability to both grow and decrease 
in size regularly throughout lifespan. Skeletal muscle homeostasis is maintained in 
adulthood through the balance of two dynamic processes, skeletal muscle protein 
synthesis (MPS) and breakdown (MPB), with each displaying clear day-to-day variation 
(10, 11). Following ingestion of protein, typically rich in AAs, increased substrate 
availability for MPS and the activation of signalling pathways causes MPS to rise (11-
13), while the insulinogenic effects of AAs and other constituents of meals 
(carbohydrates) elicit a slight suppression of MPB (14). This culminates in a transient 
period in which MPS exceeds MPB and net protein balance (NPB) is positive. In these 
periods muscle proteins will be accreted. In post-absorptive states, when substrates for 
MPS are not readily available, MPS will lower and MPB (ubiquitin-ligase and autophagic 
systems) will increase in order to break down proteins to provide any needed AAs and 
remove damaged/dysfunctional proteins (15, 16). During these time periods, MPB will 
surpass MPS causing a negative NPB and muscle protein loss. In individuals who have a 
reasonably active lifestyle and a healthy, balanced diet, the fluctuations in MPS and MPB 
will be equal thereby maintaining NPB and muscle mass.  
An exercise stimulus, both aerobic and resistive in nature, also stimulates MPS (17, 18) 
although the extent of this is much greater following resistance exercise (19). However, 
exercise conducted in the fasted/postabsorptive state, when no post-exercise protein/AA’s 
ingested is unable to produce a positive NPB (18). However, exercise does serve to 
sensitise the muscle to nutrients, and an increase in the amount of AAs available post-
exercise i.e. via a protein beverage will cause a rise in MPS that is greater than that 
stimulated by either exercise and nutrients alone (12, 20). Again, in this scenario, a slight 
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suppression of MPB is elicited via the effects of insulin (14) causing NPB to become 
positive and the muscle enters a state of protein accretion. If this process is repeatedly 
regularly such that daily NPB is frequently in a positive state then, over time, skeletal 
muscle hypertrophy will most likely occur (21). Although this would suggest that the time 
spent in a positive muscle NPB should be maximised in order to elicit the greatest 
hypertrophy, it is important to acknowledge that times of negative NPB are essential in 
order to remove damaged and dysfunctional proteins which may cause muscles to 
function at suboptimal standards (15, 16). These periods allow muscle remodelling 
permitting muscle phenotypic changes to occur in response to different stimuli (19). 
Overall, the control of the dynamic balance between MPS and MPB is essential in human 
skeletal muscle in order to permit optimal function and metabolism.  
Recent research has implicated MPS as the more important contributor to NPB (22). At 
the molecular level, the mechanistic target of rapamycin (mTOR), in particular mTOR 
complex 1 (mTORC1), is noted as a significant contributor to the stimulation of MPS (23, 
24). This was displayed through the administration of the mTORC1 inhibitor rapamycin 
to individuals prior to a bout of resistance exercise (23) or ingestion of essential AAs 
(EAAs) (24). On occasions where rapamycin had been ingested, MPS responses to either 
anabolic stimulus were unchanged from baseline values, whereas placebo conditions 
displayed the common significant elevations in MPS. This data displays that mTORC1 is 
an essential regulator of MPS in skeletal muscle, and as such the dynamic regulation of 
this protein complex in human skeletal muscle will be the focus of this thesis. 
1.2 – mTOR Overview 
1.2.1 Introduction to mTOR 
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The mechanistic target of rapamycin (mTOR), is an evolutionarily conserved 
serine/threonine kinase belonging to the PIKK family of specific serine/threonine kinases 
(25). mTOR contains 2549 AA residues which formulate the entire protein including its 
functional domains (26). At the N-Terminus resides 22 HEAT tandem repeats followed 
by the first of two FAT (FRAP, ataxia telangiectasia, transformation/translation) domains 
which are believed to be needed for the binding of regulatory components of mTOR 
complexes (25). The subsequent domain is the FRB (FKBP12/FK506 binding protein) 
domain, to which rapamycin can bind and inhibit mTOR kinase function (26). Following 
this is the catalytic domain of mTOR that includes an ATP binding site in addition to two 
sites for potential phosphorylation. Finally, the C-Terminus contains a second FAT 
domain (FATC) which is neighboured by two further phosphorylation sites, one of which 
is the site of mTOR auto-phosphorylation (27). In all, the mTOR protein has 5 sites of 
potential phosphorylation, each causing conformational changes in the protein structure 
and altering kinase activity of mTOR. The protein structure of mTOR is depicted in 
Figure 1.1. In most eukaryotic cells, mTOR resides as two complexes referred to as 
mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2), each purported to 
reside in different locations and exhibiting divergent functions (28). 
1.2.2 mTORC1 & Components 
Of the two distinct heteromeric mTOR complexes found in eukaryotic cells, mTORC1 is 
consistently reported as the master regulator of anabolic processes such as cellular growth 
and proliferation (29-31) whilst contributing to a concomitant inhibition of autophagy 
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(32-38). mTORC1 is comprised of several proteins (RAPTOR, PRAS40, DEPTOR, 
GβL/mLST8) which each individually contribute to the unique function of this complex. 
Figure 1.1. Protein structure of mTOR 
At the N terminus of mTOR is 22 HEAT tandem repeats followed by the first FAT (FRAP, ataxia 
telangiectasia, transformation/translation) domain. The subsequent domain is the FRB (FKBP12/FK506 
binding protein) domain which both rapamycin (inhibitory) and phosphatidic acid (PA, stimulatory) can 
bind to. The catalytic domain of this protein lies next to the FRB domain and is the main site of mTOR’s 
catalytic activity. This domain is also the site to which Rheb binds to in order to enhance the kinase activity 
of mTOR. Finally, at the C terminus is the second FAT domain termed FATC. 
1.2.2.1 Raptor 
RAPTOR is commonly believed to be the prominent regulator of this complex, acting as 
a scaffold protein for mTOR and substrates such as S6K1 and 4EBP1 (39, 40) and as such 
the mTOR-RAPTOR interaction is critical for mTOR to complete its kinase activity (41). 
Several knockdown and deletion trials of the RAPTOR protein have highlighted its 
importance to the normal physiological function of the complex i.e. protein synthesis and 
cellular growth (41-43). Specifically, the utilisation of short interfering RNA strands 
(siRNA) which diminished RAPTOR protein expression in HEK293T cells were found 
to cause a reduction in leucine stimulated S6K1Thr389 phosphorylation, a proxy measure 
for mTORC1 activity. In addition, RAPTOR-deficient mice are developmentally lethal at 
day 7 of gestation (42), a response identical to that observed in mTOR-null animals (44). 
More recently, a more detailed role for RAPTOR within mTORC1 signalling has been 
implicated. Frey et al. (45) elegantly displayed that, in response to eccentric contractions 
in mouse tibialis anterior (TA) muscles, RAPTOR becomes phosphorylated at several 
sites (Ser696, Thr706, Ser863) and this process lies upstream of mTORC1 activation as 
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rapamycin treatment failed to inhibit these modifications (45). Transfection of a mutant 
RAPTOR protein, lacking all three phosphorylation sites, into mouse TA then revealed 
the crucial contribution these phosphorylation events provide to full mTORC1 activation. 
In muscles containing this mutant protein, a 65% reduction in the contraction-induced 
phosphorylation of S6K1, compared to control muscles, was reported (45). Furthermore, 
this decrease was accompanied by an inhibition of RAPTOR-S6K1 disassociation 
following contractions which may have contributed to an alteration of substrate 
availability to mTORC1 (45). A further postulation is that the mechanism underpinning 
rapamycin-induced inhibition of mTORC1 may involve RAPTOR (46).  Following 
administration of rapamycin to HEK293T cells, co-immunoprecipitation of RAPTOR and 
mTOR is reduced in a dose-dependent fashion (46). Moreover, this disassociation was 
related to a reduction in mTOR-dependent phosphorylation of both S6K1 and 4EBP1, the 
two prominent mTORC1 substrates. These data combined, therefore implicate RAPTOR 
as an essential component of mTORC1 which can directly affect the mTORC1 
physiological function through both the recruitment and proximity of mTORC1 to its 
substrates. 
1.2.2.2 PRAS40 
PRAS40 is a 14-3-3 binding protein which interacts with mTORC1 through the substrate 
binding site of RAPTOR (47, 48). The effects of this protein on the complex are believed 
to be inhibitory as the connection with RAPTOR blocks the site at which S6K1 and 
4EBP1 can bind (40). Upon activation mTOR phosphorylates PRAS40 at Ser183 and 
causes its dissociation from the complex, relieving its inhibitory effects (49). 
Furthermore, PRAS40 is inhibited through phosphorylation by Akt at Thr246, which also 
causes the dissociation from RAPTOR due to increased binding with the cytosolic 14-3-
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3 protein (50, 51). This redistribution of PRAS40 into the cytosolic fraction and away 
from mTORC1 is believed to be key for optimal mTORC1 function (49, 52). Consistent 
with its role as an mTOR inhibitor, overexpression of PRAS40 reduced insulin- and AA-
stimulated phosphorylation of S6K1 and 4EBP1 in HEK293T cells (48, 53), as well as 
reducing overall cell size (52). Similarly, knockdown of PRAS40 increased basal 
mTORC1 activity in a variety of cell models (48, 54, 55). However, recent findings also 
suggest that mTORC1 pathway activity may be impaired due to PRAS40 silencing. 
Fonseca et al. (56) displayed an inhibition of insulin- and AA-mediated mTORC1 
substrate phosphorylation in HEK293 cells when siRNAs targeting PRAS40 were 
introduced. These results have been corroborated further in both C2C12 myoblasts (57) 
and human primary skeletal muscle cells (58), and the extent of the inhibition of mTORC1 
signalling is reported as similar to that induced by ethanol administration (51). These 
findings are counterintuitive due to PRAS40’s believed role as an mTOR inhibitor 
however may be explained by the reduction in total GβL, an mTOR activator, and mTOR-
GβL interaction that is noted upon PRAS40 silencing (51). Therefore, it is apparent that 
PRAS40 is a second component of mTORC1 that is essential in controlling this 
complex’s action as a promoter of protein synthesis and cellular growth. 
1.2.2.3 DEPTOR 
Similar to PRAS40, DEPTOR acts as an mTOR inhibitor, blocking mTOR’s ability to 
phosphorylate its substrates, S6K1 and 4EBP1 (59). During normal physiological 
stimulation of mTORC1, i.e. growth factors or AAs, DEPTOR becomes phosphorylated 
and targeted for degradation by the ubiquitin-proteasome pathway (59, 60). This 
breakdown releases the DEPTOR inhibition on mTORC1 and allows the initiation of 
protein translation and cell growth. DEPTOR knockdown, as expected from its inhibitory 
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function, causes hyperactivation of mTORC1, elevated phosphorylation of mTORC1 
substrates (S6K1 and 4EBP1), increased protein synthesis and an enhanced proliferation 
rate in C2C12 myoblasts (60). Furthermore, in vivo knockdown of this protein in 
C57/BL6 mice prevented the typical muscle atrophy noted with hindlimb immobilization, 
an adaptation modulated by an increase rate of protein synthesis post-immobilization 
(60). Correspondingly, DEPTOR overexpression results in an opposite phenomena in 
which signalling from both mTOR complexes is inhibited (60). However, other reports 
suggest a catabolic consequence of DEPTOR knockdown. Zhang et al. (61) studied the 
effects of DEPTOR silencing in multiple myeloma cells, finding that this cell 
modification suppressed autophagy and induced apoptosis in this cancer cell line. Further 
research conducted by the same laboratory  reinforced these findings showing a 
suppression of cell proliferation elicited by DEPTOR knockdown (62). These data 
suggest that DEPTOR is needed for normal mTORC1 function through the regulation of 
catabolic pathways and cellular replication (60-62). In addition the hyperactivity of 
mTORC1 induced by DEPTOR knockdown could cause unregulated cell growth, a 
process implicated in cancer progression (63). As such, DEPTOR also seems to be an 
essential component of mTORC1. 
1.2.2.4 GβL/mLST8 
The final component of mTORC1 complex is GβL which binds both to RAPTOR and 
directly to the kinase domain of mTOR (64). Several theories implicating a role of GβL 
in mTORC1 complex signalling have been proposed, with suggestions that it can regulate 
both upstream and downstream signalling of mTORC1 in addition to stabilising the 
RAPTOR-mTOR association (64). Despite these discrepancies, a constant finding across 
much of the literature regarding GβL is its positive role on mTORC1 signalling. Kim et 
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al. (64) utilised siRNA targeting GβL in HEK293T cells and displayed reduced mTORC1 
activity (myc-S6K1Thr389 phosphorylation) in response to both serum and leucine 
starvation/reintroduction treatments. Furthermore, this suppression of mTORC1 
signalling was similar to that noted with transfection of mTOR or RAPTOR targeting 
siRNA and was accompanied by a reduction in cell size, whilst overexpression elevated 
S6K1 and 4EBP1 phosphorylation in a dose-dependent manner (64). Several other studies 
have also reported this positive role as GβL-deficient mouse embryos are smaller their 
wild-type counterparts (42). However, this group did also report that GβL is not essential 
for mTORC1 signalling in response to serum deprivation/reintroduction (42). Therefore, 
it seems GβL is a component of mTORC1 which can positively regulate the activity of 
this kinase complex however; it may not be an essential factor (42, 64). Further research 
into this protein is needed such that its’ true role in mTORC1 signalling and necessity to 
the complex can be elucidated. 
1.2.2.5 Importance of complex formation 
Each member of mTORC1 displays a unique and specific role related to the signalling of 
the complex such that its optimal activity cannot be achieved if any single protein is 
removed/inhibited. In addition to the effects of singular protein knockdown, the formation 
of the entire mTORC1 complex has been reported to be of importance. Ramirez-Rangel 
et al. (65) studied how GRp58, a protein disulphide isomerase which can regulate protein-
protein binding, can affect mTORC1 complex assembly and subsequent kinase activity. 
Firstly, it was reported that GRp58 knockdown in HEK293T cells caused a significant 
reduction in the amount of RAPTOR and GβL co-immunoprecipitated alongside mTOR 
(65). Moreover, an opposite effect was noted when GRp58 was overexpressed as a 
RAPTOR-mTOR and GβL-mTOR co-immunoprecipitation was augmented (65). This 
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data suggested that GRp58 is implicated in the assembly of mTORC1. The authors then 
reported that knockdown of GRp58 elicited a reduction in the phosphorylation of 
mTORC1’s downstream substrates S6K1 and 4EBP1, whilst overexpression caused an 
elevated baseline phosphorylation of these substrates but an unaltered maximal 
phosphorylation capacity (65). This data proposes that the assembly of the entire 
mTORC1 complex is vital for the full kinase activity, therefore reinforcing the notion that 
all components of the complex are needed for optimal physiological function of cells. 
1.2.3 mTORC2 & Components 
The second heteromeric mTOR complex found in many eukaryotic cells is mTORC2, 
implicated in glucose homeostasis and actin cytoskeleton dynamics (66). This complex 
is purported to be insensitive to rapamycin (67), however longer treatment has recently 
been shown to effectively inhibit mTORC2 (68). Several cellular locations have been 
observed for this kinase complex, most notably close to mitochondria (69-71), at the 
plasma membrane (71) and shuttling between the nucleus and cytoplasm (72). mTORC2 
consists of mTOR and 5 associated proteins, RICTOR, mSIN1, Protor1/2, GβL/mLST8 
and DEPTOR.     
1.2.3.1 Rictor 
RICTOR, similar to RAPTOR within mTORC1, is believed to be the major regulator of 
this complexes’ kinase activity, allowing the kinase to phosphorylate a separate set of 
substrates to that of mTORC1. Rictor knockout mice display developmental impairments 
(42) and premature death 10 days into gestation. Furthermore, knocking out this protein 
in MEF cells reduced the phosphorylation of AKTSer473, a major mTORC2 substrate (42), 
in basal, serum-stimulated and insulin-stimulated states (42). Moreover, the 
phosphorylation of AKT substrates (Tuberous Sclerosis Complex 2 (TSC2)Thr1462 & Ser939 
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and Forkhead box O3 (FoxO3)Thr32)  was also reduced in these cells, displaying that loss 
of mTORC2 kinase activity has significant downstream consequences (42). In skeletal 
muscle, the specific knockout of the rictor protein has a similar effect, reducing AKTSer473 
phosphorylation, however this effect was reversed when the mTORC1 component 
RAPTOR was also deleted (73). These data have been replicated in several other mouse 
models lacking the RICTOR protein in skeletal muscle, showing large reductions in 
insulin-stimulated AKTSer473 phosphorylation (74), foetal growth (42) and glucose 
transport (74). Encapsulated, these data implicate RICTOR as essential for full mTORC2 
kinase activity and suggest this component is essential for substrate phosphorylation and 
downstream effects of this kinase complex. 
1.2.3.2 mSIN1 
mSIN1 is a stress activated protein kinase which occurs in five different isoforms, three 
of which can occur in mTORC2 (75). Each of these isoforms generate mTORC2 
complexes with varying functionalities, each responding to differing upstream signals 
(75). mSIN1 co-immunoprecipitates with both mTOR and RICTOR in HEK293 and 
HeLa cells, yet is absent from mTOR immunoprecipitates when RICTOR expression is 
inhibited (75), suggesting a possible association between these two proteins in the 
assembly of mTORC2. However, when mSIN1 expression is inhibited with shRNA, 
RICTOR no longer co-immunoprecipitates with mTOR proposing a possible co-
dependence of the two proteins in proper mTORC2 assembly (75). Further studies have 
reported this ablation of RICTOR-mTOR association in mSIN1 null MEF cells (76) 
showing its importance to mTORC2 complex assembly. In addition, mSIN1 seems to be 
critical for mTORC2 kinase activity, although this may be a secondary effect following 
the disruption of complex assembly. When mSIN1 expression was removed through the 
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use of shRNA, phosphorylation of AKTSer473, a major mTORC2-regulated site, was no 
longer apparent (75). As previously discussed, this finding is identical to that noted when 
RICTOR protein expression is ablated. Interestingly, AKT phosphorylation at the second 
site which is implicated in its activity (Thr308) is unaltered in cells lacking mSIN1 (76) 
confirming the effects are due to reduced mTORC2 activity. FoxO1/3A phosphorylation 
was also reduced in these cells (76) suggesting AKT kinase activity, as well as 
phosphorylation status, is somewhat governed by mSIN1. Conversely both TSC2Thr1462 
and GSK3βSer9 phosphorylation were similar regardless of the level mSIN1 expression 
which suggests an intricate mechanism controlling AKT kinase activity which does not 
solely involve mTORC2. Furthermore, it is possible that mSIN1 acts as a scaffold for 
AKT allowing mTORC2 to phosphorylate this substrate as mSIN1 immunoprecipitates 
contain the AKT protein (76). This data provides insightful information as to how mSIN1 
knockdown/inhibition reduces mTORC2 kinase activity towards AKT.  Taken together 
these data propose that, in vitro, mSIN1 is critical for full mTORC2 complex assembly 
and kinase function. In vivo studies of the importance of mSIN1 to mTORC2 are rare, 
most likely due to the embryonic lethality caused by the knockdown of this gene (76). 
Nevertheless, it can be concluded that mSIN1 is vital for mTORC2 formation and activity 
as well as cell survival. 
1.2.3.3 Protor-1 /2 
Protor-1/2, also known as proline rich-protein 5 (PRR5), was first identified as a 
component of mTORC2 by Pearce et al. (77) in HEK293 cells through co-
immunoprecipitation experiments of the major mTORC2 component RICTOR. Here, 
Protor-1/2 was observed alongside the other components of this mTOR complex. Further, 
RICTOR, mTOR and mSIN1, but not RAPTOR, were all detected in immunoprecipitates 
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of Protor-1 confirming its appearance only in mTORC2 (77). RICTOR was also noted to 
regulate the expression of Protor-1, with RICTOR-null MEF cells expressing 
significantly lower levels of Protor-1 compared to wild type cells. Interestingly, these 
novel components of mTORC2 had no apparent functional domains and as such the role 
of Protor-1/2 was difficult to determine. However, the use of siRNA or shRNA targeting 
Protor-1, and Protor-1 null MEF cells have shed some light on this matter (77-79). 
Reductions in Protor-1 expression had no effect on the expression of other mTORC2 
components or this complex’s assembly (77). In contrast, the silencing of Protor-1 with 
shRNA in HeLa cells did show an effect on mTORC2 kinase activity. Here, AKTSer473 
phosphorylation significantly decreased compared to a scrambled control (78), though 
this finding was not replicated in Protor-1 null MEF cells (79). This group however did 
observe a reduction in late-phase phosphorylation of PKCδ at its hydrophobic motif (79) 
suggesting some potential role of Protor-1 on mTORC2 kinase activity. More recently, 
Pearce et al. (80) produced Protor-1/2 single and double knockout mice in order to further 
elucidate the physiological role of the Protor isoforms. Again, the removal of Protor-1/2 
expression had no effect on the complex assembly of mTORC2. Moreover, in vitro kinase 
assays, conducted on immunoprecipitated mTORC2 from the kidneys and liver of these 
mice, displayed no alterations in mTORC2 kinase activity compared to wild type controls 
(80). In fact, the only noticeable effect of Protor-1/2 removal was a reduction in NDRG1 
and SGK1 phosphorylation in the kidneys of Protor-1 knockout and Protor-1/2 double 
knockout animals (80), measures which were unaffected in all other tissues analysed 
including skeletal muscle. This therefore suggests that, in vivo, only the Protor-1 isoform 
has an effect on mTORC2 kinase activity. Overall, it seems that Protor-1/2 may be a 
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dispensable component of mTORC2 in most tissues but more research is needed to fully 
understand the roles of these Protor isoforms on mTORC2. 
1.3 – Mechanisms of mTORC1 activation 
1.3.1 Direct mTOR activators 
1.3.1.1 Rheb 
Ras homolog enriched in brain (Rheb) is a small GTPase protein, which has been 
identified as a potent mTOR activator (81). Rheb’s mode of action is through direct 
binding to mTOR’s catalytic domain thereby enhancing its kinase activity (81). In a 
similar manner to many other small GTPases, Rheb is active when it is GTP-bound and 
also possesses intrinsic GTPase activity, which can drive the shift from GTP- to GDP-
bound states (81). In most cell types the activation of Rheb intrinsic activity is governed 
by TSC2, a GTPase activating protein (GAP). When associated with Rheb, TSC2 will 
stimulate its GTPase activity and maintain the protein in its inactive (GDP-bound) state 
(82, 83). However, if TSC2 is inactive or disassociates from Rheb, intrinsic GTPase 
activity is no longer stimulated and Rheb is converted to the active, GTP-bound state 
allowing binding and activation of mTOR (81). This process has been well characterised 
in both Drosophilia and mammalian cell lines. When Rheb expression is removed in 
Drosophilia S2 cells, S6K1Thr389 phosphorylation is completely ablated (81). These 
results mirror those noted in HEK293 cells where mutations to the Rheb protein, which 
cause its inactivation, significantly reduce S6K1Thr421 phosphorylation despite adequate 
AAs and serum availability (81). Furthermore, Rheb overexpression can rescue 
S6K1Thr421 phosphorylation in cells which have been starved of AAs (81). Other 
investigations have reinforced this critical role of Rheb toward growth factor-induced 
mTORC1 activation confirming its importance to cell anabolism and growth (84, 85).  
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1.3.1.2 Phosphatidic acid 
A second direct mTOR activator which has been identified is phosphatidic acid (PA), a 
phospholipid expressed in all mammalian cell membranes (86, 87). This compound 
consists of two fatty acids and a phosphate group bound to a glycerol backbone and 
directly activates mTOR through binding to the FRB domain (88), the same site which 
rapamycin exerts its inhibitory effects on mTOR. The importance of PA for mTORC1 
activation has been well documented. In vitro, exogenous PA, combined with AAs 
exerted a 5-fold greater increase in S6K1 activity compared to AAs alone (88). 
Furthermore, the disruption of PA production through the use of 1-butanol removed any 
effect of serum stimulation on S6K1 activity (88). Ex vivo investigations have since 
reinforced this notion, displaying that mouse EDL muscles incubated in 1-butanol, before 
being subjected to eccentric contractions, exhibited no increase in S6K1Thr389 
phosphorylation (89). The production of DGKζ-/- mice provided further insight into the 
importance of PA to mTORC1 activation as this enzyme was identified as the major 
contributor to endogenous PA production in skeletal muscle (90). Here, DGKζ-/- muscle 
displayed a diminished anabolic response (S6K1Thr389) to eccentric contractions compared 
to wild-type animals (90), emphasising how critical endogenous PA production is to 
mTORC1 activity. 
1.3.2 mTOR and the lysosome 
Lysosomes are spherical organelles that function as the waste disposal system in 
eukaryotic cells (91). These membrane-covered organelles contain a variety of hydrolytic 
enzymes which digest redundant components of the cell i.e. damaged proteins or cellular 
debris (91). With an internal pH maintained at ~4.5, lysosomal enzymes function in an 
environment similar to that of the stomach, whereby digested materials are further utilised 
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in the production of new cellular components (91). In addition to this role in cellular 
homeostasis, the lysosome has also been implicated in cellular signalling pathways (31, 
92-96). Seminal work from Sancak et al. (97) using immuno-fluorescence microscopy 
displayed that mTORC1, when activated under conditions of AA removal and subsequent 
reintroduction, localised with Rab7 positive cellular structures, a protein associated with 
late endosomes/lysosomes (92). This work suggested that mTORC1 may need to 
associate with the lysosome in order to become optimally active. 
Further reports have since reinforced the notion that mTORC1 interaction with the 
lysosome can enhance mTORC1 activity. In vitro work in HEK293T cells undertaken by 
the Sabatini laboratory (98) first displayed how the forced targeting of mTORC1 to the 
lysosomal surface can stimulate mTORC1 signalling and render this pathway AA 
insensitive. This enforced localisation of mTORC1 with the lysosome was achieved 
through modifying RAPTOR proteins. The final 15-17 AAs in Rheb1 or Rap1b peptide 
chains were fused to the RAPTOR peptide chain (coined raptor-Rheb15 and raptor-
Rap1b17), whilst a control protein was produced by adding the Rheb1 peptide chain 
lacking the CAAX box (RAPTOR-Rheb15ΔCAAX) which should not localise to the 
lysosome (98). The transient expression of either raptor-Rheb15 or –Rap1b17 resulted in 
a constant localisation of mTORC1 to LAMP2 positive structures independent of AA 
availability. This continuous interaction elicited an increase in mTORC1 activity, as 
assessed by S6K1Thr389 phosphorylation, which again was insensitive to the reduction 
normally noted with AA withdrawal (98). A more physiological model, whereby 
HEK293 cells stably expressed RAPTOR-Rheb15, was also investigated by these authors 
(98). Identical results were found as mTORC1 remained on the lysosome irrespective of 
AA availability and signalling downstream of this complex was heightened. Furthermore, 
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cells stably expressing this mutant form of RAPTOR were larger in comparison to those 
expressing wild-type RAPTOR, suggesting greater growth rates in this cell line. 
Targeting mTORC1 to other membrane structures was insufficient to activate signalling 
displaying it is association with the lysosome itself which can elevate mTORC1 
activation. More recent work has replicated this method in vivo by transfecting a plasmid 
encoding the RAPTOR-Rheb15 protein into mouse tibialis anterior muscles via 
electroporation (92). Here, the mutant RAPTOR protein stimulated a 5-fold increase in 
mTORC1 activity (S6K1Thr389 phosphorylation) compared to wild-type and RAPTOR-
Rheb15ΔCAAX mice phenotypes (92). Therefore, it seems that both in vitro and in vivo 
the association of mTORC1 to the lysosome is sufficient for mTORC1 activation and is 
also essential to its kinase activity.  
1.3.2.1 Rheb and PA at the lysosome 
In addition to residing in a location where there is an abundant supply of AAs, the 
presence of mTORC1 at the lysosome positions this kinase complex in close proximity 
to both Rheb and PA, two direct mTORC1 activators. Rheb is observed to associate with 
lysosomal proteins both in vitro (81, 93, 99) and in vivo in rodent skeletal muscle (90). 
As such, the need for mTORC1 to be associated with the lysosome for optimal kinase 
activity is possibly due to an increase in the association of mTOR with Rheb. This would 
increase the likelihood of Rheb associating with the catalytic domain of mTOR and 
thereby enhancing its activity. However, the close proximity of these two proteins at the 
lysosome is not a prerequisite for mTORC1 activation as the GAP TSC2 has also been 
observed at the lysosome (90). This means that in order for Rheb to be converted to the 
GTP-loaded state, where it can bind and activate mTOR, TSC2 must be inactivated or 
removed from this location. 
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PA is also enriched at the lysosome (100), in addition to enzymes which control its 
production (phospholipase D1 and DGKζ) (101, 102). Again, the close proximity of 
mTORC1 to its direct activator at the lysosomal membrane increases the likelihood of PA 
binding to the FRB domain of mTOR and enhancing its activity. Furthermore, during 
times of high AA availability, the activities of enzymes that produce PA are noted to 
increase (102, 103). This, in theory would cause an even greater abundance of PA at the 
lysosome and may therefore further contribute to the localisation of direct mTOR 
activators, at the lysosome, and contribute to maximal mTORC1 activation.  
1.3.2.2 Rag GTPases 
With the discovery that mTOR-lysosomal association is required for optimal mTORC1 
activity, it was next imperative to understand how mTORC1 is recruited and affixed to 
the lysosomal membrane. This knowledge arrived through the unearthing of a family of 
small GTPases called the Rag proteins (97). This family of GTPases has four members 
(RagA/B/C/D) which bind to form stable heterodimers consisting of either RagA/B 
associated with RagC/D. Similarly to Rheb, as these proteins are GTPase proteins, their 
activity levels are governed by their guanosine loading status (97). These heterodimers 
are active when RagA/B are GTP-bound and RagC/D GDP-loaded, in which state they 
can associate with mTORC1 and recruit the kinase complex to the lysosomal surface. The 
specific mechanism by which this occurs is through an association of the Rag protein 
heterodimer with the RAPTOR component of mTORC1. This has been confirmed 
through several immunoprecipitation experiments in vitro by the Sabatini laboratory (97). 
Furthermore, this group displayed the importance of these proteins through the genetic 
variants of these GTPases, which remained permanently GTP- or GDP-loaded. Here, a 
mutant heterodimer containing RagBGTP and RagCGDP co-immunoprecipitated with more 
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RAPTOR protein than any other mutant heterodimer tested. Next, in the HEK293 cell 
line, this group investigated the effect of these variants on mTORC1 signalling. 
Interestingly, and in agreement with the increased RAPTOR association previously noted, 
overexpression of the heterodimer containing RagBGTP and RagCGDP not only activated 
mTORC1 (shown via S6K1Thr389 phosphorylation) but caused this pathway to become 
insensitive to AA withdrawal (97). The knockdown of these proteins with shRNA 
significantly reduced mTORC1 activity in response to leucine administration, suggesting 
these proteins are important for mTORC1 activation by AAs. Finally, immunofluorescent 
staining of mTOR in HEK293 cells treated with AAs, following deprivation, resulted in 
mTOR-positive puncta being observed when mTOR associated with the lysosome. In 
contrast, when cells were treated with shRNA targeting the Rag proteins, puncta staining 
was no longer observed with mTOR remaining diffuse throughout the cell, a pattern 
normally noted in AA deprived cells (29, 97, 98, 104-108). This seminal work identified 
that the association of Rag protein heterodimers with RAPTOR is required for mTORC1 
recruitment to the lysosome and is essential for mTORC1 kinase activity. 
1.3.2.3 Ragulator 
Following the identification of Rag proteins as binding partners of mTORC1 at the 
lysosomal surface, it was revealed that the Rag protein heterodimer’s AA sequence did 
not contain a lipid-binding motif (98). It was therefore hypothesised that this heterodimer 
must have another binding partner which can bind to membrane lipid bi-layers allowing 
Rag protein scaffolding to the lysosome. Mass spectrometry analysis of HEK293 cells 
expressing active Rag mutants led to the identification of a trimeric complex associating 
with both the Rag proteins (98) and the lysosomal membrane (98, 104). The components 
of this trimeric complex were named MP1, p14 and p18. Furthermore, mTORC1 co-
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immunoprecipitated with components of the ragulator when RagBGTP constructs were 
stably expressed in HEK293 cells. Genetic mutants of one component of the ragulator, 
p18, which targeted the protein to mitochondrial surfaces rather than the lysosome were 
then utilised. Here, upon AA stimulation, Rag proteins were seen to localise with the 
mitochondria yet mTOR did not and mTORC1 activity was low. Moreover, cells lacking 
either the p14 or p18 component of the Ragulator became insensitive to AAs and 
mTORC1-dependent phosphorylation of S6K1 remained low (98). These data display the 
importance of the Ragulator as a docking site for Rag proteins, and mTORC1, at the 
lysosome surface and also the need for this trimeric complex for full mTORC1 activation.  
More recently, a further two components of the Ragulator complex have been identified 
(104), assembling a pentameric complex alongside MP1, p14 and p18. These two 
proteins, named HBXIP and C7orf59, bind to form a heterodimer which associates with 
p18. A second heterodimer consisting of p14 and MP1 is also associated with p18, which 
acts as a bridge between the two heterodimers associating them with the lysosome (104). 
These two novel members of the Ragulator complex are essential for mTORC1 activation 
in both HEK293 and Drosophilia cell lines, as the use of siRNA targeting HBXIP or 
C7orf59 greatly reduced S6K1Thr389 in response to AAs (104). Intriguingly, this complex 
does not act solely as a scaffold for the Rag proteins at the lysosomal surface. Bar-Peled 
et al. (104) recently reported that the Ragulator complex is a guanosine exchange factor 
(GEF) toward RagA and RagB, catalysing the conversion of these proteins from the GDP-
bound to GTP-bound active state. Furthermore, it was shown that the Ragulator had to be 
in its full form, the pentameric complex, for this effect to be seen (103). Therefore, the 
Ragulator complex’s role in mTORC1 activation is two-fold, first to act as a scaffold for 
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the Rag proteins and second as a GEF towards RagA and RagB proteins, aiding their 
conversion to the active state. 
1.3.2.4 V-ATPase 
The vacuolar-type H+-ATPase (v-ATPase) is a multiprotein enzyme complex primarily 
implicated in the transport of protons across a membrane, a process fuelled by the 
hydrolysis of ATP (109). This complex is comprised of two domains, the V1 domain 
which catalyses ATP hydrolysis, and the V0 domain which controls proton transport 
(109). Specifically, the process of ATP hydrolysis, by the V1 domain, generates force 
which rotates the V0 domain allowing for the transport of protons across the membrane 
(109). A potential role for the v-ATPase in mTORC1 signalling was recently proposed 
by Zoncu et al. (29) Thr389when they reported that deletion of several genes encoding 
components of the v-ATPase significantly reduced S6K1Thr389 phosphorylation (25). 
These findings were then confirmed using two polyketides, concanamycin A (conA) and 
salicylihalamide A (salA), which specifically inhibit the v-ATPase. Both these 
compounds inhibited amino-acid induced S6K1Thr389 phosphorylation in a concentration-
dependent manner with no concomitant change in growth factor signalling. It was next 
displayed that the importance of this complex to mTORC1 activation was not due to the 
v-ATPase’s role in proton-gradient assisted AA transport into the lysosome, but is 
downstream of intracellular AAs in this pathway. These findings then led to the 
hypothesis that the v-ATPase may be implicated in the recruitment of mTORC1 to the 
lysosomal surface. Congruent with this hypothesis, the use of conA, salA, or a shRNA 
targeting a v-ATPase subunit, all reduced mTORC1 translocation to the lysosome 
following AA stimulation (29). The forced activation of RagB (GTP-loaded) removed 
this effect, leading to ‘normal’ mTORC1 activation, suggesting that the v-ATPase lies 
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upstream of the Rag proteins. Subsequent co-immunoprecipitation and mass spectrometry 
analysis displayed a structural link between both v-ATPase domains and the Ragulator 
complex, and a weaker link between the V1 domain and Rag proteins (29). This 
implicated a role for the v-ATPase as a scaffold forming a v-ATPase-Ragulator-Rag 
complex allowing mTORC1 to be recruited to lysosomal membranes and therefore 
become activated.  
1.3.2.5 Inside-Out Mechanism 
In addition to the identification of v-ATPase as a component of the AA-mTORC1 
pathway, Zoncu et al. (29) also displayed how mTORC1 activation is mainly driven by 
intralysosomal AA concentrations. This was elegantly demonstrated through the 
overexpression of proton-assisted transporter 1 (PAT1), an AA transporter which 
removes intralysosomal AAs to the cytosol, in HEK293 cells. Here, the removal of 
intralysosomal AAs completely abolished mTORC1 activity, however this effect was 
rescued via the expression of constitutively active Rag proteins (29). The inhibition of 
ATPase hydrolysis activity was then shown to reduce RagB-Raptor interaction and 
subsequent mTORC1 activation, suggesting the v-ATPase may signal intralysosomal 
AAs levels. This led to the authors proposing an inside-out mechanism of mTORC1 
activation at the lysosome. They suggest that, upon AA exposure, intralysosomal AAs 
are elevated. This activates the v-ATPase which signals the alteration in AA levels to the 
Ragulator complex, activating this complex’s GEF activity toward Rag A/B. 
Subsequently Rag proteins are activated (through GTP loading of RagA/B) and recruit 
mTORC1 to the lysosomal surface where it can become active (97). Overall the data 
supporting this mechanism implicate the v-ATPase as an integral component in the AA 
induced activation of mTORC1 and cell growth.   
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1.3.3 Other regulators of mTORC1 
1.3.3.1 Folliculin 
Folliculin is a tumor suppressor protein that interacts with folliculin interacting proteins 
1 and 2 (FNIP1/2), however the specific function of these proteins is poorly defined. This 
protein complex’s role in mTORC1 activation was identified upon the discovery that the 
activation of the Rag protein heterodimer, involved in mTORC1 recruitment to 
lysosomes, is dependent on the GDP-loading status of RagC (105). The forced di-
phosphate loading of RagC co-immunoprecipitated a greater amount of RAPTOR than 
any other Rag heterodimer mutant, and caused mTORC1 activity to be resistant to AA 
starvation. Therefore, it was important to identify potential GEF or GAP proteins for 
RagC which could be regulators of mTORC1 activation. Mass spectrometry screens of 
RagC-associated proteins displayed a regular association with Folliculin and FNIP1/2 
(105). Co-immunoprecipitation analysis then confirmed this association, mTORC1 
association only occurred when folliculin and FNIP2 were stably co-expressed. The use 
of shRNA targeting folliculin in HEK293 cells inhibited mTORC1 activation 
(S6K1Thr389) in response to AAs, and mTORC1 did not associate with lysosomes in these 
cells (105). In contrast, the knockdown of folliculin expression had no effect on the 
localisation of Rag proteins to the lysosome, thus only their ability to recruit mTORC1 
was affected.  
In non-transfected cells, folliculin was observed to localise to Rag proteins and the 
lysosomes during AA starvation. Upon AA exposure, folliculin dispersed into the cytosol 
in a mTORC1-independent fashion as Torin-1 had no effect on these measures (105). 
Following this, the function of the folliculin-FNIP2 complex was discovered. This 
complex was seen to have GAP activity toward RagC/D, hydrolysing GTP into GDP on 
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these proteins and allowing the Rag heterodimer to convert to the active state 
(RagA/BGTP-RagC/DGDP) (105). This was confirmed through the use of various Rag 
protein mutants, displaying how folliculin-FNIP2 can contribute to the activation of the 
Rag heterodimer allowing mTORC1 to be recruited to the lysosomal membrane. It is 
purported that, as Rag proteins leave the lysosome to recruit mTORC1, folliculin may be 
removed from the heterodimer and this results in the diffuse cytoplasmic staining pattern 
of folliculin under AA rich conditions (105). Such, data has since been replicated 
elsewhere (110), indicating that folliculin recruitment to the lysosome during AA 
deprivation is integral to mTORC1 activation upon subsequent AA reintroduction. 
Therefore, it seems, the folliculin-FNIP2 complex is a further integral component in the 
AA-mTORC1 pathway regulating protein synthesis and cell growth.  
1.3.3.2 GATOR Complexes 
The Sabatini laboratory next undertook several investigations into possible negative 
regulators of the Rag protein heterodimer. This led to the identification of 8 proteins, 
divided into 2 sub-complexes and coined the GATOR complexes (106). GATOR1, 
comprised of DEPDC5, Nprl2 and Nprl3 associates strongly with Rag proteins compared 
to GATOR2, consisting of Mios,Seh1L, WDR24, WDR59 and Sec13, which only appears 
weakly in Rag protein immunoprecipitates (106). The reduction in expression of each 
complex surprisingly had varying results. When those proteins included in GATOR1 
were targeted with shRNA, mTORC1 became constitutively active and became resistant 
to AA withdrawal. In contrast, when the expression of GATOR2 components was 
reduced, mTORC1 activation in response to AAs was attenuated (106). These data 
therefore suggested opposing roles of the GATOR complex in mTORC1 activation. 
Inhibiting GATOR2, alongside concomitant reductions in GATOR1 expression, had no 
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effect on mTORC1 activity displaying a possible role for GATOR2 as an inhibitor of 
GATOR1 and as such explains GATOR2’s positive regulation of mTORC1 activity. 
The same group then displayed how GATOR1 functions as a GAP for RagA/B proteins, 
increasing GTP hydrolysis at its targets and causing the conversion to the GDP-bound 
(inactive) state (106). This displays how GATOR1 performs its inhibitory role toward the 
AA activation of mTORC1. Interestingly, mutations to this part of the mTORC1 are 
apparent in several cancers, where mutations to GATOR1 causes its inhibition and 
dysregulation of mTORC1 resulting in tumorogenesis (106). It therefore seems that 
GATOR1 acts as a negative regulator of mTORC1, primarily during nutrient starvation. 
Furthermore, a second GATOR complex acts as an inhibitor to GATOR1 during times of 
AA sufficiency. This would remove the inhibitory effects of GATOR1 on RagA/B, 
allowing mTORC1 to be recruited to the lysosome and become active.  
1.3.3.3 Sestrins 
In an attempt to further elucidate potential regulators of mTORC1, mass spectrometry 
analysis has been conducted in order to identify GATOR2-interacting proteins. This led 
to the identification of Sestrin2, which consistently appeared to be associated with 
GATOR2, along with Sestrin1 and 3, although these appeared at lower concentrations 
(107). Again, co-immunoprecipitation experiments were conducted in order to confirm 
these findings, which demonstrated that Sestrin2 immunoprecipitated with components 
of GATOR2 and vice versa.  Sestrin2-GATOR2 association seemed to occur in an AA 
dependent manner, with a stronger association observed under conditions of AA 
deprivation (107). Overexpression of Sestrin2 caused a significant blunting of S6K1Thr389 
phosphorylation and cell size congruent with its purported role as an mTORC1 inhibitor. 
Furthermore, the concomitant reduction in expression of Sestrin1 and Sestrin2 resulted in 
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elevated mTORC1 activity during AA starvation although the response to AA sufficiency 
was largely unchanged (107).  
Such data have been replicated in other investigations, where Sestrin2 was also identified 
as a GATOR2-interacting protein (111). Here, increased levels of Sestrin2 were shown 
to reduce the association between GATOR1 and GATOR2 complexes, leading to the 
increased GAP activity of GATOR1 to RagA/B, even whilst AAs levels are elevated. 
Moreover, Sestrin2 was not present on lysosomal membranes yet could control mTOR 
cellular localisation, through a mechanism which was GATOR1-dependent. Interestingly, 
another investigation found that Sestrin2 did not affect GATOR1-GATOR2 association 
however still inhibited mTORC1 activation in a GATOR-dependent manner (112). This 
suggests a need for further investigation regarding the effect of Sestrin proteins on the 
formation of the GATOR1/2 supercomplex. 
Recently, a leucine sensing role for Sestrin2 has been identified (108). The AA leucine is 
known to be the most potent activator of mTORC1, rapidly and transient elevating 
mTORC1 activity in many cell types (108, 113, 114). Wolfson et al. (108) elegantly 
displayed that the removal of leucine alone from HEK293 cells was sufficient to increase 
the association of Sestrin2 and GATOR2, thereby causing the activation of GATOR1. 
Furthermore, the re-addition of leucine rapidly reversed this effect, reducing Sestrin2’s 
binding to GATOR2 (108). These findings were also apparent for Sestrin1 but not 
Sestrin3 revealing a possible diverse regulation of this homologous set of proteins. 
Interestingly, it was then shown that leucine could bind directly to Sestrin1 and Sestrin2 
and that this binding was needed in order for mTORC1 to be activated in response to 
leucine exposure (108). Therefore, taken together, these data identify the Sestrin family 
of proteins, in particular Sestrin2, as a negative regulator of mTORC1. These proteins act 
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as inhibitors of GATOR2, removing its inhibitory effect on GATOR1 (possibly via 
decreased association) and increasing the GDP-loaded state of RagA/B. As the Rag 
heterodimer would then be inactivated, mTORC1 recruitment to the lysosome will no 
longer occur. Moreover, it seems the Sestrins can act as leucine sensors, binding to this 
AA directly and removing its inhibition on GATOR2. GATOR2 is then free to inhibit 
GATOR1, allowing RagA/B to be GTP-loaded and recruit mTORC1 to the lysosomal 
surface.  
1.3.3.4 Leucyl-tRNA Synthetase 
Leucyl-tRNA synthetase (LRS) is an enzyme which governs the charging of leucine to 
its corresponding tRNA ready for translation into a peptide chain at active ribosomes 
(115). In this canonical role, LRS is one of 9 total tRNA synthetases which form the 
multi-tRNA synthetase complex allowing efficient translation of new proteins in addition 
to controlling rRNA biogenesis and anti-apoptotic signalling (116). More recently, a 
potential role in AA sensing of LRS has been described. Firstly, through both 
immunofluorescent imaging and immunoprecipitation techniques, LRS was observed to 
associate with mTOR and RAPTOR at the lysosome, though only in the presence of 
leucine sufficiency (116). Subsequent reductions in LRS expression through the use of 
siRNA inhibited mTOR activity (S6K1Thr389), lysosomal recruitment of mTOR and 
overall cell size (116) suggesting LRS is implicated in AA induced mTOR signalling. 
Further to this it was revealed that LRS possesses GAP activity towards RagD, enabling 
the conversion to its GDP-loaded, active form (116). A second group have also recently 
displayed how the leucine-dependent increase in LRS-lysosome localisation serves to 
negatively regulate autophagy (117). Therefore it seems LRS positively regulates 
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mTORC1 activity through its GAP activity toward RagD, and this effect may negatively 
affect autophagy possibly through mTOR-dependent means.  
Similar investigations in yeast have replicated these findings, reporting LRS to associate 
with Gtr1, a GTPase yeast analogue, in a leucine dependent manner (118). Further, this 
association seems essential for full mTORC1 activation in response to leucine 
administration. Interestingly, Gtr1 is the analogue of RagA/B in human cells and as such 
this mechanism varies from that previously described (116, 118), where LRS affects the 
other component of the Rag heterodimer (RagD). This suggests that the LRS-
Gtr1(RagA/B) axis may not be conserved from yeast to eukaryotic cells, yet may have 
adapted to have an effect on a different component of the mTORC1 activation pathway. 
Adding further confusion to the potential role of LRS in mTORC1 activation is work 
from the Sabatini lab. This group have consistently found LRS to possess no GAP activity 
toward the Rag proteins (105, 106), and as such may not be implicated in leucine-induced 
mTORC1 activation. Most recently, it has been proposed that LRS may mediate it’s 
action on mTORC1 through the vesicle sorting protein Vps34, a potential AA sensor 
(119). This potential mode of action will be discussed in subsequent sections of this thesis.  
1.3.4 Growth Factor Activation of mTORC1 
It is well known, particularly in vitro, that growth factors activate mTORC1 and 
subsequently regulate cell size/growth (120). The intricate mechanism by which this 
activation occurs has been well documented, beginning at a cell’s plasma membrane and 
culminating at the lysosome where mTORC1 associates with its direct activator Rheb. 
Specifically, growth factors i.e. insulin/IGF-1 bind to their corresponding tyrosine kinase 
receptors on the cell membrane (121, 122). This causes the activation of the Class I 
phosphatidylinositol-3-kinase (PI3K) signalling pathway involving several kinase 
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enzymes, catalysing the conversion of phosphatidylinositol to PI 3,4,5-triphosphate 
(PIP3)  (122, 123). This compound then binds to AKT, allowing a conformational change 
in this protein’s structure revealing potential phosphorylation sites which govern AKT’s 
kinase activity (124). AKT can then be phosphorylated at two sites, AKTThr308 by 
phosphoinositide-dependent kinase 1 (PDK1) and AKTSer473 by PDK2 and integrin-
linked kinase (ILK) (124). Activated AKT is then able to phosphorylate downstream 
targets and initiate a two-fold effect on mTORC1 activity. Firstly, AKT can 
phosphorylate TSC2 at Thr1462 and Ser939, a process which was initially thought to 
inhibit the GAP activity of TSC2 toward Rheb (125). However more recent work suggests 
that the GAP activity is not affected by this, yet the cellular location of TSC2 is altered 
in response to this post-translational modification (92, 126). This results in the removal 
of TSC2’s association with Rheb, removing its GAP activity toward this protein and 
allows Rheb to become GTP-loaded. This allows Rheb to be active and bind to mTORs 
catalytic domain to enhance its kinase activity (81). 
The second effect of AKT kinase activity on mTORC1 is through a component of 
mTORC1, PRAS40. As previously discussed, PRAS40 inhibits the kinase activity of 
mTOR by blocking the substrate binding site of RAPTOR. AKT catalyses the 
phosphorylation of PRAS40Thr246, which has been shown to causes the dissociation of 
PRAS40 from mTORC1 (40, 48, 52). This will then clear RAPTOR’s substrate binding 
site, allowing S6K1 and 4EBP1 to associate with the complex and be phosphorylated by 
mTOR (40, 56). As such, AKT plays a dual role in mTORC1 activation in response to 
growth factors both through the increased association of mTOR with its direct activator 
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(Rheb) and the removal of the mTORC1 inhibitor PRAS40 from this complex. This 
complex signalling pathway is depicted in Figure 1.2. 
Figure 1.2. Regulation of mTORC1 by growth factors/amino acids. 
Insulin/growth factors bind to their corresponding receptor on the cell membrane, initiating a signalling 
cascade which, via PI3K and mTORC2, results in the phosphorylation and activation of AKT at Thr308 
and Ser473. AKT is then able to phosphorylate TSC2 at Ser939 and Thr1462, causing its translocation 
away from Rheb, lifting its GAP activity toward Rheb and allowing Rheb to become active in the GTP-
loaded state. This will then allow Rheb to bind to mTOR’s catalytic domain and activate mTORC1. 
Simultaneously, AKT phosphorylates PRAS40 at Thr246, removing it from its association with Raptor and 
allowing Raptor to bind mTORC1 substrates. A rise in intracellular amino acids (AAs) relieve the inhibition 
on GATOR2, allowing it to bind and inhibit GATOR1. This removes GATOR1’s GAP activity toward 
RagA/B and allow it to become GTP-loaded. Simultaneously folliculin is activated, exhibiting its GAP 
activity toward RagC/D and converting it to its active GDP-loaded state. At this time, the elevated 
intralysosomal AA concentrations activate ATPase which activates Ragulator to act as a scaffold for the 
active Rag heterodimer and express GEF activity toward RagA/B, aiding their conversion to the GTP-
loaded state. The Rag heterodimer then recruits mTORC1 to the lysosomal surface through binding to 
Raptor. This then places mTORC1 close to its direct activators, Rheb and phosphatidic acid, and an ample 
supply of AAs. 
1.3.5 AA activation of mTORC1 
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Another widely described pathway of mTORC1 activation in many eukaryotic cells is 
that of AA induced mTORC1 activation. This pathway centres on mTORC1 recruitment 
to the lysosomal membrane and includes many of the proteins/complexes described in 
previous sections of this chapter. Intriguingly, the processes by which AAs are initially 
sensed in cells are yet to be fully elucidated. As previously discussed, potential AA 
sensors including the Sestrins and LRS have been purported yet direct evidence for this 
role remains inconclusive. Several other enzymes are also alleged to be AA sensors i.e. 
Vps34 and MAP4K3 and these will be discussed in detail in later chapters of this thesis. 
Nevertheless, it is now well established that when there is an increase in intracellular 
AAs, several differing pathways converge to recruit mTORC1 to the lysosomal 
membrane where it is in close proximity to Rheb and PA as well as an abundant supply 
of free AAs. The GATOR complexes, GATOR1 and GATOR2, function in opposing 
roles to negatively and positively regulate AA activation of mTORC1 respectively. 
During times of low AA availability, GATOR2 is not associated with GATOR1, which 
is active and has GAP activity toward RagA/B (106). This stimulates the Rags intrinsic 
GTPase activity and keeps RagA/B in the inactive, GDP-loaded state (97, 106). Upon AA 
stimulation, GATOR2 is able to complex with GATOR1 and inhibit this complex, 
possibly through the removal of Sestrins, from GATOR2, by an association with leucine 
(106, 107, 111, 112). The inhibition of GATOR1 removes its GAP activity from RagA/B, 
reducing its GTPase activity and allowing a conversion back to the active GTP-loaded 
form. Simultaneously to this, and also affecting RagA/B, the v-ATPase-Ragulator-Rag 
protein axis is activated through and inside-out mechanism (29, 97, 98). Here, the v-
ATPase recognises an increase in intralysosomal AAs and causes the activation of the 
Ragulator to act as a scaffold for the Rag proteins. These proteins can then recruit 
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mTORC1 to the lysosome through binding with RAPTOR (97). Further, the Ragulator 
complex has a secondary role in which it possesses GEF activity toward RagA/B aiding 
in the conversion of this protein from the GDP- to the GTP-loaded state when GATOR1 
has been inhibited. The second half of the Rag heterodimer, comprised of RagC/D is also 
affected by AAs. The folliculin-FNIP2 complex becomes activated by AAs and possesses 
GAP activity towards RagC/D (105, 110). This means that under AA stimulation, 
folliculin activates the conversion of RagC/D from the GTP- to GDP-loaded state and 
combined with the effects of other GAPs and GEFs allows the Rag heterodimer to be 
fully active (RagA/BGTP-RagC/DGDP). mTORC1 is then recruited to the lysosomal surface 
where both Rheb and PA are able to bind with the catalytic and FRB domains of the 
mTOR protein respectively (83, 89, 103, 127, 128) and activate its kinase activity. 
Interestingly, enzymes which produced PA such as PLD1 are noted to elevate in activity 
when levels of AAs are high, therefore producing more of this direct mTOR activator (89, 
102, 103). This pathway of AA-induced mTORC1 activation is also depicted in Figure 
1.2. 
1.4 – mTORC1 activation in skeletal muscle 
1.4.1 Growth Factors/Hormones 
Both growth factors and hormones are noted to induce hypertrophy of muscle cells both 
in vitro and in vivo (120, 129, 130). Seminal work in C2C12 myotubes displayed that 
incubation with IGF-1 (10ng/ml) for 15 minutes elicited a substantial increase in 
S6K1Thr389 phosphorylation, an alteration which was subsequently blocked when 
rapamycin was co-incubated (120). This work suggested that IGF-1 stimulated the 
phosphorylation of S6K1 in an mTORC1 dependent matter. Furthermore, a second 
downstream target of mTORC1, 4EBP1, exhibited an upward gel shift suggesting an 
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increased phosphorylation status (120). The authors then demonstrated that expression of 
a dominant-negative form of the phosphatase SH2 domain containing inositol 5-
phosphatase 2 (SHIP2), which dephosphorylates AKT elicited a greater 
hyperphosphorylation of S6K1, in response to IGF-1, when compared to a scrambled 
vector (120). Therefore, it was apparent that in muscle cells, IGF-1 stimulates mTORC1 
through the canonical pathway. In subsequent studies, this group demonstrated that 48h 
of IGF-1 incubation elicited hyperphosphorylation of S6K1, an effect again blocked by 
rapamycin (121). Moreover, this effect inversely regulated atrophy-related genes (121), 
contributing to a shift toward cellular anabolism. Other reports also concur these findings, 
displaying that 2h IGF-1 exposure significantly elevated mTORC1 activity in C2C12 
myotubes, possibly via a mechanism dependent on Focal Adhesion Kinase (FAK) (131). 
Additionally, myotubes exposed to a stretching stimulus were noted to release IGF1, 
which in turn phosphorylated S6K1 (132). Overall, it is well established that growth 
factors such as IGF-1 can activate mTORC1 through the PI3K/AKT pathway, resulting 
in the phosphorylation, and subsequent removal of TSC2 from Rheb. 
Intriguingly, however, it has now become well established that growth factor mediated 
stimulation of mTORC1 is not a prerequisite for load-induced mTORC1 activation in 
vivo. Original research purported a paradigm by which mechanical strain induced an 
increase in IGF-1 production, which then activated the PI3K/AKT/mTOR axis, 
stimulating MPS and allowing hypertrophy to occur (133). Several models have since 
rejected this hypothesis, finding that the inhibition or genetic removal of IGF-1 signalling 
pathways did not diminish the activation of mTORC1 in response to mechanical stimuli 
(134-136). Furthermore, an elegant in vivo model in human skeletal muscle has echoed 
these findings. West et al. (137) utilised a unique study design where by participants 
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completed a single arm, unilateral resistance exercise bout either alone or following a 
heavy bilateral lower body resistance exercise bout. This produced two distinct systemic 
growth factor milieu, where significant elevations in systemic IGF-1 levels were only 
noted when the lower body exercise bout was completed (137). Interestingly, mTORC1 
activation and MPS were similar in response to each exercise bout suggesting systemic 
levels of growth factors did not govern the anabolic response of skeletal muscle. 
Therefore, it is apparent that although growth factors can activate mTORC1 through the 
PI3K/AKT/mTOR axis, they most likely do not play a significant role in vivo in human 
skeletal muscle. 
In addition to growth factors such as IGF-1, hormones are also known to activate 
mTORC1 (130, 138). Testosterone is considered the main ‘anabolic’ hormone and has 
been shown to initiate increases in mTORC1 signalling in vitro in as little as 5 minutes 
(138). Testosterone also elicits dose- (139) and time-dependent (130, 138) increases in 
mTORC1 activity and causes hypertrophy in vitro in L6 myoblasts (130) and isolated 
primary rat myotubes (138). Several studies have also investigated the mechanisms by 
which this stimulation of mTORC1/hypertrophy occurs. In rodent primary myotubes, 
testosterone administration for 60 minutes elicited 3-fold elevations in S6K1Thr389 
phosphorylation (138). Furthermore, incubation with testosterone for 12h caused 
significant hypertrophy, however both these effects did not occur in the presence of PI3K, 
AKT or mTOR inhibitors (138). These findings suggested that the effects of testosterone 
on muscle anabolism occurred through the PI3K/AKT/mTORC1 pathway, similar to 
many other growth factors. Other studies however, contradict these findings displaying 
that varying lengths of testosterone incubation stimulate rises in S6K1Thr389 
phosphorylation without concomitant elevations in AKT phosphorylation (130). These 
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authors suggested that testosterone may signal through extracellular signal-regulated 
kinase 1/2 (ERK1/2) as elevations in ERK1/2Thr202/Tyr204 phosphorylation occurred 
alongside changes in S6K1Thr389 phosphorylation upon testosterone administration. 
Furthermore, when testosterone was removed, the phosphorylation of both of these 
proteins returned rapidly to baseline. In agreement with these results, White et al. (139) 
noted increases in AKTSer473 phosphorylation only when testosterone concentrations of 
500nM were administered to C2C12 myoblasts, whereas lower concentrations (5nM & 
50nM) elicited significant elevations in ribosomal protein S6 (rpS6)Ser235/236 
phosphorylation, a common readout of mTORC1 activity. Here, however, the 
phosphorylation of downstream substrates of AKT (GSK3βSer9 & FoxO3aSer253) were 
observed to rise with lower testosterone concentrations suggesting earlier AKT activity 
may have been missed (139). Nevertheless, further research is needed in order to elucidate 
the full mechanism which underpins testosterone mediated mTORC1 activation, a 
process probably occurring through both AKT and ERK1/2 pathways. 
In vivo experiments have also examined the effects of testosterone on mTORC1 activity 
in skeletal muscle. An elegantly designed study in rodents utilising 42 days of castration 
significantly reduced AKTSer473, S6K1Thr389 and 4EBP1Thr37/46, occurring alongside 
reductions in both fibre cross-sectional area (CSA) and MPS (139). This implicated a role 
for systemic testosterone in the maintenance of muscle anabolism and mass and again 
suggested testosterone may act through the canonical growth factor signalling pathway. 
In humans however, systemic levels of testosterone do not seem to be important for load-
induced skeletal muscle anabolism. The work of West et al. (137), as described earlier, 
created an exercise protocol which elicited two varying systemic ‘anabolic’ milieu 
whereby unilateral bicep exercise, conducted after lower-body resistance exercise, 
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occurred in the presence of elevated levels of growth factors and testosterone. In contrast, 
bicep exercise conducted alone occurred with no elevated levels of these factors yet 
displayed no differences in skeletal muscle anabolism (mTORC1 signalling and MPS) 
when compared to the bicep and lower body exercise trial (137). Moreover, when this 
resistance exercise paradigm was extended to a long-term training study, no differences 
in skeletal muscle hypertrophy, between the conditions, was observed (140). This 
therefore suggested that physiological rises in systemic hormone levels do not contribute 
to skeletal muscle anabolism in humans. It is apparent however, that alterations in 
hormone levels outside of the physiological range do affect skeletal muscle anabolism as 
previously purported (129, 141-143).  
1.4.2 AAs 
As previously discussed, AAs possess an ability to both transiently and potently activate 
mTORC1 to stimulate protein translation and cell growth in various eukaryotic cell lines 
(29, 97, 98, 107, 122). Much research has since focussed on the translation of this research 
into skeletal muscle both in vitro and in vivo in order to elucidate the signalling pathways 
by which AAs stimulate skeletal muscle hypertrophy. Correspondingly, AA solutions, in 
particular leucine, have been consistently observed to activate mTORC1-dependent 
signalling pathways (113, 144-148), often in a dose-dependent manner (144, 145) in 
C2C12, L6 and human myotubes. Interestingly, in several investigations, leucine is 
reported to be the only AA able to initiate a greater than 2-fold increase in S6K1Thr389 
phosphorylation in vitro (113, 144, 145). Furthermore, AAs do not elevate AKTSer473 
phosphorylation (113) suggesting AAs activate mTORC1 via a pathway other than that 
of growth factors, an observation concurrent with that noted in other cell lines (29, 30, 
97, 98, 122). Currently, however, no further investigations into the precise mechanisms 
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by which mTORC1 is activated by AAs in skeletal muscle cell lines has been conducted. 
Although it is probable that these mechanisms will be similar to those discovered by the 
elegant work from the Sabatini laboratory (29, 30, 42, 97, 98, 104-108), research 
confirming this is required. 
The anabolic potential of AAs toward mTORC1 and its associated pathways have also 
been reported in vivo in both rodent and human skeletal muscle. In rodents, the infusion 
of an AA mixture (149), or the ingestion of protein (150), elicit skeletal muscle mTORC1 
activation as measured by 4EBP1Thr37/46 and S6K1Thr389 phosphorylation. Following this, 
several other laboratories repeated these results showing that various methods of 
elevating skeletal muscle AA levels caused an increase in mTORC1 activity (151-153). 
These effects were again observed to be primarily driven by leucine (153-155) and occur 
in a dose-dependent manner (153) as reported in vitro. Rapamycin administration 
attenuated the increase in mTOR-target phosphorylation, confirming AAs exert their 
anabolic effects on these targets via mTORC1 (151). Therefore, these data confirm that 
AAs can potently activate mTORC1 in rodent skeletal muscle.  
In humans, the positive and dose-dependent effects of AAs are regularly reported (24, 
114, 156-162), however in some instances dose-dependent relationships are not apparent 
(163). Seminal work from the laboratory of Eugene Barrett utilised AA infusions in 
human participants to understand their effects in skeletal muscle (164, 165). Here, 
infusions of AAs (165) or branched chain AAs (BCAAs) alone (164) elicited significant 
upward gel shifts in both 4EBP1 and S6K1 proteins, indicative of greater phosphorylation 
status. Interestingly, these elevations occurred with no change in AKTSer473 
phosphorylation (165), resonating the notion that AAs activate mTORC1 in a growth 
factor-independent manner (30). Further work by several prominent laboratory groups 
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exhibited how the simple ingestion of protein or AAs has a very similar effect of 
mTORC1 activity to that of infusions (157, 160, 166-168). In human skeletal muscle, 
leucine is again observed to be the most potent activator of mTORC1, with the ingestion 
of a leucine-enriched essential AA supplement prompting rapid, transient and significant 
increases in the phosphorylation of downstream mTORC1 targets (166). Furthermore, the 
addition of leucine to lower amounts of ‘whole protein’ sources can rescue 
phosphorylation of some mTORC1 targets to comparable levels to those noted with 
higher ‘whole protein’ doses (114). Through the unique use of rapamycin administration 
in humans, Dickinson et al. (24) displayed a complete attenuation of mTORC1-dependent 
signalling following essential AA ingestion, reiterating the concept that these proteins are 
phosphorylated in a mTORC1-dependent manner. In summary, it is well reported and 
accepted that AAs, and in particular leucine, can activate mTORC1-dependent signalling 
pathways in vivo in human skeletal muscle. 
1.4.3 Mechanical Loading 
One particular anabolic stimuli known to activate mTORC1 in skeletal muscle is that of 
mechanical loading. This paradigm is comparatively understudied in vitro as it does not 
reflect a valid physiological stimulus in the organs from which many cell lines are 
derived. Nonetheless, in skeletal muscle, the primary organ controlling locomotion, this 
stimulus occurs regularly in varying intensities and frequencies. Resistance exercise has 
garnered much attention in relation to mTORC1 as periodic repetitions of this exercise 
format often result in skeletal muscle hypertrophy (140, 169-179). In accordance with 
this, acute bouts of mechanical stretch, electrical stimulation and resistance exercise 
consistently elevates mTORC1-related signalling in rodent and human skeletal muscle 
(180). As previously discussed, the initial hypothesis of how mTORC1 was activated in 
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response to mechanical loading centred on an increase in circulating growth factors (132, 
133). However, through the elegant use of the PI3K inhibitor wortmannin (134), genetic 
models (135) and unique resistance exercise models (137, 140), mTORC1 activation 
following a load stimulus is now believed to occur independently of growth factors and 
AKT signalling. These observations led to further investigations into the precise 
mechanisms by which mechanical loading activates mTORC1. 
Pivotal work conducted in the Hornberger laboratory utilised immunofluorescent 
microscopy to study mTORC1 activation (90). Surprisingly, an event that occurs in 
response to growth factors, the removal of TSC2 from Rheb, also occurred following 
eccentric contractions in mouse skeletal muscle (90). This therefore suggested that 
proteins other than AKT could also elicit TSC2 removal and subsequent elevations in 
GTP-bound Rheb. Moreover, eccentric contractions were observed to increase the 
colocalisation of mTOR and a marker of the lysosome (LAMP2) (90), an event commonly 
reported to occur due to an elevation in AA availability (29-31, 97, 98, 104, 122). This 
notion may in fact be true in this context as resistance exercise is known to increase 
intracellular AA levels either through increased autophagy/breakdown or AA influx 
(181). Nevertheless, these results suggested a new mechanism whereby a currently 
unknown kinase phosphorylated TSC2 within its RxRxxS*/T* consensus motif (90), 
removing it from its association with Rheb and allowing Rheb to become GTP-loaded 
and active. Simultaneously mTORC1 may be recruited to the lysosomal membrane, 
where it can associate with Rheb, either due to an increase in intracellular AAs or by a 
hitherto undefined mechanism specific to skeletal muscle. Further work by this laboratory 
utilising inducible skeletal muscle-specific knockout models for both TSC2 and Rheb 
proteins identified 6 phosphorylation sites on TSC2 that were regulated by eccentric 
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contractions, the majority of which had not been reported previously (182). These 
phosphorylation sites were also distinct from those which had been identified in the 
canonical growth factor pathways adding credence to the notion that mechanical 
activation of mTORC1 occurs independently of IGF1/PI3K/AKT. All 6 of these 
phosphorylation sites were then shown to be required for mTORC1 activation following 
eccentric contractions, an effect that was no longer noted when TSC2 was mutated to 
become partially phospho-defective (182). This data would therefore suggest that it is the 
combination of TSC2 phosphorylation at these sites which stimulates its removal from 
Rheb following contraction. Intriguingly, the effects of eccentric contractions on 
mTORC1 activity were only reduced by ~50% in either genetic model (182) suggesting 
pathways other than the TSC2-Rheb axis may contribute to mTORC1 activation in this 
scenario. 
A possible candidate for this contribution is the second mTOR direct activator, PA. PA 
concentrations in rodent skeletal muscle are observed to rise following eccentric 
contractions (89, 102, 103), and this occurs upstream of mTORC1 itself (89). PA is 
believed to accumulate at the lysosome where it can be in close proximity to mTORC1, 
allowing efficient activation through binding of the FRB domain (103). In vitro, PA 
exhibits a dose-dependent relationship with S6K1Thr389 phosphorylation in C2C12 
myoblasts and exerts its effect in an insulin/growth factor independent manner, 
suggesting PA alone activates mTORC1 (89). The inhibition, or genetic deletion, of the 
two main enzymes which produce PA, PLD1 and DGKζ, significantly reduces S6K1Thr389 
phosphorylation in response to eccentric contraction or stretch (89, 102). Again, in 
agreement with previous data, this inhibition/deletion did not completely abolish the 
effects of mechanical load on mTORC1 activation, confirming the belief that multiple 
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pathways regulate mTORC1 following contraction (102, 182). Therefore it seems that in 
response to mechanical load/muscle contraction TSC2 becomes phosphorylated and is 
removed from Rheb, Rheb’s intrinsic GTPase activity is no longer activated and then 
becomes GTP-loaded and active. Simultaneously, PA production is stimulated, now 
believed to be mainly catalysed by DGKζ (102) , and accumulates at the lysosome. 
mTORC1 is then recruited to the lysosome, most likely as a result of an elevation in 
intracellular/intralysosomal AAs, where it is in close proximity to both of its direct 
activators. Even though this mechanism is now well characterised in rodent skeletal 
muscle, research regarding this topic in humans is scarce and as such requires further 
investigation.  
1.5 – Downstream effects of mTORC1 activation  
Once activated, the mTORC1 kinase complex is able to phosphorylate a myriad of 
downstream targets, many of which are encompassed in the areas of protein translation 
and autophagy. The next section of this thesis will describe how mTORC1 affect both of 
these cellular mechanisms, focussing on how these apply to skeletal muscle plasticity. 
1.5.1 Stimulation of protein translation 
1.5.1.1 S6K1 
The most characterised consequence of mTORC1 activation is the stimulation of protein 
translation. This effect is mediated through the phosphorylation of mTORC1’s most well-
known substrates, S6K1 and 4EBP1, which as previously discussed, are often used as 
readouts of mTORC1 activity (25). When phosphorylated, specifically at Threonine 
residue 389, S6K1 kinase’s activity is elevated. S6K1 has several downstream targets 
which all contribute toward efficient protein translation. Firstly, S6K1 will phosphorylate 
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rpS6 at several different serine residues (including Ser235/236 and Ser240/244) (25, 183). 
The specific function of this phosphorylation was initially believed to allow enhanced 
recruitment of 5’TOP mRNAs to ribosomes (183). This was concluded as S6 
phosphorylation correlated highly with the translation of these mRNAs (183). More 
recently, however, this mechanism has been questioned as mice expressing a phospho-
deficient form of rpS6 are still able to alter the translation of 5’TOP mRNAs (184). 
Interestingly, a physiological role for rpS6 phosphorylation remains elusive, with some 
reports even suggesting it negatively regulates protein synthesis (184). Nevertheless it 
still serves as a valid and accurate readout of S6K1 activity (25).  
A second target of S6K1’s kinase activity is eIF4B, a translation pre-initiation factor. This 
protein is phosphorylated on Serine residue 422 (185), an event which seems to positively 
regulate translation. When phosphorylated, eIF4B is able to associate with 
eIF4G/eIF4A/eIF3, a complex which recruits the 40S ribosomal subunit to mRNA strands 
(186). Here eIF4B activate the helicase activity of eIF4A, which acts to unwind the 
mRNA’s secondary structure permitting more efficient binding of the ribosome to mRNA 
strands (187). Ribosomal footprinting assays have been utilised to confirm that eIF4B is 
needed for the translation of mRNAs containing a secondary structure (188), whilst RNA 
interference targeting eIF4B inhibits the translation of these mRNAs (189). Furthermore, 
recombinant, unphosphroylated forms of eIF4B are unable to enhance translation, 
suggesting eIF4Bs activity is dependent on its phosphorylation status (188). Therefore, it 
can be postulated that this is a mechanism by which mTORC1 elicits S6K1-dependent 
effects on protein translation. 
The translation elongation factor eEF2 is also regulated in an mTORC1 dependent 
fashion. When mTORC1 is activated, the phosphorylation of eEF2 at Thr56, an inhibitory 
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site, is reduced (190). This reduced inhibition allows eEF2 to bind with ribosomes and 
accelerate translation elongation (190-192). The phosphorylation of eEF2 at this site is 
governed by eEF2 kinase, which in turn can be phosphorylated, and inhibited, at 3 
different sites in times of high mTORC1 activity (193-195). Of note, one particular 
phosphorylation site on eEF2 kinase, Ser366, is believed to be phosphorylated by S6K1 
(193). Following this phosphorylation eEF2 kinase is inactivated and eEF2 is free to bind 
to ribosome and enhance protein translation (190). Therefore, characterisation of the 
unknown kinases controlling the phosphorylation of the further phosphorylation sites on 
eEF2 kinase will provide extra insight into the regulatory role mTORC1 demonstrates 
towards protein translation. 
1.5.1.2 4EBP1 
The second direct target of mTORC1 implicated in protein translation is 4EBP1, however, 
unlike S6K1, mTORC1-dependent phosphorylation of this target exhibits inhibitory 
effects (196). 4EBP1 is a binding protein of eIF4E, a translation initiation factor whose 
role involves the recruitment of the 40s ribosomal subunit to the 5’ end of nuclear 
transcribed mRNA strands (197). The binding of 4EBP1 to eIF4E is inhibitory as it 
competes for the binding site at which eIF4G associates with eIF4E allowing the 
recruitment of the 40S ribosomal subunit to mRNA strands (198). mTORC1-dependent 
phosphorylation of 4EBP1 occurs at 4 different serine residues, which are phosphorylated 
in a hierarchical manner and are all required for the removal of 4EBP1 from eIF4E (196, 
199). Initially, serine residues 37 and 46 are phosphorylated (196), acting to prime 4EBP1 
for subsequent phosphorylation of Ser65 and Ser70 and removal of 4EBP1 from eIF4E 
(196, 198). These phosphorylation sites are noted to be in close proximity to the site at 
which 4EBP1 binds to eIF4E, and as such may create electrostatic repulsion of eIF4E due 
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to the additional phosphate molecules (25, 200).  Hereafter the binding site for eIF4G is 
unblocked and the 40S subunit can be recruited to the mRNA strand where translation 
can be initiated (199). 
1.5.1.3 Other Targets 
Several other proteins display phosphorylation events which seem to be mTORC1-
dependent. The two proteins which comprise the eIF4G scaffolding complex, eIF4GI and 
eIF4GII, become phosphorylated on 3 different serine residues (1148, 1188 & 1232) 
when mTORC1 activity is high (201). The precise mechanism and role of this 
phosphorylation is unclear, however it most likely causes a conformational change in 
these proteins which allows more efficient construction of the ribosomal pre-initiation 
complex (201). Therefore, eIF4G is the third component of the pre-initiation machinery 
which is regulated by mTORC1 activity. The most intriguing of potential mTORC1 
targets is PP2A, a phosphatase which catalyses the dephosphorylation of mTORC1 
substrates (202). mTORC1 is observed to phosphorylate this phosphatase in vitro, 
seemingly inhibiting its activity and preventing the dephosphorylation of S6K1 and 
4EBP1 (200). Thus mTORC1 may exert positive effects on substrate phosphorylation via 
a two-fold mechanism whereby substrates are phosphorylation occurs directly by 
mTORC1 itself and dephosphorylation is reduced indirectly via inhibition of PP2A. The 
positive effect of mTORC1 on protein translation seems to predominantly occur through 
enhancing the recruitment of the 40S subunit to mRNA, via the efficient construction of 
the pre-initiation complex, whilst also enhancing translation elongation by inhibiting 
eEF2 kinase. This intricate mechanism of the regulation of protein translation by 
mTORC1 is depicted in Figure 1.3. 
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1.5.1.4 mTORC1-dependent protein translation in skeletal muscle 
As previously discussed, mTORC1 is a popular topic of investigation in skeletal muscle 
due to its role in augmenting cellular growth potentially contributing to hypertrophy. 
Therefore, the downstream effects of mTORC1 are regularly measured in response to 
anabolic stimuli in this tissue. Mechanical loading and AA ingestion are known to elevate 
the phosphorylation of downstream mTORC1 substrates in both rodent and human 
skeletal muscle (156, 160, 162, 166, 169, 176, 178, 203-207). For example, the 
phosphorylation of both S6K1 (23, 24, 162, 166) and 4EBP1 (24, 166) is elevated 
transiently following contraction and/or feeding, although the extent of this 
phosphorylation is not always congruent between the two substrates (23, 24, 162). In 
addition, the phosphorylation levels of differing 4EBP1 residues often do not align (208), 
possibly due to the hierarchical fashion in which this protein is phosphorylated and the 
inability to measure rapid perturbations in phosphorylation in skeletal muscle. 
Downstream of S6K1, rpS6Ser235/236 & rpS6Ser240/244 phosphorylation is a measure often 
utilised by muscle physiologists as a readout of S6K1 activity (205, 209), and is noted to 
significantly increase in response to various muscle loading and feeding protocols (167, 
205, 209-212). Translation elongation, measured indirectly through the phosphorylation 
of eEF2, has also been shown to be altered in response to muscular contraction and/or 
protein feeding (23, 162, 166, 208, 213). Therefore, it is apparent that the downstream 
effects of mTORC1, on proteins implicated in protein translation, extend to skeletal 
muscle and allow valid measurements of mTORC1 activity in this tissue.  
The culmination of these signalling pathways, protein translation, is also regularly 
measured in skeletal muscle via the use of stable isotope methodology (22). Here, the 
infusion of an AA with a higher mass, due to increased neutrons within its nucleus, than 
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its regular form produces a scenario whereby the incorporation of this AA into newly 
synthesised proteins can be measured using mass spectrometry (22, 214). Comparing the 
incorporation of this AA between time points can then be used to infer the amount of 
protein translation within a given tissue in this timeframe, a paradigm referred to as 
fractional synthesis rate (FSR) (215). Early studies displayed that mixed muscle FSR was 
enhanced by an acute bout of mechanical loading (18, 216-218), and this effect remained 
for 36-48h (18, 218), albeit in a small sample size. Since reporting these seminal findings, 
research conducted in larger subject populations has replicated these findings in specific 
functional fractions of human skeletal muscle (137, 162, 206, 213, 219, 220). 
Specifically, acute bouts of resistance exercise elicit large elevations in MPS/FSR in the 
initial recovery period (up to 6h) (137, 219, 221-223), decreasing progressively and 
returning to baseline values by 24-48h post-exercise, dependent on training status (18, 
218, 224). Oral ingestion of the mTORC1 inhibitor, rapamycin, prior to a resistance 
exercise bout completely abolished the post-exercise augmentation of MPS/FSR in 
human skeletal muscle (23), providing direct evidence that mTORC1-dependent 
signalling is required for resistance exercise mediated increases in protein translation. 
AAs and whole proteins are also known to stimulate MPS/FSR. Early studies utilised 
intravenous AA infusions to study these effects, finding that these infusions can raise 
mixed muscle FSR by up to 100% (20). Later research then suggested that AA-stimulated 
increases in FSR were associated with increased mTORC1 signalling (157, 166, 223, 225-
229). Furthermore, this enhancement of FSR is often seen to occur dose-dependently (12, 
163) before arriving at a ‘breakpoint’ where FSR is maximally stimulated and greater 
protein intake will have no effect (230). This point has recently been coined the ‘muscle-
full’ effect, as time at which muscle cells reach their maximum capacity of intracellular 
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AAs (160, 231).  Of the 20 proteinogenic AAs found in eukaryotes, the nine EAAs are 
believed to be the main drivers of MPS (232). Indeed, ingestion of a combination of only 
EAAs stimulates increases in both mTORC1 signalling and MPS/FSR (159, 162, 206, 
208, 232-234). In particular, the BCAAs, leucine, isoleucine and valine, seem to 
contribute considerably to the effect of EAAs on muscle protein translation (208, 235). 
Leucine itself has been suggested as the most potently anabolic BCAA and, as previously 
discussed, can increase mTORC1 related signalling when ingested alone (162, 208). 
These effects translate to FSR measurements where leucine ingestion alone significantly 
elevates rates of MPS (162, 208). However, these elevations are of lower magnitude 
compared to those reported with essential AA or whole protein ingestion (162, 208). This 
led to the hypothesis that leucine acts to stimulate FSR/MPS, however, the other EAAs 
are needed to act as substrates in this process (114). To this end, the addition of leucine 
to lower amounts of whey protein rescues FSR to a similar level to that seen when higher 
amounts of whey protein are ingested (114). Rapamycin ingestion alongside EAAs 
blocked increases in FSR/MPS (24), reaffirming the notion that MPS responses to 
anabolic stimuli are governed by mTORC1. 
Interestingly, the combination of these two anabolic stimuli are often observed to elevate 
rates of FSR over and above those witnessed when either practice is completed in 
isolation (12, 20, 220, 221, 236). This synergistic effect of mechanical loading and protein 
ingestion is in fact the only method by which NPB can become positive, as the large rise 
in MPS exceeds the exercise-induced rise in MPB (20). When these practices are 
completed regularly over a sustained period of time, skeletal muscle hypertrophy occurs 
to a greater extent than when resistance exercise is completed without protein 
supplementation (170, 171, 237-239). In addition to this synergism, a single bout of 
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resistance exercise seems to ‘sensitise’ the muscle to AA intake for up to 48h post-
exercise (224). Here any protein ingestion enhances rates of FSR to a greater extent than 
when ingested at rest, although the extent to which rates are stimulated decrease 
progressively throughout this timeframe (224). The molecular basis for these synergistic 
effects is most likely through the divergent mechanisms by which each stimuli can 
activate mTORC1 kinase activity. As previously discussed, mechanical load/resistance 
exercise elicits an increase in the phosphorylation of TSC2 within its RxRxxS*/T* 
consensus motif, removing it from its association with Rheb/the lysosome and allowing 
Rheb to become GTP-loaded (90, 182). Production of PA also increases through 
enhanced activity of DGKζ, and possibly PLD1, and associates with the lysosome (89, 
102, 103). The simultaneous ingestion of AAs/protein elevates 
intralysosomal/intracellular AAs, activating the v-ATPase/Ragulator/Rag complex, 
recruiting mTORC1 to the lysosome (29, 97, 98). mTORC1 is therefore in closer 
proximity to its direct activators and an abundance of AAs, the substrates for the process 
of MPS, becomes active and stimulates protein translation. Completion of either activity 
alone will only initiate portions of the process and therefore the stimulation of protein 
translation will be lower. Thus, it can be concluded that anabolic stimuli enhance protein 
translation in human skeletal muscle and this happens in an mTORC1-dependent manner, 
most likely through the downstream mechanisms discussed.   
1.5.2 Repression of autophagy 
1.5.2.1 ULK1 & Atg13 
Recent advances in the field of mTORC1 signalling have discovered that mTORC1 is 
able to directly inhibit autophagy. The first complex which mTORC1 is known to affect 
in this process is the Unc-like kinase 1 (ULK1) complex, comprised of the kinase ULK1 
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bound to 3 regulatory subunits, Autophagy related protein 13 (Atg13), Atg101 and focal 
adhesion kinase family interacting protein of 200 kD (FIP200) (240). The action of this 
complex when active is to phosphorylate downstream targets, in particular Beclin1 (240, 
241), which in turn cause the nucleation of newly formed phagophores (241). mTORC1 
is believed to phosphorylate two components of the ULK1 complex, ULK1 itself at serine 
residues 637 and 757 (242, 243) and the regulatory subunit Atg13 at Ser258 (244). The 
addition of phosphate groups to these particular residues on ULK1 elicits a 
conformational change to this protein such that it can no longer associate with AMPK 
(243), which normally phosphorylates and activates ULK1 under nutrient-deplete 
conditions (242). Indeed, under nutrient sufficient conditions the phosphorylation of 
ULK1Ser757 is observed to rapidly increase, whereas the phosphorylation of this kinase at 
AMPK-specific sites is markedly reduced (242). The removal of this potential activation 
reduces ULK1s ability to phosphorylate Beclin1 and initiate phagophore nucleation.  
The second substrate of mTORC1 in the ULK1 complex, Atg13, is also phosphorylated 
following serum-stimulation in MEF cells (244). This phosphorylation event reduces 
ULK1 kinase activity and is regulated in an mTORC1-dependent manner (244). The 
precise mechanism by which Atg13Ser258 phosphorylation is believed to inhibit ULK1 
kinase activity is through a reduction in ULK1s translocation to locations of need (244). 
Thus, ULK1 is no longer able to move to the cellular locations where its downstream 
substrates reside. Interestingly, the phosphatase PP2A has been shown to dephosphorylate 
ULK1 at its mTORC1-specific site (245), relieving this inhibition during starvation and 
allowing ULK1 to associate with AMPK. As previously mentioned, when nutrient levels 
are high, PP2A is phosphorylated by mTORC1 causing its inhibition. Therefore, it seems 
mTORC1 also represses autophagy induction by a dual mechanism whereby the 
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phosphorylation of ULK1 is directly affected and its dephosphorylation is indirectly 
inhibited, similar to the mechanism noted in the stimulation of protein translation. In 
summary, mTORC1 acts to reduce the kinase activity of the ULK1 complex which 
impacts autophagy induction through a reduction in phagophore nucleation.  
Figure 1.3. mTORC1-dependent regulation of protein translation 
When mTORC1 is activated, this kinase complex phosphorylates several downstream targets to elevate 
protein translation. mTORC1 directly phosphorylates S6K1 at Thr389, activating this kinase. S6K1 then 
phosphorylates 3 downstream targets, the first of which is ribosomal protein S6 which becomes 
phosphorylated at Ser235/236 and Ser240/244, although the function of this phosphorylation remains 
unknown. S6K1 also phosphorylates eIF4B at Ser422, allowing this initiation factor to elevate eIF4A’s 
helicase activity to elevate the translation of mRNA strands with a secondary structure. The final target of 
S6K1 is eEF2 kinase which becomes inhibited, alleviating its inhibition of eEF2 and enhancing translation 
elongation. The second target of mTORC1 is 4EBP1 which is phosphorylated, and inhibited, at 4 sites. This 
removes 4BP1’s inhibition of eIF4E and allowing the recruitment of the 40S ribosomal subunit to mRNA 
strand. mTORC1 can also phosphorylate eIF4G, a component of the pre-initiation complex, at 3 sites which 
allows the more efficient construction of this complex. Finally, mTORC1 phosphorylates the phosphatase 




The second autophagic complex which is directly inhibited by mTORC1 kinase activity 
is the Vps34 complex, which is comprised of 4 proteins, Vps34, Vps15, Beclin1 and 
Atg14 (246). Vps34 is a PI3Kinase which directly phosphorylates phosphatidylinositol 
to generate phosphatidylinositol-3-phosphate (PI3P) (247), a compound which can 
control vesicle trafficking (248). Further research into the function of PI3P has implicated 
it as an essential component in autophagy induction (246). This PI3Kinase has been 
implicated in several differing, and in some cases opposing, cellular processes and as such 
it is now believed that the other components of each Vps34 complex direct it activity 
toward differing pathways (249). In the autophagic complex, Atg14 seems to be of 
specific importance to Vps34-dependent autophagy regulation (249). A regulatory role of 
mTORC1 toward the complex was first revealed by the finding that exposing MEF cells 
to rapamycin elevated the activity of this specific Vps34 complex (250). Results from 
several in vitro assays suggested that mTORC1 was in fact regulating Atg14 specifically. 
Mass spectrometry analysis then confirmed this notion, finding 5 residues on the Atg14 
peptide chain which were directly phosphorylated by mTORC1 (250). When these sites 
were mutated to block phosphorylation mTORC1 could no longer inhibit Vps34-
dependent PI3P production in vitro. HEK293 cells expressing phospho-deficient Atg14 
had greater autophagic flux under nutrient-rich conditions (250), confirming the 
inhibitory role mTORC1 would normally exert at these times. Thus mTORC1 can directly 
affect another site of autophagy induction, alongside its inhibitory role toward the ULK1 
complex. Interestingly, as the ULK1 complex can also phosphorylate Beclin1 (241), a 
component of the autophagic Vps34 complex, it seems mTORC1 also exerts an indirect 




The final mechanism by which mTORC1 can inhibit autophagy is at the gene 
transcription level. Transcription factor EB (TFEB) is a transcription factor which 
regulates the expression of a variety of mRNAs involved in both autophagy and lysosomal 
biogenesis (251). It was recently displayed that mTORC1 can directly phosphorylate this 
transcription factor at Ser211 (252, 253). The action of this phosphorylation event is 
inhibitory, sequestering TFEB to the cytoplasm via an association with 14-3-3 binding 
proteins (252). Here TFEB is then unable to associate with DNA and elevate gene 
transcription. Upon nutrient withdrawal, TFEB is rapidly dephosphorylated and localises 
to the nucleus (252). Intriguingly, TFEB also controls the transcription of several proteins 
implicated in mTORC1 activation including RagD and certain components of the v-
ATPase (254, 255). This suggests a potential feedback mechanism which reduces the 
transcription of mTORC1-related genes when this kinase complex’s activity is elevated. 
Nevertheless this is a third intricate mechanism by which mTORC1 inhibits autophagy, 
whilst simultaneously elevating protein translation. 
1.5.2.4 mTORC1-dependent autophagy inhibition in human skeletal muscle 
The effect of anabolic stimuli on autophagy regulation in skeletal muscle has begun to 
become a more popular tropic of research in recent times. Several investigations have 
studied this paradigm, however results remain equivocal. Initial research from the 
Rasmussen laboratory (256) reported that an acute bout of resistance exercise increased 
autophagy for at least 24 hours post-exercise. Specifically, the conversion of microtubule-
associated proteins 1A/1B light chain 3bI (LC3bI) to LC3bII, indicative of autophagy 
induction, was reduced for this entire period which is suggestive of reduced 
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autophagasome formation (256). Another study found that LC3bI protein expression was 
reduced at 1 and 4h following a resistance exercise bout, depending on protein 
supplementation (34). The levels of LC3bII protein were not reported in this study making 
conclusions about autophagy initiation challenging. Interestingly, this seems to be the 
only investigation to study mTORC1-dependent ULK1Ser757 phosphorylation in human 
skeletal muscle. Here, phosphorylation at this site was increased at 1h following exercise 
only when protein was ingested following the bout (34). This suggests there may be a 
threshold of mTORC1 activation needed before ULK1 phosphorylation occurs. 
A combination of resistance and endurance exercise has also been observed to elicit 
changes in some markers of autophagy in human skeletal muscle. Specifically, this 
concurrent exercise bout, followed by protein ingestion caused attenuation in LC3bII 
protein levels at 4 hours post-exercise, whilst LC3bI expression remained similar 
suggesting blunted autophagy induction (257). Again, this may have been partly driven 
by an increase in mTORC1-associated autophagy inhibition as mTORC1 activation is 
known to increase in response to such exercise bouts (213). Moreover, the amount of 
nuclear TFEB protein expression was decreased 8h following this exercise bout (257), 
suggesting possible cytoplasmic sequestration of this protein due to mTORC1-driven 
phosphorylation at TFEBSer211. This notion was not reflected in cytoplasmic TFEB levels 
which were largely unchanged and even decreased slightly at the same time point (257). 
Therefore, as little research has been conducted into this area, and results are 
contradictory, it is difficult to draw full conclusions at this time. 
1.6 - Novel Regulators of mTORC1 
The mechanisms by which mTORC1 is activated by anabolic stimuli, and how mTORC1 
affects its downstream targets, have been well characterised, principally in vitro. 
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However, there still remain certain gaps in the knowledge of this field. In particular, the 
mechanisms by which both AAs and mechanical loading are ‘sensed’ and their signals 
propagated to mTORC1 have not yet been elucidated, especially in skeletal muscle (30, 
31, 90, 92, 182, 258). The next section of this thesis will discuss three potential novel 
regulators of mTORC1 activation which are beginning to garner attention. Furthermore 
the investigation of these mechanisms in human skeletal muscle will be the focus of this 
thesis hereafter. 
1.6.1 Lysosomal Trafficking 
As discussed, several cell and rodent-based investigations have suggested that the 
recruitment of mTORC1 to the lysosome is a critical factor in mTORC1 activation in 
response to elevated AA availability (97, 98, 104, 105). However, more recently, a role 
for the translocation of mTORC1-lysosome complexes has been proposed as an 
additional layer of mTORC1 activation (33). Korolchuk et al. (33) first proposed this 
hypothesis following the observation that physiologically relevant AA deprivation, 
milder in nature to that previously utilised (29, 97), did not result in mTOR disassociation 
from the lysosome yet reduced mTORC1 activity in HeLa cells. This notable observation 
suggested that under physiological nutrient-deprived conditions, i.e. the post-absorptive 
period in human skeletal muscle when autophagy and protein breakdown increase to 
maintain intracellular AA concentrations (38, 259), mTORC1 activity may not be 
governed by lysosomal association. Following this, the authors reported an association 
between the number of cells with predominantly peripheral lysosomes, measured through 
immunofluorescence microscopy, and the extent of mTORC1 activation following AA 
stimulation. This notion was then tested more directly through the use of nocodazole, a 
drug which depolymerises microtubules and prevents lysosomal movement. When this 
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drug was administered to cells, the response of mTORC1 activity to nutrient 
reintroduction following deprivation was abolished (33). Further investigation through 
the use of siRNA targeting a protein implicated in lysosomal movement, ADP-
ribosylation factor-like protein 8B (ARL8B), confirmed these observations. The knock 
down of this protein fixed lysosomes close to the nucleus of HeLa cells, and prevented 
S6K1Thr389 phosphorylation irrespective of intracellular AA levels (33). Moreover, when 
this protein was overexpressed in HeLa cells, the amount of peripheral lysosomes were 
raised by 350% but mTORC1 activity was only elevated when AA concentrations were 
sufficient (33).  
This data has been replicated in the osteosarcoma cell line U2OS (260) expressing an 
increased activity of the transcription factor E2F1. Upon activation of E2F1, lysosomal 
associated membrane protein 2 (LAMP2)-positive structures (lysosomes) were seen to 
translocate to the cell membrane and once again this movement coincided with an 
increase in mTORC1-dependent S6K1 phosphorylation. Furthermore, this movement 
was displayed to be a result of a v-ATPase-dependent mechanism as the use of siRNA 
targeting V0 subunit C of ATP-ase resulted in a reduction in mTORC1 activity and 
peripheral lysosome content.  These data, taken together, suggest that the cellular 
localisation of mTOR-lysosome complexes, rather than the trafficking of mTOR to the 
lysosome, could be a fundamental regulator of mTORC1 activation. We believe these 
differing findings are a result of the divergent nutrient-deprivation models utilised 
(complete vs. milder and more ‘physiologically relevant’). Therefore, this potential 
mechanism of mTORC1 activation is more likely to relate to the physiological processes 
occurring in human skeletal muscle, and consequently deserved further investigation.  
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Recently, our laboratory has made significant advances in this field of research by 
investigating the translocation of mTOR/lysosomal compartments within human skeletal 
muscle following resistance exercise in the presence or absence of protein-carbohydrate 
feeding (261). Similar to the findings of Korolchuk et al. (33), and contrary to complete 
starvation protocols (29, 97, 98, 113), our results display no changes in co-localisation of  
mTOR and the lysosome between the initial post-absorptive period and any post-
exercise/feeding time point, reinforcing the notion that physiological states of nutrient 
deprivation do not appear to alter mTOR localisation at the lysosome (33). In further 
agreement with Korolchuk et al. (33) we also displayed an increase in mTOR and LAMP2 
localisation with a marker of the muscle plasma membrane (WGA) following resistance 
exercise with or without feeding (261). This translocation of mTOR/LAMP2-positive 
structures was accompanied by a significant increase in S6K1 activity in both subject 
cohorts, with a greater increase apparent in subjects consuming a protein-carbohydrate 
beverage post-exercise, a finding consistent with previous data in the field (224, 262). An 
increase in S6K1 activity is suggestive of a greater phosphorylation status in response to 
mTOR activation and results from these kinase assays are proposed to be comparable to 
immunoblotting techniques targeted toward mTOR activity (S6K1-Thr389) (162). 
Therefore, together with the findings discussed previously (33), our data reinforces the 
notion that mTORC1/lysosomal translocation is a principal event mediating mTORC1 
activation following both resistance exercise and nutrient availability. However, as this 
area of research in human skeletal muscle is still in its infancy, more investigations into 






It is well established that skeletal muscle cells require an abundance of AAs in order for 
anabolism to be stimulated (11). One mechanism by which AAs are provided to cells is 
through AA transport, a vital cellular function (263). This process is catalysed by AA 
transporters, whose action is to move AAs across plasma membranes (264). As alterations 
in the activity of these transporters could affect mTORC1 activation, and subsequent 
skeletal muscle anabolism, these proteins have garnered greater attention in recent times. 
In particular, the L-Type AA transporter 1 (LAT1) is purported to be central in skeletal 
muscle as it controls the transport of leucine (265), and other BCAAs, the most potently 
anabolic AA (113). LAT1 is a permease which associates with the glycoprotein CD98, 
forming a heterodimer at the cell membrane (266). The formation of this heterodimer is 
integral to the activity of this transporter, as without it LAT1 cannot associate with the 
cell membrane and transport AAs (266). The transport of leucine by LAT1 occurs via bi-
directional transport and requires a second AA transporter, the sodium-coupled neutral 
AA transporter 2 (SNAT2). SNAT2 transports glutamine into mammalian cells in a 
process which also involved the influx of sodium ions (267). It is this intracellular 
glutamine that is needed in the bi-directional transport system catalysed by LAT1. 
Glutamine is transported from the cell whilst leucine, or other BCAAs, are simultaneously 
transported into the cell by LAT1 (265). As such, the blockage/deletion of SNAT2 which 
reduces intracellular glutamine, also reduces intracellular BCAAs due to LAT1 inhibition 
(268). Moreover, when the activity of this bi-directional transport system is 
pharmalogically attenuated in, mTORC1-dependent phosphorylation is vastly reduced in 
response to EAAs (269), suggesting this system plays a pivotal role mTORC1 activation.  
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In skeletal muscle, the role of LAT1 has been investigated via the creation of a muscle-
specific LAT1 knockout mouse strain (LAT1 mKO) (270). These mice exhibited reduced 
AA transport into muscle in response to feeding (270), displaying that this system is the 
primary method of essential AA transport. Furthermore, no change is S6K1Thr389 
phosphorylation was observed in response to intraperitoneal leucine injections in LAT1 
mKO muscles whereas wild-type (WT) muscles exhibited a 100% increase (270), 
suggestive of an inability to activate mTORC1. Furthermore, when these mice were fed 
a high protein diet (30%), mKO muscles were again unable to activate mTORC1. These 
data implicate LAT1 in the regulation of mTORC1 activity in response to AAs in skeletal 
muscle. Investigations into LAT1 in human skeletal muscle have focussed mainly on the 
protein and gene expression of this transporter. Bolus protein ingestion (159), acute 
resistance exercise (271), and a combination of these anabolic stimuli (234), have been 
reported to enhance both the mRNA and protein expression of LAT1, however these 
alterations occurred at varying time points in each investigation (159, 234, 271). 
Additionally, as these effects were measured following anabolic stimuli, at the same time 
as mTORC1 activity is raised, these changes are unlikely to have affected mTORC1 
activity itself. Conclusions from these data are therefore hard to infer. This difficulty may 
be due to the methods by which LAT1 was measured. As a transporter, LAT1 needs to 
be associated with a membrane in order to be active. Thus, the cellular location of LAT1 
in basal skeletal muscle, and in response to various anabolic stimuli could provide a vital 
insight into how AA transport, and mTORC1 activity, is regulated. One such study has 
begun to tackle this research question through the preparation of skeletal muscle 
membrane fractions (272). Immunoblotting targeting LAT1 in these fractions suggested 
a greater amount of this transporter associated with the membrane following resistance 
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exercise and protein feeding (272). This method can require fairly large amounts of 
muscle tissue (at least 30mg) and as such the identification, optimisation and validation 
of methods which can be used to determine LAT1 cellular location in a smaller tissue 
sample are needed. Subsequently, this method can then be utilised to ascertain any 
alterations to LAT1 cellular location in response to anabolic stimuli. Recently a new 
potential role for LAT1 has also been purported, that of a ‘transceptor’. This theory 
suggests that LAT1 may be able to initiate intracellular signalling cascades in response 
to elevated extracellular AA levels (273-275). As this is only a hypothesis based on in 
vitro data, further research is needed to confirm this. 
1.6.3 Vps34 
As previously mentioned Vps34 is a class III PI3Kinase which acts to phosphorylate 
phosphatidylinositol to generate phosphatidylinositol-3-phosphate (PI3P) (247), and 
exists in several different complexes (249). One of these complexes has recently been 
particularly scrutinised due to its sensitivity to nutrient provision. In vitro, the kinase 
activity of non-autophagic Vps34 complexes is elevated when nutrient levels are high and 
reduced with nutrient starvation (119). A potential role for Vps34 as a nutrient sensor was 
first hypothesised following the discovery that the overexpression of Vps34 in HEK293 
cells elicited a significant rise in S6K1 kinase activity similar to that induced by insulin 
administration (276). Moreover, the effect of insulin on S6K1Thr389 phosphorylation could 
be completed abolished if Vps34 expression was inhibited with siRNA (276). This effect 
extended to AA-induced mTORC1 activation, where shRNA targeting Vps34 also 
completely blocked S6K1Thr389 hyper-phosphorylation following AA administration 
(119). Collectively, these data suggest that Vps34 is required for mTORC1 activation in 
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response to nutrients, a mechanism which may translate to skeletal muscle, a highly 
nutrient-sensitive tissue. 
Very little research into the nutrient-sensing role of Vps34 in skeletal muscle has been 
conducted. Gran and Cameron-Smith (147) studied the effects of leucine and insulin 
incubation of varying lengths on anabolic signalling and Vps34 protein expression in 
human primary myotubes. Here, incubation with 5mM leucine, 100nM insulin or a 
combination of both significantly elevated Vps34 protein expression no matter whether 
incubation occurred for 30 minutes, 3 hours or 24 hours (147). The majority of these 
elevations were accompanied by corresponding changes in mTORC1 activity, suggesting 
a possible relationship between these two measures. However, from this data it is 
impossible to conclude whether increases in Vps34 protein expression were affecting 
mTORC1 activity or vice versa, or in fact whether these measures were truly associated 
at all. In addition, no functional measures of Vps34 were conducted and as such we do 
not know if the experimental conditions affected the kinase activity of Vps34.  
A more in-depth investigation was conducted by MacKenzie et al. (203) who investigated 
the effects of muscular contractions on Vps34 kinase activity in rodent skeletal muscle. 
Forced contraction of the lower limbs of rodents elicited large increases in Vps34 kinase 
activity, predominantly in muscle which underwent eccentric contractions (203). These 
increases were most apparent at 3h, but remained elevated at 6 hours post-contraction 
(203). Concomitant rises in S6K1 kinase activity were also noted at these time points, 
however a more substantial increase in this mTORC1-activity readout was observed 30 
minutes following contraction (203). Nevertheless the change in S6K1 activity at 3h post 
contraction in each muscle analysed (tibialis anterior, soleus & plantaris) was positively 
associated with the corresponding change in Vps34 kinase activity. Thus, it seems that 
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the regulation of Vps34 and S6K1 kinase activity may be tightly regulated. Given its 
purported role as a leucine sensor, the authors then hypothesised that the increase in 
Vps34 activity noted with contraction would be related to alterations in intramuscular 
leucine concentrations. To confirm this they measured intramuscular leucine following 
contractions and added this amount of leucine to C2C12 myotubes. Following 
supplementation with leucine, Vps34 activity rose 3-4 fold compared to control 
conditions (203), suggesting Vps34 may be able to sense alterations in intracellular 
leucine which in turn may enhance its intrinsic activity. As there currently is no data 
regarding the regulation of Vps34 in response to protein-carbohydrate feeding, alone or 
in combination with resistance exercise, the true nature of this mechanism within human 
skeletal cannot yet be determined.  
1.7 – Specific Aims of this Thesis 
The overarching aim of this thesis is to investigate novel mechanisms of mTORC1 
activation and muscle protein synthesis in human skeletal muscle. 
Chapter 2 describes the general methodology and analytical techniques used throughout 
the thesis. 
Chapter 3 describes the effect of acute resistance exercise and/or protein-carbohydrate 
feeding on the cellular localisation and activity of mTOR complexes and lysosomal 
structures. 
Chapter 4 describes the validation and optimisation of immunofluorescent staining 
approaches to characterise LAT1 localisation and distribution in human skeletal muscle. 
Chapter 5 describes in vitro and in vivo examination as to the role of Vps34 as a nutrient 
sensor in mouse and human skeletal muscle.  
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Chapter 6 describes the effect of acute resistance exercise and/or protein-carbohydrate 
feeding on LAT1 cellular location, novel sites of Vps34 regulation and mTORC1 activity 
in human skeletal muscle.  
Chapter 7 then provides a general discussion focussing on the results gleaned from this 
thesis and the implications of these findings on the field of skeletal muscle physiology 
and mTORC1 research. 
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2.1 – Ethical Approval 
The study presented in Chapter 3 was conducted in the Department of Kinesiology at 
McMaster University (Hamilton, ON, Canada) and analysed at the University of 
Birmingham (U.K.). This study was approved by the Hamilton Integrated Research Ethics 
Board (REB 14-736). The data presented in Chapter 4 were collected at The University 
of Birmingham, McMaster University and The University of Guelph, under approval of 
the NHS West Midlands Black Country Research Ethics Committee (14/WM/0088 and 
15/WM/0003), the Hamilton Health Sciences Research Ethics Board (12-631), and the 
University of Guelph Research Ethics Board (120C018) respectively. Ethical approval 
for the study presented in Chapter 5 was obtained from the NHS West Midlands Black 
Country Research Ethics Committee (15/WM/0003). Finally, the study presented in 
Chapter 6 was approved by NHS West Midlands Black Country Research Ethics 
Committee (17/WM/0068). For each experiment written informed consent was obtained 
from all participants prior to commencement in the study. All studies conformed to the 
standards presented by the Declaration of Helsinki (seventh version). 
2.2 – Sample Collection 
All human muscle samples were obtained from the vastus lateralis using the Bergstrom 
percutaneous needle biopsy technique, modified for suction (1), under local anaesthesia 
(1% lidocaine). Briefly, local anaesthesia was administered following which a small 
incision (1cm) was made in the skin and fascia above the vastus lateralis muscle. The 
Bergstrom biopsy needle was then inserted and suction applied to obtain muscle samples. 
Each separate muscle biopsy sample (~100mg) was obtained from a different incision 
site. Following sample collection, samples were blotted free of blood and any apparent 
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adipose or connective tissue was dissected. Specific details of experimental designs of 
each study are included in each individual chapter. 
2.3 – Sample Processing 
2.3.1 Standard processing 
For all analysis other than histology, muscle samples were snap-frozen in liquid nitrogen 
immediately following sample collection. These samples were then stored at -80ºC until 
analysis was completed. 
2.3.2 Processing for histology 
For histological analysis, a small piece of skeletal muscle (~20mg) was covered in Tissue-
Tek OCT and frozen in liquid nitrogen-cooled isopentane. Samples were then stored at -
80ºC until further analysis. Muscle samples were sectioned in a cryostat (Bright 5040, 
Bright Instrument Company limited, Huntingdon, England)) maintained at -25ºC. Here, 
samples were fixed to cylinders by Tissue-Tek OCT and positioned in front of the 
microtome blade in the correct orientation to produce cross-sectional muscle sections. 
5µm muscle sections were then cut and transferred to room-temperature glass slides 
(Corning, NY, USA.) and allowed to dry for ~30 minutes. The integrity and orientation 
of sections were visualised under an optical microscope with 10X magnification and 
damaged sections discarded. Slides were stored at -80ºC until staining. 
2.4 – Histology 
2.4.1 Fixation, Blocking and Antibody Incubation 
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Muscle sections were fixed in a 3:1 solution of acetone and ethanol for 5 minutes, 
following which they were blocked in 5% normal goat serum (NGS), diluted in phosphate 
buffered saline (PBS). NGS was chosen to prevent non-specific secondary antibody 
binding.  
2.4.2 Overall Staining Procedure 
Slides were removed from the freezer and left to thaw for 45 minutes before being fixed 
as previously described. Sections were then outlined with a PAP pen to prevent liquid 
leaving sections during incubations and washed for 3 x 5 minutes in 1XPBS 
(supplemented with 0.2% Tween20 (PBST)). Primary antibodies were then diluted in 5% 
NGS (diluted in PBS) to the required predetermined concentration. For each new 
antibody used, preliminary testing was conducted to determine an optimal staining 
dilution. If multiple protein targets were being stained for then an antibody cocktail was 
made in 5% NGS allowing multiple proteins to be simultaneously stained for. At this 
point, primary antibodies were administered to muscle sections and incubated for 2 hours 
at room temperature (RT). Following primary incubation, excess primary antibody was 
removed through 3 x 5 minute PBST washed. Secondary antibodies, conjugated to Alexa 
fluorophores (1:200 dilution in PBS for all secondary antibodies) were then applied to the 
muscle sections and left to incubate for 1 hour at RT. Again excess antibody was removed 
via 3 x 5 minute PBST washes. If needed, sections were then incubated for 30 minutes in 
Wheat Germ Agglutinin (WGA, conjugated to 350nm fluorophore) in order to mark the 
sarcolemmal membrane. After this, a final wash in PBST and then 1 x 5 minute wash in 
PBS was conducted. Slides were left to air dry in a dark cabinet before being mounted in 
Mowiol to protect fluorophores. A glass coverslip was subsequently applied and slides 
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left at RT overnight to dry. At this point, slides were then frozen until imaging 
commenced. 
2.4.3 Antibody Validation 
Antibodies targeting RAPTOR (Abcam no. ab40768) and RICTOR (CST no.53A2) were 
validated using muscle-specific knockout (mKO) tissue for the target protein kindly 
donated by Prof. Markus Ruegg. The antibody used to target LAT1 (SLC7A5 – Abcam 
no. ab85226) was validated through the use of mKO tissue (2) and a peptide competition 
assay.  
2.4.3.1 mKO Tissue 
For RAPTOR and RICTOR antibody validation using mKO tissue, slides were prepared 
with 5µm sections of mKO gastrocnemius muscle (n=2) alongside wild-type (WT) 
littermate controls (n=2). Staining for each protein was then conducted as described above 
with a subset of samples stained with primary antibodies omitted (CON). This was 
conducted to examine any background staining from the secondary antibody alone which 
may have occurred in mKO tissue. If valid, the intensity of the stain produced in mKO 
tissue should be equivalent to that apparent in CON samples. All sections were imaged 
in identical conditions in order to allow accurate comparisons to be made.  
For LAT1 (SLC7A5) antibody validation slides were prepared with 5µm sections of mKO 
extensor digitorum longus (EDL) muscle (n=2). Separate slides were prepared containing 
WT littermate control EDL sections. Again, staining was conducted as described above 
and image capture protocols were identical for each sample analysed. The staining 
intensity of each section was visualised to determine specificity of the antibody.  
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2.4.3.2 Peptide Competition Assay 
For peptide competition assays, 5µm muscle sections from the vastus lateralis of one 
young, healthy male were loaded onto slides. A subset of sections were stained for the 
protein of interest as described previously. For the second subset of sections, primary 
antibodies were pre-incubated with its corresponding peptide (20x concentration of 
antibody) for 1 hour at RT on an orbital shaker. This cocktail was then added to the 
sections. If the antibody is specific to its target protein, it should bind to its corresponding 
peptide and be fully quenched. Therefore, the staining intensity on these samples should 
be greatly reduced compared to normal staining procedures.  
2.4.4 Image Capture 
Prepared slides were observed under a Nikon E600 widefield microscope using a 40×0.75 
numerical aperture objective. Images per area were captured under three colour filters 
achieved by a SPOT RT KE colour three shot CCD camera (Diagnostic Instruments Inc., 
MI, USA), illuminated by a 170 W Xenon light source. For image capture, DAPI UV 
(340–380 nm) filter was used to view WGA-350 (blue) signals and proteins tagged with 
Alexa 488 fluorophores (green) were visualised under the FITC (465–495nm) excitation 
filter. The Texas-Red (540–580 nm) excitation filter was used to capture signals of 
proteins conjugated to Alexa Fluor 594 fluorophores. All images were taken were taken 
using a 40X magnification objective (0.75NA). Filter box switching was conducted with 
a semi-automated filterwheel (10B 10 Position Filterwheel, Sutter, USA). On average, 6 
images were captured per human section, and each image contained ~8 muscle fibres. All 
sections were imaged in duplicate and therefore approximately 100 fibres per subject 
were used for analysis. All image capture factors factors i.e. exposure time and gain, were 
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kept constant between all images on each individual slide, Image processing and analysis 
was undertaken on ImagePro Plus 5.1 (Media Cybernetics, MD., USA.) and all factors 
i.e. exposure time and gain, were kept constant between all images on each individual 
slide. All images underwent flattening and de-speckling prior to quantification of co-
localization to limit the contribution of background, non-specific fluorescence. Image 
signals generated by WGA or dystrophin were used to estimate cell membrane borders, 
and MHC1 staining was utilised to identify type I fibres. The intensity of LAT1 staining 
in these groups of fibres was used to assess any differences in fibre type abundance of the 
LAT1 protein. 
2.4.5 Image Analysis 
2.4.5.1 Fluorescence Intensity 
For fluorescence intensity analysis of antibody validity, FIJI (ImageJ) software was 
utilised. Images were analysed for mean pixel intensity across the entire image and the 
mean of these intensities was calculated across all images from a particular section. These 
values were then compared between WT, mKO and, where applicable, CON samples to 
suggest antibody specificity. For fibre-type specific fluorescence intensity, type I muscle 
fibres were identified using a MHCI antibody (DSHB, A4.480) and the membranes of 
fibres were identified via dystrophin (DSHB, MANDYS1 3B7) or WGA-350 
(ThermoFisher, ##11263). Regions of interest (ROIs) were then produced around these 
fibres and the fluorescence intensity of LAT1-positive signals were measured. MHCI-
negative fibres (type II fibres) underwent an identical process and these values were then 





Image processing and analysis for colocalisation was undertaken on ImagePro Plus 5.1 
(Media Cybernetics, MD., USA.). All images underwent flattening and despeckling to 
limit the contribution of background, non-specific fluorescence to quantification. Image 
signals generated by WGA or dystrophin were used to estimate cell membrane borders. 
Signals from each individual filter were then overlaid and the Pearson’s correlation 
coefficients produced to estimate colocalisation of proteins in each image. This method 
of assessing colocalisation was chosen as it measures colocalisation between two 
channels on pixel-by-pixel basis and is relatively free of user bias (3). In cases where 
muscle tissue did not cover the entire image, or there was extensive background/non-
specific staining in certain areas, then a ROI was manually drawn around the area to be 
used for analysis and Pearson’s correlation coefficient measured in this area only. 
2.5 – Immunoblotting 
2.5.1 Tissue Homogenisation and Protein Content Analysis 
For western blot analysis of human tissue, snap-frozen muscle tissue was powdered using 
a Cellcrusher tissue pulverizer (Cellcrusher, Co. Cork, Ireland) on dry ice. Subseuently, 
~20mg of powdered muscle was homogenised in ice-cold sucrose lysis buffer (50 mM 
Tris, 1mM EDTA, 1mM EGTA, 50mM NaF, 5mM Na4P2O7-10H2O, 270mM sucrose, 
1M Triton-X, 25mM β-glycerophosphate, 1µM Trichostatin A, 10mM Nicotinamide, 
1mM 1,4-Dithiothreitol, 1% Phosphatase Inhibitor Cocktail 2; Sigma, 1% Sigma 
Phosphatase Inhibitor Cocktail 2; Sigma, 4.8% cOmplete Mini Protease Inhibitor 
Cocktail; Roche) using a hand-held Polytron homogeniser. The subsequent solution was 
briefly vortexed before centrifugation at 8000g for 10 minutes at 4ºC to remove insoluble 
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material. For western blot analysis of C2C12 and human primary myotubes, cells were 
collected in ice-cold sucrose lysis buffer and underwent ultrasonic homogenisation for 3 
x 15 seconds at 50% maximal wattage. This cell lysate was then briefly vortexed and 
centrifuged at 8000g for 10 minutes at 4ºC to remove insoluble material. Protein content 
was determined by the DC protein assay (Bio-Rad, Hercules, California, USA) and 
samples were diluted to the desired protein concentration in sucrose lysis buffer and 1 x 
Laemmli Sample Buffer (LSB). Western blot samples were then boiled for 5 minutes at 
95ºC to denature proteins and stored at -80ºC until further analysis. 
2.5.2 Gel Preparation and Electrophoresis 
8-15% polyacrylamide separating gels were prepared using relative amounts of 30% 
acrylamide (BioRad), Tris-SDS (pH 8.8) and doubly-distilled water (ddH2O). Small 
amounts of 10% ammonium persulfate (APS, 100µL) and TEMED (12-16µL) were then 
added to catalyse polymerisation. When separating gels were set, 5% polyacrylamide 
stacking gels were prepared as described above and added on top of the separating gel. 
10- or 15-well combs were then added depending on number of samples loaded. Once 
set, equal volumes of protein were loaded to gels and separated by SDS-PAGE at a 
constant current of 23mA per gel. Proteins were allowed to run to the bottom of gels 
(~60mins) before transfer to membranes was undertaken. 
2.5.3 Transfer and Blocking 
Proteins were transferred on to BioTrace NT nitrocellulose membranes (Pall Life 
Sciences, Pensacola, Florida, USA) via wet transfer at 100 V for 1 h. Membranes were 
stained with Ponceau S (Sigma-Aldrich, Gillingham, UK) and imaged to check for even 
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loading. Membranes were then blocked in 3% dry-milk in tris-buffered saline with tween 
(TBST) for 1 hour to minimise non-protein specific binding.   
2.5.4 Antibodies 
2.5.4.1 Primary Antibody 
Following blocking, membranes were washed for 5 minutes in 1X TBST to remove 
excess milk. Membranes were then incubated in primary antibodies (diluted in TBST) 
overnight at 4ºC.  
2.5.4.2 Secondary Antibody 
Following primary antibody incubation, membranes were again washed for 3 x 5 minutes 
in 1X TBST to remove excess antibody solution. Membranes were the incubated in the 
appropriate horse radish peroxidase-conjugated secondary antibody at room temperature 
for 1 hour. Subsequently membranes were again washed 3 x 5 minutes in 1X TBST before 
imaging commenced. 
2.5.5 Imaging and Analysis 
Antibody binding was detected via the use of enhanced chemiluminescence horseradish 
peroxidase substrate detection kit (Millipore, Watford, UK). Images were acquired using 
a G:Box Chemi-XR5 (Syngene, Cambridge, UK) and band quantification was undertaken 
on the corresponding GeneSys software (Syngene, Cambridge, UK). Background 
corrections were also completed to remove any effects of background antibody binding. 
2.6 – Kinase Assays 
2.6.1 S6K1 and AKT Kinase Assays 
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200µg of protein from muscle lysates was used for the S6K1 kinase assay. The target 
protein was then immunoprecipitated using 4µg of anti-S6K1 antibody (santa cruz 
biotech, no.2708) and 2.5µL of Protein G Sepharose beads for 2 hours at 4ºC. 
Immunoprecipitates were then washed in high-salt buffer (50mM Tris·HCl pH 7.5, 
0.1mM EGTA, 1mM EDTA, 0.5M NaCl, 1% (vol/vol) Triton X-100, 50mM NaF, 5mM 
NaPPi, 0.27M sucrose, 0.1% -mercaptoethanol, 1mM Na3(OV)4, and 1 Complete (Roche) 
protease inhibitor tablet per 10mL) and once in assay buffer (50mM Tris·HCl pH 7.4, 
0.03% Brij35, and 0.1% β-mercaptoethanol). The immunoprecipitates were then 
resuspended in 10µL assay buffer and activity assays commenced every 20 seconds. This 
occurred through the addition of a hot assay mix, which consisted of assay buffer, ATP-
MgCl2 (100µM ATP +10mM MgCl2), 32γ-ATP and a synthetic peptide substrate (S6tide 
- KRRRLASLR at 30µM). Reactions ceased at 20 second intervals by spotting onto 
chromatography paper (Whatman; GE Healthcare, UK) and immersing in 75 mM 
phosphoric acid. Chromatography papers were washed 3 x 5 minutes in 75 mM 
phosphoric acid and 1 x 5 minutes in acetone and then dried. Following immersion in 
Gold Star LT Quanta scintillation fluid (Meridian Biotechnologies, Chesterfield, UK), 
spots were counted in a Packard 2200CA TriCarb scintillation counter (United 
Technologies). Assays were quantified in quantified in fmol·min-1·mg-1. For AKT kinase 
assays, AKT was immunoprecipitated (santa cruz biotech, no.4691) from the same lysates 
used for S6K1 immunoprecipitates, a method previously validated (4). Kinase assays 
were then completed in an identical manner, with the only alteration being the synthetic 
peptide substrate used (Crosstide - GRPRTSSFAEG at 30µM). Assays occurred for 45 
minutes for S6K1 and 20 minutes for AKT. This methodology has previously been 
completely validated (4). 
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2.6.2 Vps34 Kinase Assay 
Target proteins were immunoprecipitated from lysates overnight at 4ºC in the presence 
of 2µg anti-Vps34 antibody (sheep antibody produced by Dr. James Murray, Trinity 
Biomedical Science Institute, Trinity Collage Dublin) and immobilised on Protein G 
sepharose beads for 1hour. Immunoprecipitates were then washed 3 times in Cantley lysis 
buffer, once in Tris-LiCl (10mM Tris, pH 7.5, 5mM LiCl, 0.1mM Na2VO4) and 2 times 
in TNE (10mM Tris, pH 7.5, 150mM NaCl, 1mM EDTA, 0.1mM Na2VO4), before 
resuspension in 60μL TNE+ (TNE, 0.5mM EGTA, pH 8.0, 1:1000 2-mercaptoethanol). 
This suspension was then incubated with 20µg of Vps34 antigen peptide for 10 minutes 
at RT. Substrates for this assay were 10μL of 30mM MnCl2 and 10μL of 2mg/ml-1 
phosphotidylinositol (PI, sonicated for 5 min in 10mM Tris, pH 7.5–1mM EGTA prior to 
addition) (bovine liver, Avani Polar Lipids), added to each sample. Reactions were 
performed at 30ºC on a shaker. Reactions were initiated by the addition of 5μL of ATP 
mix (400μM unlabelled ATP, 12.5μCi of 32γ ATP, 4.3μL water) and occurred for 10 
minutes. Termination of the reaction was achieved by the addition of 20μL of 8M HCl 
and phase separated with 160μL 1:1 chloroform:methanol and centrifugation for 1 minute 
at 16000g. The lower phase of this suspension was then spotted onto an aluminium-
backed 60A silica ˚ TLC plate (Merck, Damstadt, Germany) and run in a TLC chamber 
solvent system (60mL chloroform, 47mL methanol, 11.2mL water and 2mL ammonium 
hydroxide). The plates were then left to develop and air dry before quantification by 
densiometry. Again this method has been previously optimised and validated (5). 
2.7 – Blood analyses 
2.7.1 – Serum Insulin Concentrations 
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Serum insulin concentrations were determined using an enzyme-linked immunosorbent 
assay (ELISA, IBL International, Hamburg, Germany) following manufacturers 
instructions. Briefly, 25µL serum samples, and provided standards, were combined with 
25µL enzyme conjugate in a microtiter plate, mixed thoroughly and incubated for 30 mins 
at RT. 50µL of provided enzyme complex was then added to each well and incubated for 
30 mins at RT. Following 3 washes with the provided wash solution, 50µL of substrate 
solution was added to each well and reactions were allowed to occur for 15 minutes at 
RT. The provided stop solution was then added to terminate reactions and absorbance at 
450nm was read on a FluoStar Omega plate reader (BMG Labtech, Aylesbury, UK). A 
standard curve was then created using known standard concentrations, allowing serum 
insulin concentrations to be estimated. 
2.7.2 – Plasma AA concentrations 
Plasma concentrations of leucine, phenylalanine and threonine were determined using gas 
chromatography-mass spectrometry (GCMS;model 5973; Hewlett Packard, Palo Alto, 
CA, USA). Once thawed, known concentrations of stable isotope-labelled internal 
standards corresponding to each AA of interest were added to the plasma samples (100µL 
per 1mL plasma). Samples were then diluted 1:1 with acetic acid and purified on acidified 
cation-exchange columns (Dowex50W-X8-200; Sigma-Aldrich, Poole, UK). AAs were 
collected into glass tubes through the addition of ammonium hydroxide to columns and 
subsequently dried under N2. AAs were then converted to their N-tert-butyldimethyl-
silyl-N-methyltrifluoracetamide (MTBSTFA) derivative through the addition of 
acetonitrile and MTBSFTA (1:1 ratio) to the dried AAs before heating at 70℃ for 1h. 
Samples were then run on GCMS and AA concentrations (peaks on ions of interest) were 
calculated based on the known concentration of each internal standard. 
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2.8 – In vitro experimental studies 
2.8.1 C2C12s 
C2C12 myoblasts were purchased from American Type Culture Collection (Manassas, 
VA). C2C12 myoblasts were initially cultured on 150mm culture plates in high glucose 
Dulbecco’s minimum essential medium (DMEM, ThermoFisher Scientific, Waltham, 
MA, USA.), supplemented with 10% Foetal bovine serum (FBS, Hyclone, VWR, 
Lutterworth, UK.) and 1% penicillin-streptomycin (PS, ThermoFisher Scientific, 
Waltham, MA, USA.). When 80% confluent, cells were trypsinised (ThermoFisher 
Scientific, Waltham, MA, USA.) and transferred to 6-well plates at a concentration of 2 
x 105 cells per well. Myoblasts were then cultured until 90% confluency (~36 hours) when 
media was changed to elicit differentiation into myotubes (high glucose DMEM 
supplemented with 2% horse serum (HS, Hyclone, VWR, Lutterworth, UK.) and 1% PS). 
Differentiation was allowed to occur for 5 days, until fully-formed myotubes were 
visualised, before experimental procedures were began. Specific details of experimental 
procedures will be described in specific chapters. Upon completion of experimental 
procedures, myotubes were briefly washed twice in ice-cold PBS (ThermoFisher 
Scientific, Waltham, MA, USA.) before being collected via scraping into ice-cold sucrose 
lysis buffer (formulation described above, 150µL per well). These cell lysates were then 
snap-frozen in liquid nitrogen and placed at -80ºC until further analysis. 
2.8.2 Human Primaries 
Human primary myoblasts from 4 patients (age – 60.8±6.4yrs, BMI – 28.7±0.65kg/m2, 
Mean±SEM) were obtained from the laboratory  of Dr. Simon Jones (Queen Elizabeth 
Hospital, Institute of Inflammation and Ageing, Birmingham, U.K.). Fresh muscle 
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samples were minced with scissors for 5 minutes and the sample transferred to a universal 
tube. 5mL of 1x trypsin-EDTA was added to the sample and vortexed to mix. This was 
then placed at 37ºC for 15 minutes whilst rotating. Following this, 5mL of Hams F-10 
media (ThermoFisher Scientific, Waltham, MA, USA, supplemented with 20% FBS and 
1% PS) was added to inactivate the trypsin. This suspension was then passed through a 
filter (70µm, Corning, NY, USA.) to remove residual connective tissue etc. The cell 
suspension was then centrifuged for 5 minutes at 1700rpm and the supernatant 
subsequently discarded. The cell pellet was then resuspended in 10mL of Hams F10 
media (20%FBS, 1%PS) and added to an uncoated 100mm culture plate. The plate was 
then incubated for 30 minutes at 37ºC to allow fibroblasts to adhere to the plate, yet 
maintain myoblasts in suspension. The residual cell suspension (myoblasts) was then 
removed and added to a 0.2% gelatin (Sigma Aldrich, Dorset, UK.) coated 10mm culture 
plate. This plate was then incubated for 48-72 hours before the first media change to allow 
myoblasts to fully adhere to the plate. A second ‘pre-plate’ procedure was then conducted 
at first passage to remove further fibroblast cells. This isolation method has previously 
been shown to consistently remove a large proportion of fibroblasts from muscle samples 
(6). Thereafter media was changed every 48 hours until 60% confluent. 
Cells were passaged at 60% confluency to prevent spontaneous fusion of myoblasts to 
myotubes. At passage 3, cells were trypsinised and seeded onto 6-well plates at a 
concentration of 5 x 104 cells per well. These cells were then cultured to 80-90% 
confluency at which point media was changed to elicit differentiation (Hams F10 
supplemented with 2% HS and 1% PS). Experiments were then conducted when fully 
formed myotubes could be visualised, which occurred after 6-10 days. Specific details of 
experimental conditions will be described in later chapters. Upon completion of 
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experimental procedures, myotubes were briefly washed twice in ice-cold PBS before 
being collected via scraping into ice-cold sucrose lysis buffer (formulation described 
above, 100µL per well). Cell lysates were then snap-frozen in liquid nitrogen and placed 
at -80ºC until further analysis.  
2.9 – Statistics 
Statistical analysis was completed using SPSS (version 22 for Windows; SPSS, Chicago, 
IL) with post-hoc analysis completed in Microsoft Excel (version 14 for Windows, 
Microsoft). Specific details of the statistical tests used are described in each individual 
chapter. 
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3.1 – Abstract 
Mechanistic target of rapamycin (mTOR) resides as two complexes within skeletal 
muscle. mTOR complex 1 (mTORC1–Raptor positive) regulates skeletal muscle growth, 
whereas mTORC2 (Rictor positive) regulates insulin sensitivity. To examine the 
regulation of these complexes in human skeletal muscle, we utilised 
immunohistochemical analysis to study the localisation of mTOR complexes prior to and 
following protein-carbohydrate feeding (FED) and resistance exercise plus protein-
carbohydrate feeding (EXFED) in a unilateral exercise model. In basal samples, mTOR 
and the lysosomal marker LAMP2 were highly co-localized and remained so throughout. 
In the FED and EXFED states, mTOR/LAMP2 complexes were redistributed to the cell 
periphery (WGA positive staining) (time effect; p=.025), with 39% (FED) and 26% 
(EXFED) increases in mTOR/WGA association observed 1h post-feeding/exercise. 
mTOR/WGA colocalisation continued to increase in EXFED at 3h (48% above baseline) 
whereas colocalisation decreased in FED (21% above baseline).  A significant effect of 
condition (p=.05) was noted suggesting mTOR/WGA co-localization was greater during 
EXFED. This pattern was replicated in Raptor/WGA association, where a significant 
difference between EXFED and FED was noted at 3h post-exercise/feeding (p=.014). 
Rictor/WGA colocalization remained unaltered throughout the trial. Alterations in 
mTORC1 cellular location coincided with elevated S6K1 kinase activity, which rose to a 
greater extent in EXFED compared to FED at 1h post-exercise/feeding (p<.001), and only 
remained elevated in EXFED at the 3h time point (p=.037). Collectively these data 
suggest that mTORC1 redistribution within the cell is a fundamental response to 
resistance exercise and feeding, whereas mTORC2 is predominantly situated at the 
sarcolemma and does not alter localisation.  
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3.2 – Introduction 
Resistance exercise and protein ingestion are potent anabolic stimuli, elevating muscle 
protein synthesis (MPS) (1, 2) resulting in a positive net protein balance (NPB) (2). Such 
elevations in MPS are underpinned by the activation of the conserved serine/threonine 
kinase, mechanistic target of rapamycin (mTOR). This kinase can both augment MPS (3) 
and offset muscle protein breakdown (MPB) (4). In skeletal muscle, mTOR resides in 
two distinct complexes distinguishable by the composition of proteins within each. For 
example, complex 1 (mTORC1) contains mTOR, RAPTOR, GβL, PRAS40 and 
DEPTOR (5), believed to activate protein synthetic machinery (6), whereas complex 2 
(mTORC2) is comprised of mTOR, RICTOR, DEPTOR, GβL, Sin1 and Protor, and is 
implicated in insulin sensitivity and actin cytoskeleton dynamics (5). Due to the critical 
role mTORC1 plays in regulating protein synthesis, this complex has received the most 
detailed examination in relation to resistance exercise and protein feeding. Acute 
resistance exercise, protein ingestion, or combinations of such stimuli are consistently 
reported to elevate mTORC1 activity (1, 2), with effects maintained for up to 24 hours 
(7). Furthermore, the acute inhibition of mTORC1 with rapamycin administration ablates 
any effect of anabolic stimuli on MPS (8, 9). 
As mTORC1 activity seems to be directly implicated in the stimulation of MPS, research 
has focussed on understanding the mechanism by which mTORC1 is activated. Sancak 
et al. (10), identified the interaction of mTORC1 with the lysosome to be of particular 
importance to the activation of the kinase complex in vitro. A similar mechanism has also 
been reported in rodent skeletal muscle, where eccentric contractions of the tibialis 
anterior muscle induce mTOR-lysosome colocalisation (11) in parallel to increases in 
mTORC1 activity (inferred by the phosphorylation of S6K1Thr389). Together these data 
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infer an importance of mTOR-lysosome colocalisation in the activation of molecular 
pathways implicated in protein synthesis. Recently, however, Korolchuk et al. (12) 
reported that the cellular localisation of these mTOR/lysosomal complexes play a pivotal 
role in mTOR activation. In support of this hypothesis, we recently reported that a single 
bout of resistance exercise initiated mTOR/lysosome translocation to the cell periphery, 
and occurred in parallel to an increase in mTOR activity and interaction between mTOR 
and proteins involved in translation initiation (13).  
Whilst the use of immunofluorescence approaches allowed us to study the cellular 
localisation of mTOR, this approach did not enable us to distinguish between mTOR 
complexes. Consequently, we were unable to conclude whether the movement of mTOR 
following anabolic stimuli was mTORC1 or mTORC2 specific. Further, given the parallel 
group design we employed(13), we were unable to assess whether mTOR translocation 
was amplified by feeding. Therefore, the aim of the current study was to evaluate whether 
mTOR translocation following resistance exercise and/or protein-carbohydrate feeding is 
specific to mTORC1. In addition, we utilised a within-subject design to evaluate whether 
a synergistic effect of exercise and feeding exists. We hypothesised that exercise plus 
protein-carbohydrate feeding would elicit a greater mTOR/LAMP2 translocation to the 
cell periphery compared to feeding alone. Further, we hypothesised this translocation 
would be specific to mTORC1. 
3.3 – Methods 
3.3.1 Subjects 
Eight young, healthy, recreationally active males (age=22.5±3.1y, BMI=24.6±2.2kg/m2, 
body fat=17.6±4.8%) volunteered to partake in the study. Potential participants were 
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informed about all experimental procedures to be undertaken and any risks involved 
before written informed consent was obtained. The study was approved by the Hamilton 
Integrated Research Ethics Board (REB 14-736) and adhered to the ethical standards 
outlined by the Canadian tri-council policy statement regarding the use of human 
participants in research as well as the principles according to the Declaration of Helsinki 
as revised in 2008. 
3.3.2 Experimental design 
Following initial assessment for 1 repetition maximum (1-RM) on leg extension 7 d 
previously, participants reported to the laboratory  at ~7.00am after a 10-h overnight fast. 
Participants then rested in a semi-supine position on a bed and an initial skeletal muscle 
biopsy was taken from the vastus lateralis using a modified bergstrom needle. Following 
this biopsy, participants performed 4 sets of unilateral leg extension (Atlantis, Laval, QC, 
Canada) at 70% 1RM until volitional failure interspersed by 2 min recovery. Immediately 
following the cessation of the final set of leg extension all participants consumed a 
commercially available beverage (Gatorade Recover®, Chicago, IL, USA) that provided 
20, 44, and 1g of protein, carbohydrate, and fat respectively. Subsequent bilateral skeletal 
muscle biopsies were obtained from the vastus lateralis at 1h and 3h after beverage 
ingestion to examine mTORC1-related signalling and associated localisation.  
3.3.3 Skeletal muscle immunohistochemistry 
Skeletal muscle immunohistochemical preparation and staining was conducted as 
described previously in Chapter 2 (section 2.4). All samples from each subject were 
sectioned onto the same slide, in duplicate, to ensure accurate comparisons between time 




The mouse mono-clonal anti-mTOR (#05-1592) antibody was purchased from Merck 
Chemical Ltd. (Nottingham, UK). The corresponding conjugated secondary antibody to 
this was Goat anti-mouse IgGγ1 Alexa®594 (#R37121, ThermoFisher, UK). Antibodies 
targeting LAMP2 (#AP1824d, Abgent, USA), Rictor (CST#53A2, Cell Signalling 
Technologies, USA) and Raptor (#ab40768, Abcam, Cambridge, UK) were visualised 
using Goat anti-rabbit IgG(H+L) Alexa®488 secondary antibodies (#A11008, 
ThermoFisher, UK). Finally, wheat germ agglutinin (WGA-350, #11263, ThermoFisher, 
UK) was used to identify the sarcolemmal membrane of muscle fibres. 
3.3.5 Antibody Validation 
The specificity of Rictor (CST#53A2) and Raptor (Abcam#ab40768) primary antibodies 
were tested utilising skeletal muscle samples from the gastrocnemius of muscle-specific 
knockout (mKO) mice for each protein respectively (14). Wild-type, littermate muscle 
samples for each mouse model were used as controls. Primary antibodies were also 
omitted from a subset of samples on slides to examine any background staining from the 
secondary antibody utilised. The fluorescence intensity of each image was then calculated 
using ImageJ software (Version 1.51 for Windows). 
3.3.6 Image capture 
Prepared slides were imaged as described previously in section 2.4.5 of this thesis. DAPI 
UV (340–380 nm) filter was used to view WGA-350 (blue) signals and mTOR proteins 
tagged with Alexa Fluor 594 fluorophores (red) were visualised under the Texas red (540–
580 nm) excitation filter. The FITC (465–495nm) excitation filter was used to capture 
signals of mTOR-complex proteins and LAMP2, which were conjugated with Alexa 
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Fluor 488 fluorophores. On average, 8 images were captured per section, and each image 
contained ~8 muscle fibres such that around 120 fibres per time point (per subject) were 
used for analysis. Image processing and analysis was undertaken on ImagePro Plus 5.1 
(Media Cybernetics, MD., USA.) and all factors i.e. exposure time and de-speckling, were 
kept constant between all images on each individual slide. Image signals generated by 
WGA were used to estimate cell membrane borders, which were merged with the 
corresponding target protein images to identify the association between the protein of 
interest and the plasma membrane. Pearson’s correlation coefficient (Image-Pro software) 
was used to quantify colocalization with the plasma membrane and mTOR-associated 
proteins. This process was also completed to quantify the localization of mTOR with 
complex-associated proteins (Raptor & Rictor) and a marker of the lysosomal membrane 
(LAMP2).  
3.3.7 AKT and S6K1 Kinase Activity Assays 
At each time point during the experimental trial, a separate piece of muscle tissue was 
blotted and freed from any visible adipose or connective tissue. The tissue was then frozen 
in liquid nitrogen and stored at -80ºC. The kinase activity of AKT and S6K1 was 
determined via [-γ-32P] ATP kinase assays following immuno-precipitation of the target 
protein, as previously described in Chapter 2 (Section 2.6.1).  
3.3.8 Statistical Analysis 
All statistical analysis was conducted on SPSS version 22 for Windows (SPSS Inc., 
Chicago, IL, USA). Differences in staining intensity between mKO, wild type (WT) and 
primary omitted (CON) muscle sections were analysed using a one-way analysis of 
variance (ANOVA). Differences in kinase activity, fluorescence intensity and staining 
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colocalisation were analysed using a two-factor mixed-model ANOVA with two within 
subject factors (time; three levels – PRE.vs.1h.vs.3h and condition; two levels – 
FEDvs.EXFED), with Bonferonni correction for multiple comparisons. Pairwise 
comparisons were conducted when a significant main/interaction effect was found. 
Significance for all variables analysed was set at p≤.05. Data are presented as 
means±SEM unless otherwise stated. 
3.4 – Results 
3.4.1 Rictor and Raptor antibodies are specific to their target proteins 
Rictor protein staining intensity in Rictor mKO tissue was significantly lower than that 
in littermate WT controls (p<.001, Fig. 3.1b). Furthermore, the staining intensity in this 
tissue was comparable to when the primary antibody was omitted in both mKO and WT 
tissue (p>.999, Fig. 3.1b). Raptor protein staining intensity in Raptor mKO tissue was 
also significantly lower than that noted in littermate WT controls (p<.001, Fig. 3.1c), with 
this staining intensity again similar to when the primary antibody was omitted in either 
tissue (p>.999, Fig. 3.1c). Therefore, we take this as evidence that the Rictor (CST#53A2) 




Figure 3.1. Rictor and Raptor antibody validation and S6K1 and AKT kinase activity. Immuno-
fluorescent staining of each protein was performed in mKO and littermate WT samples, in addition to 
staining of each sample with primary antibodies omitted (CON). Rictor/Raptor is displayed in green and 
WGA (cell membrane) is stained in blue. Representative images of staining in each condition are displayed 
(A) alongside the corresponding quantifications for Rictor (B) and Raptor (C). Scale bars are 50µm. Data 
presented as mean±SEM. *Significantly different WT (p<.001). S6K1 (D) and AKT (E) kinase activity 
following unilateral resistance exercise and/or protein-carbohydrate feeding. Black bars denote FED 
condition and open bars denote EXFED condition. Data presented as Mean±SEM. *Significantly different 





3.4.2 S6K1 and AKT kinase activity 
A significant condition by time effect was observed for S6K1 activity (p<.001). S6K1 
activity rose above baseline in both conditions at 1h post-exercise/feeding (FED-p=.015, 
EXFED-p<.001), and kinase activity at this time point was 165% greater in the EXFED 
condition (p<.001, Fig. 3.1d). At 3h post-exercise/feeding, kinase activity only remained 
above baseline values in the EXFED condition (52.8% greater than baseline, p=.037, Fig. 
3.1d). A significant main effect for time was noted for AKT kinase activity (p=.023, Fig. 
3.1e). Pairwise comparisons displayed a trend toward an increase in AKT kinase activity 
1h post-intervention, when conditions were combined, compared to 3h post-intervention 
(p=.073). 
3.4.3 Lysosomal content and colocalisation with mTOR 
LAMP2 fluorescence intensity was unchanged from baseline in either condition, however 
a significantly greater intensity was noted in the EXFED condition, compared to FED, at 
3h post-exercise/feeding (p=0.41, Fig. 3.2b). A significant condition  time effect was 
observed for mTOR-Lamp2 colocalisation (p=.004). Consistent with our previous work 
(13), mTOR and LAMP2 were highly localised in basal skeletal muscle (Fig. 3.2c). The 
colocalisation of these two proteins did not change from baseline in either condition over 
the 3h post-exercise/feeding period. However, at the 3h time point, the colocalisation of 
the proteins was greater in the FED condition compared to the EXFED condition 




Figure 3.2. The effect of resistance exercise and/or protein carbohydrate feeding on mTOR-LAMP2 
and mTOR-WGA colocalisation. Representative images of mTOR-LAMP2 and mTOR-WGA co-
localisation at rest, and following resistance exercise and/or protein-carbohydrate feeding (A). 
Orange/yellow regions denote areas of mTOR localisation with the marker of the lysosome in images on 
the top row. mTOR-positive staining is shown in red, LAMP2-positive in green and WGA-positive in blue. 
Quantification of LAMP2 fluorescence intensity (B), mTOR-LAMP2 colocalisation (C) and mTOR-WGA 
(D) co-localisation at each time point. Scale bars are 50µm.  Data presented as Mean±SEM. ¥Significant 
difference between conditions at this time point (p<.05), #significantly difference compared to baseline 





3.4.4 mTOR/lysosome translocation to the cell membrane 
Significant main effects of condition (p=.05) and time (p=.025) were observed for mTOR 
colocalisation with the cell membrane (WGA positive staining). The significant main 
effect of condition suggests that, when all time points are combined, mTOR-WGA was 
greater in the EXFED condition compared to the FED condition. Subsequent pairwise 
comparisons also display that when both conditions were combined, mTOR 
colocalisation with the cell membrane was greater at 3h post-exercise/feeding compared 
to baseline values (p=.008, Fig. 3.2c). Further comparisons also displayed a trend toward 
a difference between mTOR-WGA colocalisation between conditions at the 3h time point 
(0.16(FED) vs. 0.19(EXFED), p=.085). This pattern of colocalisation was mirrored when 
analysing LAMP2-WGA colocalisation (main effect of time, p=.031, data not shown.), 
reiterating the constant colocalisation of mTOR and the lysosome.  
3.4.5 Rictor colocalisation with mTOR and WGA 
Significant main effects of group (p=.046) and time (p=.035) were noted for Rictor 
colocalisation with mTOR proteins (Fig.3B). Overall, there was a greater colocalisation 
of these two proteins in the EXFED condition compared to the FED condition. Following 
pairwise comparisons, there was no difference in the colocalisation between Rictor and 
mTOR between any time points (p>.05, Fig. 3.3b). Furthermore, Rictor colocalisation 
with WGA did not change from baseline at any time point in either condition (Fig. 3.3c), 





Figure 3.3. The effect of resistance exercise and/or protein carbohydrate feeding on Rictor-mTOR 
and Rictor-WGA colocalisation.  Representative images of Rictor-mTOR and Rictor-WGA co-
localisation at rest, and following resistance exercise and/or protein-carbohydrate feeding (A). 
Orange/yellow regions denote areas of Rictor localisation with mTOR on top row. mTOR-positive staining 
is shown in red, Rictor-positive in green and WGA-positive in blue Quantification of Rictor-mTOR (B) 








3.4.6 Raptor colocalisation with mTOR and WGA 
The colocalisation of Raptor and mTOR proteins did not change in either group, at any 
time point, suggesting any alterations in sub-cellular location of either protein occurred 
concurrently (Fig. 3.4b). A significant condition x time effect was observed for Raptor 
colocalisation with WGA (p=.029). Here, Raptor colocalisation with WGA rose to a 
similar extent to the previously reported increase in mTOR-WGA colocalisation at 1h 
post-exercise/feeding in both conditions. At the 3h time point, Raptor-WGA 
colocalisation in the FED group dropped below baseline and 1h post-ex/feeding levels 
(p=.007, Fig. 3.4c), and colocalisation at this time point was greater in the EXFED 
condition (0.12(FED) vs. 0.17(EXFED), p=.014, Fig. 3.4c). 
3.5 – Discussion 
Utilising a within-subject design, we report that a combination of unilateral resistance 
exercise and protein-carbohydrate feeding elicits a greater mTOR translocation toward 
the cell membrane than feeding alone. This observation is consistent with previous 
findings from our laboratory  in which we reported that mTOR associates with the 
lysosome in basal skeletal muscle, with mTOR/lysosomal complexes translocating to the 
cell periphery following mTOR activation(13). Utilising immunofluorescent approaches 
to distinguish between mTORC1 and mTORC2, the present study extends this 
observation, suggesting that mTORC1 seems to be the predominant mTOR complex 
translocating in human skeletal muscle following anabolic stimuli, with mTORC2 in 





Figure 3.4. The effect of resistance exercise and/or protein carbohydrate feeding on Raptor-mTOR 
and Raptor-WGA colocalisation. Representative images of Raptor-mTOR and Raptor-WGA co-
localisation at rest, and following resistance exercise and/or protein-carbohydrate feeding (A). 
Orange/yellow regions denote areas of Raptor localisation with mTOR. mTOR-positive staining is shown 
in red, Raptor-positive in green and WGA-positive in blue Quantification of Raptor-mTOR (B) and Raptor-
WGA (C) co-localisation at each time point. Scale bar is 50µm. Data presented as Mean±SEM. ¥Significant 
difference between conditions at this time point (p=014), #significantly difference compared to baseline 
when conditions combined (p=.007). 
 
In addition to mTORC1 translocation to the cell periphery, we report a greater 
colocalisation of mTOR and LAMP2 in the FED condition, compared to the EXFED 
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condition, at the 3h time point. This finding was unexpected and contrasted our previous 
research using a parallel group design (13). The greater association of mTORC1 with 
lysosomes in the FED condition would infer greater mTORC1 activity in this leg(10, 11); 
however, this was not apparent in our S6K1 kinase activity data. A possible explanation 
for this difference is the increased lysosomal content (LAMP2 fluorescence intensity) 
noted in the EXFED condition at this time point (Fig. 3.2b). It is possible that the acute 
resistance exercise bout may have elicited an increase in chaperone assisted selective 
autophagy as a stress response to the strenuous exercise, as previously reported(15). This 
may have increased the free-lysosomal pool(15) and altered the ratio of mTOR-LAMP2 
association. As this is only a proxy measure of lysosomal content, further research 
directed towards lysosomal biogenesis in response to physiological stimuli would be 
needed to address this mechanism.  
Previous research from our laboratory  has shown an elevation in mTOR association with 
the cell membrane in response to resistance exercise, in both the fed and fasted state (13). 
This association coincided with an increase in S6K1 kinase activity, suggesting that 
mTOR trafficking is associated with an increase in intrinsic mTOR activity. Consistent 
with this hypothesis, here we report that mTORC1-cell membrane association increased 
1h post-intervention, in both FED and EXFED conditions, and the increment was similar 
to that noted in our previous work(13). However, in contrast to our previous results, 
mTOR-WGA colocalisation in the FED condition returned close to baseline values at 3h 
and colocalisation in the EXFED condition displayed a continued elevation. In addition 
to the main effects of time (p=.025) and condition (p=.05) apparent here, a trend toward 
greater colocalisation in the EXFED condition (p=.085) was noted at the 3h time point. 
This greater colocalisation is suggestive of retention of mTOR at the cell periphery when 
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resistance exercise is followed with protein/carbohydrate ingestion, inferring a synergistic 
effect of resistance exercise and protein-carbohydrate feeding, an observation previously 
reported for MPS(2).  
The mTORC1 and mTORC2 protein complexes are involved in varying metabolic 
signalling processes in skeletal muscle, and as such are suggested to reside in distinct 
cellular locations(5). As mTOR-lysosome translocation has been previously associated 
with mTORC1 activation in response to amino-acids in vitro(12), we sought to determine 
whether mTORC1 is the principal mTOR complex translocating in human skeletal 
muscle as we have previously reported(13).The colocalisation of Raptor with WGA 
increased at 1h post-intervention in both conditions, and to a similar extent to that noted 
in mTOR-WGA colocalisation, suggesting that mTORC1 is a spatially regulated mTOR 
complex in human skeletal muscle. Further to this notion, a disparity between conditions 
became apparent at the 3h time point, with Raptor-WGA colocalisation enhanced in the 
EXFED condition (p=.014). This is in agreement with the data regarding mTOR-WGA 
colocalisation where a trend toward EXFED eliciting greater membrane colocalisation 
compared to FED is reported. Raptor colocalisation with mTOR itself was not altered at 
any time point, or between conditions, however we did observe a reduction in raptor 
association with WGA at 3h in both FED and EXFED.  We are currently unable to explain 
this result, however, it could be due to an increase in free Raptor content(16) or increased 
Raptor degradation(17), both potential mechanisms proposed to regulate mTORC1 
activity. In contrast, co-staining of Rictor with WGA, suggested that mTORC2 localises 
with the cell membrane in basal tissue, with this colocalisation unaffected by resistance 
exercise or protein/carbohydrate ingestion. This finding has also been replicated using in 
116 
 
vitro models, where a large proportion of mTORC2 activity was noted at the plasma 
membrane of HEK293 cells(18). 
Our data are congruent with both in vitro(12) and in vivo(13) studies suggesting that 
mTORC1 cellular colocalisation is linked to mTORC1 activity. Whilst this observation 
is in contrast to previous in vitro studies(10, 19), where mTOR translocation to the 
lysosome is deemed essential, we believe the increase in autophagy/MPB in post-
absorptive skeletal muscle prevents the disassociation of mTOR and the lysosome noted 
in previous in vitro studies, where a complete amino acid withdrawal protocol is utilised. 
Further, many physiological mechanisms occur at the cell periphery suggesting the 
redistribution of mTORC1/lysosomal complexes to the cell periphery is physiologically 
relevant. mTORC1 is known to stimulate MPS which, through the use of the SUnSET 
technique(20) and immunohistochemical staining methods, is purported to occur 
primarily in peripheral regions of muscle fibres(21). Consistent with this, we previously 
identified mTOR to interact with Rheb, eIF3F and the microvasculature at the cell 
periphery following resistance exercise in the fed state(13). Collectively this data 
therefore suggests that both upstream regulators and downstream substrates of mTORC1 
are membrane-associated in skeletal muscle(21). Further, given we observed that 
mTORC1 association with the cell periphery was prolonged with feeding [a scenario of 
heightened MPS], we propose that maintaining mTORC1 at the cell periphery may 
provide an mechanistic explanation as to why exercise in the fed state results in prolonged 





3.6 – Conclusions 
In summary, our data show that mTOR-lysosome translocation in response to resistance 
exercise and feeding is driven primarily by mTORC1, and occurs in parallel to increases 
in S6K1 activity. Further, we report that resistance exercise combined with protein-
carbohydrate feeding sustains this response, compared to feeding alone, suggesting a 
synergistic effect of these two stimuli. Collectively, these data add further support to the 
importance of spatial regulation of mTORC1 in response to anabolic stimulation. Further 
research should now examine the relevance of mTORC1 colocalisation in clinical 
scenarios, i.e ageing(22) or obesity(23). Finally, the tools described herein to study 
mTORC2 localisation could be used to examine the regulation of skeletal muscle glucose 
uptake and insulin sensitivity, factors thought to be under the direct control of 
mTORC2(24). 
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4.1 – Abstract 
The branched chain amino acid leucine is a potent stimulator of protein synthesis in 
skeletal muscle. Leucine rapidly enters the cell via the L-Type Amino Acid Transporter 
1 (LAT1); however, little is known regarding the localisation and distribution of this 
transporter in human skeletal muscle. Therefore, we applied immunofluorescence 
staining approaches to visualise LAT1 in wild type (WT) and LAT1 muscle-specific 
knockout (mKO) mice, in addition to basal human skeletal muscle samples. LAT1 
positive staining was visually greater in WT muscles compared to mKO muscle. In 
human skeletal muscle, positive LAT1 staining was noted close to the sarcolemmal 
membrane (dystrophin positive staining), with a greater staining intensity for LAT1 
observed in the sarcoplasmic regions of type II fibres (those not stained positively for 
myosin heavy-chain 1, Type II—25.07 ± 5.93, Type I—13.71 ± 1.98, p < 0.01), 
suggesting a greater abundance of this protein in these fibres. Finally, we observed 
association with LAT1 and endothelial nitric oxide synthase (eNOS), suggesting LAT1 
association close to the microvasculature. This is the first study to visualise the 
distribution and localisation of LAT1 in human skeletal muscle. As such, this approach 
provides a validated experimental platform to study the role and regulation of LAT1 in 







4.2 - Introduction 
Amino acid transport is an essential component in the survival of all cells(1), providing 
substrates for processes such as protein synthesis(2, 3) and cell division(4). Amino acid 
transport into cells is of particular importance within skeletal muscle to maintain positive 
protein balance(2, 3). Some evidence suggests that amino acid transporter proteins may 
also act as receptors, converting extracellular amino acid abundance into intracellular 
signals(5-7), a role termed ‘transceptor’(8).  
Of the amino acid transporters identified in skeletal muscle, the L-Type amino acid 
transporter 1 (LAT1) also known as the solute carrier family 7 member 5 (SLC7A5), has 
received significant attention(9-15) due to its role in the ingress of amino acids, vital for 
optimal stimulation of muscle protein synthesis (MPS)(16-18). LAT1 transports leucine 
(or other branched chain amino acids (BCAAs)) into the cell via a bi-transport system 
which simultaneously exports glutamine(19). The increase in intracellular 
leucine/BCAAs subsequently activates the mechanistic target of rapamycin (mTOR) 
complex 1 (mTORC1) resulting in an elevation in MPS(20). Leucine’s reported potency 
toward mTORC1 in skeletal muscle(16) is modulated primarily through LAT1, as this is 
the main transporter by which leucine moves into cells(9). Other L-type amino acid 
transporters are expressed in skeletal muscle, including LAT2 and LAT4(21, 22), 
however it seems LAT1 is the primary BCAA transporter. In LAT1 muscle-specific 
knockout (mKO) mice, a compensatory increase in SLC7A8/LAT2 mRNA was 
reported(14), yet a significant reduction in amino acid transport into muscle was apparent, 
suggesting LAT1 is integral to this process. Furthermore, LAT4 is only weakly expressed 
in skeletal muscle(21) and is believed to be primarily required in placenta as this 
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transporter functions to deliver amino acids from the mother to the foetus(23). Due to its 
apparent importance to amino acid transport in skeletal muscle, understanding the role 
and regulation of LAT1 is essential for studies aimed at maximising the delivery of 
dietary protein and amino acids in the context of post-exercise recovery. 
Gene expression and protein content of LAT1 is positively associated with mTORC1 
activity; however, increases in LAT1 expression are abolished by the administration of 
rapamycin, suggesting that mTORC1 may also regulate LAT1 activity(24). In human 
skeletal muscle, essential AA (EAA) consumption elicits an early increase in LAT1 gene 
expression followed by elevations in protein content(12). Furthermore these transient 
effects have also been reported in response to resistance exercise alone (11), and in 
combination with EAA consumption(10). Such data suggest that anabolic stimuli may 
initiate signalling pathways which up-regulate both LAT1 gene expression and protein 
levels in human skeletal muscle, possibly translating to greater leucine/BCAA transport 
and a superior protein synthetic response(2, 3, 16, 25). However, it is difficult to reconcile 
the physiological relevance of changes in LAT1 gene and protein content with LAT1 
activity since LAT1 is only active when at the plasma membrane(9, 26). Therefore, any 
measure of protein or gene expression in whole muscle homogenates(10-12) may not 
allow reliable conclusions to be drawn. To date, the localisation of LAT1 in human 
muscle is unknown and requires investigation. 
Therefore, the aim of the present study was develop and validate immunofluorescent 
approaches to study LAT1 cellular distribution and localisation in human skeletal muscle. 
We hypothesised that in basal human skeletal muscle, LAT1 would be located at the 
plasma membrane and would be ubiquitously expressed across fibre types. 
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4.3 – Materials and Methods  
4.3.1 Mouse skeletal muscle sample collection and preparation 
LAT1 mKOmice were provided as a gift by Dr. Peter Taylor of the University of Dundee. 
Methods of generation of this mouse strain has been previously described(14). Mice (n=2 
mKO, n=2 wild type (WT)) were housed in a climate-controlled facility at the University 
of California Davis, in a standard 12h light/dark cycle and fed standard chow ad libitum. 
All procedures were approved by the UC Davis Institutional Animal Care and Use 
Committee (IACUC) and performed under protocol number 19244. At 3 months of age, 
mice were fasted for 5h before the extensor digitorum longus (EDL) muscle was 
surgically removed under anaesthetic (2.5% isofluorane), pinned to cork and frozen in 
liquid nitrogen-cooled isopentane. Muscles were subsequently stored at -80°C until 
sectioned.  Prior to sectioning, the belly of the EDL was blocked in Tissue-Tek Optimal 
Cutting Temperature (OCT) Compound (VWR International, Leicestershire, UK.) and 
frozen in liquid nitrogen-cooled isopentane at which point the sample was ready for cryo-
sectioning. During staining protocols, both WT and mKO samples were processed and 
stained simultaneously, and image capture paradigms were also identical. 
4.3.2 Human skeletal muscle sample collection and preparation 
Ethical approval for the collection of muscle samples was granted by the NHS West 
Midlands Black Country Research Ethics Committee (14/WM/0088 & 15/WM/0003), the 
Hamilton Health Sciences Research Ethics Board (12-631), and the University of Guelph 
Research Ethics Board (120C018). The study conformed to the standards presented by 
the Declaration of Helsinki (seventh version). Written informed consent was obtained 
from all participants before samples were collected. Muscle samples for 
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immunofluorescence were obtained from the vastus lateralis muscle of 6 young, healthy 
males (mean age - 22±2yrs), who attended the laboratory  after an overnight (10h) fast, 
using the Bergstrom percutaneous needle technique. Samples were blotted free of excess 
blood and dissected free of any fat or connective tissue before being placed in OCT 
compound and frozen in liquid nitrogen-cooled isopentane. Muscle samples were then 
stored at -80℃ until further analysis. Muscle samples for Western blot were collected 
after an overnight fast and 15min after an acute bout of exercise, as previously described 
(27). Samples (200-300mg) were immediately processed for sarcolemmal vesicles and 
cytosolic fractions, as previously described(28), before being stored at -80°C until further 
analysis. 
Table 4.1. Summary of Antibodies used. 
4.3.3 Immunofluorescent Staining 
Embedded muscle samples were fixed in front of the microtome blade (Bright 5040, 
Bright Instrument Company limited, Huntingdon, England) and cryo-sections (5μm) 
Primary Antibody Source Dilution Secondary Antibody Dilution 





IgG(H+L) Alexa®488 1:200 
SLC7A5 peptide Abcam, ab192836 1:10 N/A N/A 
Mouse monoclonal anti-Dystrophin 
antibody, isotype IgG2a 
DSHB, 
MANDYS1 3B7 1:200 
Goat anti-mouse IgG2a 
Alexa®594 1:200 
Mouse monoclonal anti-MHC1 antibody, 
isotype IgM 
DSHB,  
A4.480  1:500 
Goat anti-mouse IgM 
Alexa®594 1:200 




Goat anti-mouse IgG1 
Alexa®594 1:200 
Wheat Germ Agglutinin-350 
W11263, 
Invitrogen 1:20 




collected onto room temperature uncoated glass slides (VWR international, UK). Sections 
were left to air dry at room temperature for 10min to remove excess crystallized water 
inside sections under storage. Sections were fixed in acetone and ethanol (3:1) solution 
(Fisher, UK) for 5 min and then washed for 3 x 5min in phosphate buffered saline (PBS) 
supplemented with 0.2% Tween (PBS-T) to remove fixation reagent. Sections were then 
incubated in primary antibody solution diluted with 5% normal goat serum (Invitrogen, 
UK) for 2hr at room temperature. For blocking peptide experiments, the anti-SLC7A5 
antibody was pre-incubated with its corresponding peptide (20 times greater than primary 
antibody concentration) on an orbital shaker for 1 hour at room temperature. Following 
incubation, sections were washed for 3 x 5min in PBST and incubated in the appropriate 
secondary antibody for 1h at room temperature. If needed, sections were finally incubated 
with Wheat Germ Agglutinin (WGA-350) for 30min at room temperature to mark the 
sarcolemmal membrane. After a final wash in PBS, slides were left to air dry until the 
visual water stains evaporated: 1-2 min at room temperature. Sections were mounted with 
20μL Mowiol® 4-88 (Sigma-Aldrich, UK) and sealed by glass coverslips to protect the 
muscle sections and to preserve fluorescence signals. Slides were left overnight in a dark 
room before observation. Primary antibodies, blocking peptides and corresponding 
secondary antibodies and working dilutions are listed in Table 1. All secondary antibodies 
were sourced from ThermoFisher Scientific Inc. (Waltham, MA, USA). 
4.3.4 Image Capture  
Prepared slides were observed under a Nikon E600 widefield microscope using a 40×0.75 
numerical aperture objective. Images per area were captured under three colour filters 
achieved by a SPOT RT KE colour three shot CCD camera (Diagnostic Instruments Inc., 
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MI, USA), illuminated by a 170 W Xenon light source. For image capture, DAPI UV 
(340–380 nm) filter was used to view WGA-350 (blue) signals and LAT1 stains tagged 
with Alexa 488 fluorophores (green) were visualised under the FITC (465–495nm) 
excitation filter. The Texas-Red (540–580 nm) excitation filter was used to capture 
signals of eNOS (blood vessels), dystrophin (sarcolemma) or Myosin heavy chain 1 
(Type I Fibres), which were conjugated with Alexa Fluor 594 fluorophores. On average, 
8 images were captured per section, and each image contained ~8 muscle fibres. As 2 
sections per participant were imaged, approximately 120 fibres per subject were used for 
analysis. Image processing and analysis was undertaken on ImagePro Plus 5.1 (Media 
Cybernetics, MD., USA.) and all factors i.e. exposure time and gain, were kept constant 
between all images on each individual slide. All images underwent flattening and de-
speckling prior to quantification of co-localization to limit the contribution of 
background, non-specific fluorescence. Image signals generated by WGA or dystrophin 
were used to estimate cell membrane borders, and MHC1 staining was utilised to identify 
type I fibres. The intensity of LAT1 staining in these groups of fibres was used to assess 
any differences in fibre type abundance of the LAT1 protein.  
4.3.5 Immunoblotting 
As a qualitative methodological comparator with immunofluorescence for the spatial 
distribution of LAT1, giant sarcolemmal vesicles were isolated from the vastus lateralis 
of a subset healthy males (N=2, ~21 years of age) as previously described(29). The 
protein pellets that remained were resuspended and homogenized in a buffer containing 
MOPS (10mM), KCl (140mM), EDTA (10mM), and protease inhibitors. Samples were 
centrifuged at 800g × 10min at 4°C to remove insoluble proteins. Protein concentrations 
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in cytosolic and sarcolemmal vesicle fractions were determined by BCA assay and 
prepared at equal concentrations in 4X Laemmli buffer. Three µg of protein was loaded 
on a precast gel (BioRad 5671094), run at 200V for 45 min, transferred (100V for 1h) to 
nitrocellulose membrane, stained with Ponceau S solution, blocked in 5% skim milk, 
and probed overnight (1:1000 in TBST) using the same anti-LAT1 antibody used for 
immuno-fluorescent staining (see table 1). The membrane was incubated in goat anti-
rabbit IgG HRP conjugated secondary (Thermo Fisher,cat. 31460; 1:10 000 in TBST) 
for 1h at RT before washing in TBST and detection by chemiluminescence. Images 
were captured using a Fluorochem E Imaging system (Protein Simple; Alpha Innotech, 
Santa Clara, CA). 
4.3.6 Statistical Analysis  
All statistical analysis was conducted on SPSS version 22 for Windows (SPSS Inc., 
Chicago, IL, USA). Differences between the staining intensity in type I and type II fibres 
was analysed by a paired-samples t-test. Significance threshold was set at p≤.05. Data are 
presented as Mean±SE unless otherwise stated.3.  
4.4 – Results 
4.4.1 Characterisation and validation of LAT1 immunofluorescence labelling approaches 
In WT skeletal muscle samples, positive LAT1 signals were noted at the periphery of 
many fibres, in addition to displaying a stronger sarcoplasmic staining than seen in mKO 
samples (Fig 4.1a). In mKO samples, positive LAT1 staining was almost completely 
abolished (Fig 4.1b). We take this data to suggest that the anti-LAT1 antibody utilised 
here is specific to the LAT1 protein in skeletal muscle. This was further confirmed as the 
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pattern of staining noted in mKO samples was similar to that seen when the primary 
antibody was omitted from staining protocols. 
Next, we applied the same staining technique to human skeletal muscle (Figure 4.2a & 
4.2b). Here a similar staining pattern was noted, with positive-LAT1 puncta close to the 
sarcolemmal membrane (dystrophin positive staining) as well as within the cytosol in 
some fibres. Additionally, a possible fibre-type difference in LAT1 content was apparent 
in human tissue. Finally, when the anti-LAT1 antibody was incubated with a LAT1-
specific blocking peptide, the immunofluorescent signal and staining pattern was greatly 
reduced (Figure 4.2c), further confirming the antibody’s specificity to the LAT1 protein. 
The immunoblot data also demonstrate the presence of LAT1 in the sarcolemma and 
cytosolic protein fractions (Fig 4.2d). 
4.4.2 LAT1 protein content is greater in fast-twitch skeletal muscle fibres 
To examine fibre type distribution, LAT1 was co-stained with myosin heavy-chain 1 
(MHC1) to identify type I fibres. This allowed us to quantify LAT1 positive staining in 
type I and II fibres. Representative images of this stain (Figs 4.3a & 4.3b) displayed a 
difference in LAT1 staining between fibre types with a greater staining intensity 
seemingly apparent in type II fibres. Quantification of the staining intensity in each fibre 
type (Fig4.3c) confirmed this as an 82.7% greater staining intensity was noted in type II 
fibres compared to type I fibres (25.07±5.93 vs. 13.71±1.98, p<.01, Figure 3C). This 
results suggests a greater amount of LAT1 is expressed in more glycolytic fibres, which 
do not express MHC1; however, it seems the difference predominantly occurs in the 
sarcoplasm as positive LAT1 staining is still apparent at the sarcolemma of type I fibres 
(Fig 4.3a & 4.3b). 
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Figure 4.1. Immunofluorescent detection of LAT1 in wild type (WT) and LAT1 muscle-specific 
knockout (mKO) mouse extensor digitorum longus (EDL) muscle. Sections were stained with anti-
LAT1 antibody (far left panels, green) and then co-stained with dystrophin (middle panels, red) for the 
identification of the sarcolemma. Representative images for both WT (A) and mKO (B) are shown. 





Figure 4.2. Immunofluorescent detection of LAT1 in human vastus lateralis. muscle. Sections 
were stained with anti-LAT1 antibody (far left panels, green) and then co-stained with dystrophin 
(middle panels, red) for the identification of the sarcolemma. Representative images from two 
participants are displayed (A & B). Use of a peptide competition assay reduced the signal intensity of 
LAT1 staining (C). A strong positive signal was noted close to the sarcolemmal membrane and 
possible sites of blood vessels. In addition a possible fibre type difference in LAT1 staining was noted. 
Immunoblots for the LAT1 protein displayed bands to be apparent in both giant sarcolemmal vesicles 
and cytosolic fractions before (PRE) and after (POST) an acute bout of resistance exercise (D) (N=2). 




4.4.3 LAT1 localises close to the microvasculature 
To assess LAT1 interaction with the microvasculature, LAT1 was co-stained with anti-
eNOS antibody, to identify blood vessels. This antibody has previously been utilised in 
human skeletal muscle to positively stain capillaries, and other micro-vessels (30). Here, 
it was apparent that positive LAT1 staining occurred close to positive staining of the 
microvasculature (eNOS), as shown in the merged and zoomed images (Figure 4, right 
panels), suggesting LAT1 localises close to skeletal muscle vasculature at rest. 
4.5 – Discussion 
LAT1/SLC7A5 is a transmembrane amino-acid transporter, which imports leucine and 
other BCAAs into cells in exchange for glutamine. This places LAT1 as a central 
regulator of skeletal muscle protein dynamics given the importance of leucine in 
activating mTORC1 and initiating MPS after feeding(31). Previous studies investigating 
LAT1 in human skeletal muscle have focussed on gene expression and protein levels of 
this transporter in whole muscle homogenates, measures that do not provide much 
information about LAT1 physiological function as the LAT1 protein is only ‘active’ when 
associated with cellular membranes(9). Therefore, in this study, we aimed to validate and 
optimise an immunofluorescence staining method to visualise LAT1 in human skeletal 
muscle. Using this approach we observed LAT1 to be in two pools within in basal human 
skeletal muscle: within the sarcoplasm and associated with the sarcolemma. Furthermore, 
we report novel information showing LAT1 to be expressed in a fibre-specific manner 




Staining for LAT1 in fasted human skeletal muscle tissue displayed a strong 
immunoreactivity close to the sarcolemmal membrane (Fig. 4.2), which was confirmed 
by its presence within a giant sarcolemmal vesicle preparation (Fig. 4.2d). This fraction, 
which is primarily sarcolemmal membrane but may also contain recycling endosomal 
membranes(32), has been previously shown to contain intracellular fat (e.g. FAT/CD36) 
and glucose transporters (e.g. GLUT4) in rodent and human muscle(28, 33). This primary 
location of LAT1-positive staining along the sarcolemmal membrane is in congruence 
with its purported role as a transceptor(34). As the primary transporter of BCAAs into 
muscle cells(19), fully functioning LAT1 would need to associate with the sarcolemmal 
membrane in order to convey free amino acids into muscle fibres(35). Structurally, LAT1, 
a permease, can associate with a glycoprotein, CD98 (SLC3A2)(35, 36), to form a 
heterodimer at a membrane. This association tethers LAT1 to the membrane, allowing 
the permease to transport amino acids across the membrane(36, 37). Furthermore, any 
role as a sensor of extracellular amino acids would also require LAT1 to be associated 
with the sarcolemma. Therefore, as either a transporter or a signalling molecule LAT1 
would have to associate with the membrane(8, 34). Although our data is the first study to 
utilise immunofluorescence staining techniques to detect LAT1 in human skeletal muscle, 
this protein has previously been visualised in other tissues. In human placenta, LAT1 was 
visualised predominantly at the microvillous membrane of terminal villi and was essential 
for leucine uptake into placenta cells(38). Further, LAT1 is located at plasma membranes 
of Laryngeal Squamous tumours(39), where amino acid uptake is elevated to provide 
substrates for tumour growth(40). Several other tissues also express LAT1 principally in 
membranous structures including foetal intestines(41), non-small cell lung 
carcinomas(42) and ovarian tumours(43). This consistent visualisation of LAT1 at 
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membranes of tissues where protein synthesis/cell division is high consolidates our 
finding in human skeletal muscle, a tissue in which a regular supply of EAAs is 
imperative for optimal cell function and turnover(2). 
Figure 4.3. Immunofluorescent detection of LAT1 in human vastus lateralis. muscle co-stained 
with myosin heavy chain 1 (MHC1) and dystrophin (DYS). Sections were stained with anti-LAT1 
antibody (far left panels, green) and then co-stained with dystrophin (middle panels, red) for the 
identification of the sarcolemma and MHC1 (middle panels, red sarcoplasmic staining, marked with 
I) for the identification of type I muscle fibres. Representative images from two participants are 
displayed (A & B). Quantification of the mean immunofluorescent staining in type I and type II fibres 
displayed a greater staining in type II fibres (C). On average 103±17 fibres were quantified per 
participant. Values are Mean±SE. *Significantly different to type I (p<.01). Scale bar in top left panel 
is 50µm and all images were captured at the same magnification. 
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Skeletal muscle is perfused by an intricate network of capillaries, and other microvessels, 
providing the working tissue with adequate supplies of oxygen and substrates whilst 
simultaneously removing waste products. Essential amino acids are transported to the 
muscle via this network, entering the bloodstream via absorption in the small intestine 
after food is consumed(44). As this is the most ready supply of essential amino acids for 
skeletal muscle (other than intracellular amino acid recycling from protein breakdown), 
we investigated whether LAT1 would localise close to blood vessels. We display strong 
LAT1 immunoreactivity with eNOS. Such close association between an area of high 
supply (bloodstream) and one of high demand (skeletal muscle) suggests a high efficiency 
of amino acid transport in human skeletal muscle. Similar localisations have been 
displayed in other tissues with high LAT1 expression noted at blood-brain barriers in 
rodents(45, 46) and chickens(47). Additionally, other amino acid transporters are also 
seen in these regions (47) further implying a high efficiency of amino acid transport at 
blood-tissue junctions.  
 
When staining for the LAT1 protein in skeletal muscle, a difference in the intensity of 
LAT1 staining between some fibres was apparent. We hypothesised this may be specific 
to a particular fibre type and confirmed this by co-staining LAT1 with an anti-MHC1 
antibody to identify type I (oxidative) fibres (Fig 4.3). LAT1 expression was greater in 
type II fibres and this seemed to be driven by a greater staining intensity within the 
sarcoplasm of these fibres, suggesting a greater dynamic pool in these fibres. This was 
confirmed via immunoblotting of mixed human skeletal muscle giant sarcolemmal 
vesicles and cytoplasmic fractions (Fig 4.2d), the latter of which may include membranes 
associated with sorting endosomes, lysosomes, and intracellular organelles (e.g. 
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endoplasmic reticulum, Golgi apparatus) that would be distinct from those extracted in 
the giant sarcolemmal vesicles(32, 48). Immunoblotting displayed expression of the 
LAT1 protein in both fractions adding further validation to our observations of greater 
LAT1 staining intensity in the sarcoplasm of type II fibres. Several mechanisms within 
skeletal muscle may explain this apparent increase in sarcoplasmic LAT1 within more 
glycolytic fibres. Firstly, increases in LAT1 protein could result from mTORC1 
activation. In response to essential amino acid ingestion(12), resistance exercise(11), or 
both in combination(10, 49), stimuli which have been consistently reported to transiently 
activate mTORC1, LAT1 gene expression and protein levels are elevated in young and 
old males. In addition, alterations in LAT1 gene expression and protein levels following 
platelet-derived growth factor incubation are abolished by co-incubation with 
rapamycin(24), an mTORC1 inhibitor. As type II fibres show a greater elevation in 
mTORC1 activity in response to exercise(50), it is possible that this drives greater 
transcription/translation of LAT1 in these fibres, which remains apparent in fasted tissue. 
It may also be possible that, due to the greater levels of mTORC1 activity experienced in 
these fibres, LAT1 is required on the membrane of intracellular lysosomes as shown in 
some in vitro models (51). Here, LAT1 could maintain intralysosomal amino acid 
concentrations which are believed to then contribute to mTORC1 activation(52). It is also 
possible that sarcoplasmic LAT1 may translocate toward the sarcolemmal membrane in 
response to stimuli where an increase in amino acid transport occurs (i.e., mechanical 
stimulation or feeding(20)). In fact, the translocation capacity of LAT1 has been 
previously reported in BeWo Chariocarcinoma cells after exposure to IGF-1, where the 
transporter translocated from perinuclear regions toward the cell membrane(53). An 
increase in membrane-associated LAT1 protein will then increase the amount of amino 
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acids which can be transported into the cell for protein synthesis/repair. Since we show a 
greater intracellular concentration of LAT1 in type II fibres, if LAT1 does translocate this 
would suggest that type II fibres would have the greatest anabolic potential. It is important 
that this fibre-type difference in LAT1 expression is further investigated to fully 





Figure 4.4. Immunofluorescent detection of LAT1 in human vastus lateralis. muscle co-stained 
with endothelial nitric oxide synthase (eNOS) and Wheat Germ Agglutinin (WGA). Sections 
were stained with anti-LAT1 antibody (green) and then co-stained with eNOS (red) for the 
identification of blood vessels. WGA (blue) was used to identify membrane borders. Representative 
images from two participants are displayed. Merged images display positive LAT1 staining localising 
close to positive eNOS staining, shown in greater detail in zoomed images (bottom panels). Scale bar 
in top left panel is 50µm and all images (except zoomed images) were captured at the same 
magnification. Scale bar in bottom panels is 5µm. 
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4.6 – Conclusions  
To conclude, we have validated and optimised a method by which LAT1 can be visualised 
in human skeletal muscle. As this amino acid transporter is only active when associated 
with cellular membranes, this novel method allows a greater depth of investigation into 
the dynamics of LAT1 in human muscle in response to anabolic stimuli. For the first time, 
we have identified LAT1 to be located close to the plasma membrane of all fibres and in 
close proximity to the microvasculature. Furthermore, we note a greater 
immunoreactivity of this protein in the sarcoplasm of type II fibres, potentially supporting 
the greater anabolic potential in these fibres. We believe this technique may provide a 
valuable insight into the role of LAT1 in skeletal muscle amino acid sensing, intracellular 
signalling, and subsequently adaptation. It is important to acknowledge however, that the 
use of immunofluorescence microscopy as discussed here can only infer localization of 
target proteins. To gain greater insight into whether the LAT1 protein is directly localized 
to the sarcolemmal membrane, microvasculature or actin myosin bundles, immune-
electron microscopy could be utilized and/or isolation of giant sarcolemmal vesicles. 
However, the present immunofluorescence technique requires less tissue (i.e. ~20mg vs. 
>200mg) than isolated giant sarcolemmal vesicles and can be characterized from frozen 
as compared to fresh samples, which represent significant advantages when muscle tissue 
samples are limited. Future research should now focus on identifying the possible 
underlying mechanisms, and consequences, of the fibre type differences reported here. 
Moreover, investigations into how factors such as ageing, exercise and feeding regulate 
LAT1 cellular location should also be undertaken. As LAT1 is the principal mechanism 
by which leucine enters the cell, approaches to increase LAT1 content or activity in 
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skeletal muscle could have substantial relevance to post-exercise recovery strategies in 
which dietary protein or amino acids are of direct importance. 
 
4.7 – References  
 
1. Kilberg, M. S., Pan, Y. X., Chen, H., and Leung-Pineda, V. (2005) Nutritional 
control of gene expression: how mammalian cells respond to amino acid 
limitation. Annual review of nutrition 25, 59-85 
2. Biolo, G., Tipton, K. D., Klein, S., and Wolfe, R. R. (1997) An abundant supply 
of amino acids enhances the metabolic effect of exercise on muscle protein. The 
American journal of physiology 273, E122-129 
3. Tipton, K. D., Gurkin, B. E., Matin, S., and Wolfe, R. R. (1999) Nonessential 
amino acids are not necessary to stimulate net muscle protein synthesis in healthy 
volunteers. The Journal of nutritional biochemistry 10, 89-95 
4. Dudani, A. K., and Prasad, R. (1983) Amino acid transport: its role in cell division 
and growth of Saccharomyces cerevisiae cells. Biochemistry international 7, 15-
22 
5. Gazzola, G. C., Dall'Asta, V., and Guidotti, G. G. (1981) Adaptive regulation of 
amino acid transport in cultured human fibroblasts. Sites and mechanism of 
action. The Journal of biological chemistry 256, 3191-3198 
6. Holsbeeks, I., Lagatie, O., Van Nuland, A., Van de Velde, S., and Thevelein, J. 
M. (2004) The eukaryotic plasma membrane as a nutrient-sensing device. Trends 
in biochemical sciences 29, 556-564 
7. Hyde, R., Cwiklinski, E. L., MacAulay, K., Taylor, P. M., and Hundal, H. S. 
(2007) Distinct sensor pathways in the hierarchical control of SNAT2, a putative 
amino acid transceptor, by amino acid availability. The Journal of biological 
chemistry 282, 19788-19798 
8. Hundal, H. S., and Taylor, P. M. (2009) Amino acid transceptors: gate keepers of 
nutrient exchange and regulators of nutrient signaling. American journal of 
physiology. Endocrinology and metabolism 296, E603-613 
9. Yanagida, O., Kanai, Y., Chairoungdua, A., Kim, D. K., Segawa, H., Nii, T., Cha, 
S. H., Matsuo, H., Fukushima, J., Fukasawa, Y., Tani, Y., Taketani, Y., Uchino, 
H., Kim, J. Y., Inatomi, J., Okayasu, I., Miyamoto, K., Takeda, E., Goya, T., and 
Endou, H. (2001) Human L-type amino acid transporter 1 (LAT1): 
characterization of function and expression in tumor cell lines. Biochimica et 
biophysica acta 1514, 291-302 
10. Dickinson, J. M., Drummond, M. J., Coben, J. R., Volpi, E., and Rasmussen, B. 
B. (2013) Aging differentially affects human skeletal muscle amino acid 
transporter expression when essential amino acids are ingested after exercise. 
Clinical nutrition (Edinburgh, Scotland) 32, 273-280 
11. Drummond, M. J., Fry, C. S., Glynn, E. L., Timmerman, K. L., Dickinson, J. M., 
Walker, D. K., Gundermann, D. M., Volpi, E., and Rasmussen, B. B. (2011) 
Skeletal muscle amino acid transporter expression is increased in young and older 
adults following resistance exercise. Journal of applied physiology (Bethesda, 
Md. : 1985) 111, 135-142 
142 
 
12. Drummond, M. J., Glynn, E. L., Fry, C. S., Timmerman, K. L., Volpi, E., and 
Rasmussen, B. B. (2010) An increase in essential amino acid availability 
upregulates amino acid transporter expression in human skeletal muscle. 
American journal of physiology. Endocrinology and metabolism 298, E1011-
1018 
13. Murakami, T., and Yoshinaga, M. (2013) Induction of amino acid transporters 
expression by endurance exercise in rat skeletal muscle. Biochemical and 
biophysical research communications 439, 449-452 
14. Poncet, N., Mitchell, F. E., Ibrahim, A. F., McGuire, V. A., English, G., Arthur, 
J. S., Shi, Y. B., and Taylor, P. M. (2014) The catalytic subunit of the system L1 
amino acid transporter (slc7a5) facilitates nutrient signalling in mouse skeletal 
muscle. PloS one 9, e89547 
15. Walker, D. K., Drummond, M. J., Dickinson, J. M., Borack, M. S., Jennings, K., 
Volpi, E., and Rasmussen, B. B. (2014) Insulin increases mRNA abundance of 
the amino acid transporter SLC7A5/LAT1 via an mTORC1-dependent 
mechanism in skeletal muscle cells. Physiological reports 2, e00238 
16. Atherton, P. J., Smith, K., Etheridge, T., Rankin, D., and Rennie, M. J. (2010) 
Distinct anabolic signalling responses to amino acids in C2C12 skeletal muscle 
cells. Amino acids 38, 1533-1539 
17. Churchward-Venne, T. A., Burd, N. A., Mitchell, C. J., West, D. W., Philp, A., 
Marcotte, G. R., Baker, S. K., Baar, K., and Phillips, S. M. (2012) 
Supplementation of a suboptimal protein dose with leucine or essential amino 
acids: effects on myofibrillar protein synthesis at rest and following resistance 
exercise in men. The Journal of physiology 590, 2751-2765 
18. Churchward-Venne, T. A., Breen, L., Di Donato, D. M., Hector, A. J., Mitchell, 
C. J., Moore, D. R., Stellingwerff, T., Breuille, D., Offord, E. A., Baker, S. K., 
and Phillips, S. M. (2014) Leucine supplementation of a low-protein mixed 
macronutrient beverage enhances myofibrillar protein synthesis in young men: a 
double-blind, randomized trial. The American journal of clinical nutrition 99, 
276-286 
19. Baird, F. E., Bett, K. J., MacLean, C., Tee, A. R., Hundal, H. S., and Taylor, P. 
M. (2009) Tertiary active transport of amino acids reconstituted by coexpression 
of System A and L transporters in Xenopus oocytes. American journal of 
physiology. Endocrinology and metabolism 297, E822-829 
20. MacKenzie, M. G., Hamilton, D. L., Murray, J. T., Taylor, P. M., and Baar, K. 
(2009) mVps34 is activated following high-resistance contractions. The Journal 
of physiology 587, 253-260 
21. Bodoy, S., Martin, L., Zorzano, A., Palacin, M., Estevez, R., and Bertran, J. (2005) 
Identification of LAT4, a novel amino acid transporter with system L activity. The 
Journal of biological chemistry 280, 12002-12011 
22. Verrey, F., Closs, E. I., Wagner, C. A., Palacin, M., Endou, H., and Kanai, Y. 
(2004) CATs and HATs: the SLC7 family of amino acid transporters. Pflügers 
Archiv 447, 532-542 
23. Cleal, J. K., Glazier, J. D., Ntani, G., Crozier, S. R., Day, P. E., Harvey, N. C., 
Robinson, S. M., Cooper, C., Godfrey, K. M., Hanson, M. A., and Lewis, R. M. 
(2011) Facilitated transporters mediate net efflux of amino acids to the fetus 
across the basal membrane of the placental syncytiotrophoblast. The Journal of 
physiology 589, 987-997 
143 
 
24. Liu, X. M., Reyna, S. V., Ensenat, D., Peyton, K. J., Wang, H., Schafer, A. I., and 
Durante, W. (2004) Platelet-derived growth factor stimulates LAT1 gene 
expression in vascular smooth muscle: role in cell growth. FASEB journal : 
official publication of the Federation of American Societies for Experimental 
Biology 18, 768-770 
25. Rasmussen, B. B., Tipton, K. D., Miller, S. L., Wolf, S. E., and Wolfe, R. R. 
(2000) An oral essential amino acid-carbohydrate supplement enhances muscle 
protein anabolism after resistance exercise. Journal of applied physiology 
(Bethesda, Md. : 1985) 88, 386-392 
26. Kim, C. H., Park, K. J., Park, J. R., Kanai, Y., Endou, H., Park, J. C., and Kim, D. 
K. (2006) The RNA interference of amino acid transporter LAT1 inhibits the 
growth of KB human oral cancer cells. Anticancer research 26, 2943-2948 
27. Song, Z., Moore, D. R., Hodson, N., Ward, C., Dent, J. R., O’Leary, M. F., Shaw, 
A. M., Hamilton, D. L., Sarkar, S., Gangloff, Y.-G., Hornberger, T. A., Spriet, L. 
L., Heigenhauser, G. J., and Philp, A. (2017) Resistance exercise initiates 
mechanistic target of rapamycin (mTOR) translocation and protein complex co-
localisation in human skeletal muscle. Scientific Reports 7, 5028 
28. Bradley, N. S., Snook, L. A., Jain, S. S., Heigenhauser, G. J., Bonen, A., and 
Spriet, L. L. (2012) Acute endurance exercise increases plasma membrane fatty 
acid transport proteins in rat and human skeletal muscle. American journal of 
physiology. Endocrinology and metabolism 302, E183-189 
29. Perez-Schindler, J., Esparza, M. C., McKendry, J., Breen, L., Philp, A., and 
Schenk, S. (2017) Overload-mediated skeletal muscle hypertrophy is not impaired 
by loss of myofiber STAT3. American journal of physiology. Cell physiology 313, 
C257-c261 
30. Cocks, M., Shepherd, S. O., Shaw, C. S., Achten, J., Costa, M. L., and 
Wagenmakers, A. J. (2012) Immunofluorescence microscopy to assess enzymes 
controlling nitric oxide availability and microvascular blood flow in muscle. 
Microcirculation (New York, N.Y. : 1994) 19, 642-651 
31. Saxton, R. A., and Sabatini, D. M. (2017) mTOR Signaling in Growth, 
Metabolism, and Disease. Cell 168, 960-976 
32. Koonen, D. P., Coumans, W. A., Arumugam, Y., Bonen, A., Glatz, J. F., and 
Luiken, J. J. (2002) Giant membrane vesicles as a model to study cellular substrate 
uptake dissected from metabolism. Molecular and cellular biochemistry 239, 121-
130 
33. Whitfield, J., Paglialunga, S., Smith, B. K., Miotto, P. M., Simnett, G., Robson, 
H. L., Jain, S. S., Herbst, E. A. F., Desjardins, E. M., Dyck, D. J., Spriet, L. L., 
Steinberg, G. R., and Holloway, G. P. (2017) Ablating TBC1D1 impairs 
contraction-induced sarcolemmal glucose transporter type 4 redistribution, but not 
insulin-mediated responses in rats. The Journal of biological chemistry  
34. Taylor, P. M. (2014) Role of amino acid transporters in amino acid sensing. The 
American journal of clinical nutrition 99, 223s-230s 
35. Pfeiffer, R., Rossier, G., Spindler, B., Meier, C., Kühn, L., and Verrey, F. (1999) 
Amino acid transport of y+L-type by heterodimers of 4F2hc/CD98 and members 
of the glycoprotein-associated amino acid transporter family. The EMBO journal 
18, 49-57 
36. Warren, A. P., Patel, K., McConkey, D. J., and Palacios, R. (1996) CD98: a type 
II transmembrane glycoprotein expressed from the beginning of primitive and 
144 
 
definitive hematopoiesis may play a critical role in the development of 
hematopoietic cells. Blood 87, 3676-3687 
37. Fenczik, C. A., Zent, R., Dellos, M., Calderwood, D. A., Satriano, J., Kelly, C., 
and Ginsberg, M. H. (2001) Distinct domains of CD98hc regulate integrins and 
amino acid transport. The Journal of biological chemistry 276, 8746-8752 
38. Gaccioli, F., Aye, I. L., Roos, S., Lager, S., Ramirez, V. I., Kanai, Y., Powell, T. 
L., and Jansson, T. (2015) Expression and functional characterisation of System 
L amino acid transporters in the human term placenta. Reproductive biology and 
endocrinology : RB&E 13, 57 
39. Nikkuni, O., Kaira, K., Toyoda, M., Shino, M., Sakakura, K., Takahashi, K., 
Tominaga, H., Oriuchi, N., Suzuki, M., Iijima, M., Asao, T., Nishiyama, M., 
Nagamori, S., Kanai, Y., Oyama, T., and Chikamatsu, K. (2015) Expression of 
Amino Acid Transporters (LAT1 and ASCT2) in Patients with Stage III/IV 
Laryngeal Squamous Cell Carcinoma. Pathology oncology research : POR 21, 
1175-1181 
40. Wang, Q., and Holst, J. (2015) L-type amino acid transport and cancer: targeting 
the mTORC1 pathway to inhibit neoplasia. American journal of cancer research 
5, 1281-1294 
41. Ohno, C., Nakanishi, Y., Honma, T., Henmi, A., Sugitani, M., Kanai, Y., and 
Nemoto, N. (2009) Significance of system L amino acid transporter 1 (LAT-1) 
and 4F2 heavy chain (4F2hc) expression in human developing intestines. Acta 
histochemica et cytochemica 42, 73-81 
42. Takeuchi, K., Ogata, S., Nakanishi, K., Ozeki, Y., Hiroi, S., Tominaga, S., Aida, 
S., Matsuo, H., Sakata, T., and Kawai, T. (2010) LAT1 expression in non-small-
cell lung carcinomas: analyses by semiquantitative reverse transcription-PCR 
(237 cases) and immunohistochemistry (295 cases). Lung cancer (Amsterdam, 
Netherlands) 68, 58-65 
43. Kaji, M., Kabir-Salmani, M., Anzai, N., Jin, C. J., Akimoto, Y., Horita, A., 
Sakamoto, A., Kanai, Y., Sakurai, H., and Iwashita, M. (2010) Properties of L-
type amino acid transporter 1 in epidermal ovarian cancer. International journal 
of gynecological cancer : official journal of the International Gynecological 
Cancer Society 20, 329-336 
44. Chung, Y. C., Kim, Y. S., Shadchehr, A., Garrido, A., Macgregor, I. L., and 
Sleisenger, M. H. (1979) Protein digestion and absorption in human small 
intestine. Gastroenterology 76, 1415-1421 
45. Roberts, L. M., Black, D. S., Raman, C., Woodford, K., Zhou, M., Haggerty, J. 
E., Yan, A. T., Cwirla, S. E., and Grindstaff, K. K. (2008) Subcellular localization 
of transporters along the rat blood-brain barrier and blood-cerebral-spinal fluid 
barrier by in vivo biotinylation. Neuroscience 155, 423-438 
46. Wittmann, G., Mohacsik, P., Balkhi, M. Y., Gereben, B., and Lechan, R. M. 
(2015) Endotoxin-induced inflammation down-regulates L-type amino acid 
transporter 1 (LAT1) expression at the blood-brain barrier of male rats and mice. 
Fluids and barriers of the CNS 12, 21 
47. Van Herck, S. L., Delbaere, J., Bourgeois, N. M., McAllan, B. M., Richardson, S. 
J., and Darras, V. M. (2015) Expression of thyroid hormone transporters and 
deiodinases at the brain barriers in the embryonic chicken: Insights into the 
regulation of thyroid hormone availability during neurodevelopment. General and 
comparative endocrinology 214, 30-39 
145 
 
48. Kaisto, T., Rahkila, P., Marjomaki, V., Parton, R. G., and Metsikko, K. (1999) 
Endocytosis in skeletal muscle fibers. Experimental cell research 253, 551-560 
49. Dickinson, J. M., Gundermann, D. M., Walker, D. K., Reidy, P. T., Borack, M. 
S., Drummond, M. J., Arora, M., Volpi, E., and Rasmussen, B. B. (2014) Leucine-
enriched amino acid ingestion after resistance exercise prolongs myofibrillar 
protein synthesis and amino acid transporter expression in older men. The Journal 
of nutrition 144, 1694-1702 
50. Koopman, R., Zorenc, A. H., Gransier, R. J., Cameron-Smith, D., and van Loon, 
L. J. (2006) Increase in S6K1 phosphorylation in human skeletal muscle following 
resistance exercise occurs mainly in type II muscle fibers. American journal of 
physiology. Endocrinology and metabolism 290, E1245-1252 
51. Milkereit, R., Persaud, A., Vanoaica, L., Guetg, A., and Verrey, F. (2015) 
LAPTM4b recruits the LAT1-4F2hc Leu transporter to lysosomes and promotes 
mTORC1 activation. 6, 7250 
52. Zoncu, R., Bar-Peled, L., Efeyan, A., Wang, S., Sancak, Y., and Sabatini, D. M. 
(2011) mTORC1 senses lysosomal amino acids through an inside-out mechanism 
that requires the vacuolar H(+)-ATPase. Science (New York, N.Y.) 334, 678-683 
53. Jones, H., Crombleholme, T., and Habli, M. (2014) Regulation of amino acid 
transporters by adenoviral-mediated human insulin-like growth factor-1 in a 
mouse model of placental insufficiency in vivo and the human trophoblast line 












INVESTIGATING THE ROLE OF VPS34 







5 INVESTIGATING THE ROLE OF VPS34 AS A NUTRIENT SENSOR IN 
HUMAN SKELETAL MUSCLE 
Nathan Hodson1, Jessica Dent1, Zhe Song1, Mary O’Leary2, Tom Nicholson2, Simon W. 
Jones2, James T.Murray3, D. Lee Hamilton4, Leigh Breen1, Andrew Philp1,5. 
1. Sch. of Sport, Exercise and Rehabilitation Sciences, Univ. of Birmingham, UK. 
2. Inst. of Inflammation and Ageing, Univ. of Birmingham, UK. 
3. Trinity Biomedical Sciences Institute, Trinity College, Dublin, IRL. 
4. Sch. of Sport, Univ. of Stirling, UK. 
5. Garvan Inst. of Medical Research, NSW, AU. 
 
Author Contributions: 
Experimental design and analysis plan for the in vitro aspect of the study was conceived by 
Nathan Hodson and Dr. Andy Philp. Experimental design and analysis plan for the in vivo 
aspect of the study was conceived by Dr. Jessica Dent, Dr. Zhe Song and Dr. Andy Philp. 
Human primary myoblast isolation was completed by Tom Nicholson, Dr. Mary O’Leary in the 
laboratory  of Dr. Simon Jones. All subsequent cell culture experiments and immunoblot analysis 
was conducted by Nathan Hodson. Human testing and sample collection was conducted by Dr. 
Jessica Dent, Dr. Zhe Song and Dr. Leigh Breen. Blood analysis was completed by Dr. Jessica 
Dent. Immunohistochemical analysis was conducted by Dr. Zhe Song. All statistical analysis 





5.1 – Abstract 
The mechanistic target of rapamycin (mTOR) complex 1 (mTORC1) regulates cell size 
and growth in response to nutrients, however the full mechanisms by which alterations 
in nutrient levels are ‘sensed’ to mTORC1 are yet to be fully elucidated. Recent in vitro 
evidence has identified the Class III PI3Kinase Vps34 as a potential nutrient sensor, as 
its activity seems to be essential to mTORC1 activation in response to nutrients. As 
skeletal muscle size is principally regulated by nutrient levels, in addition to mechanical 
loading, we sought to investigate the role of Vps34 as a nutrient sensor both in vitro and 
in vivo in skeletal muscle. To understand the importance of Vps34 kinase activity to 
mTORC1 activation in vitro, we administered the Vps34-specific inhibitor SAR405 to 
C2C12 and human primary myotubes and investigated how this inhibitor affected 
mTORC1 signalling response to serum withdrawal and recovery. In addition, we then 
investigated the effects of protein-carbohydrate feeding on Vps34 kinase activity, 
cellular location and protein-protein interactions in human skeletal muscle (n=8, age – 
21.1±0.5yrs, Mean±SEM). In vitro, SAR405 had no effect on the mTORC1-related 
signalling response to serum withdrawal/recovery in either C2C12 or human primary 
myotubes (p=0.069). Furthermore, Vps34 kinase activity was found to be unresponsive 
to protein-carbohydrate feeding in human skeletal muscle (p>0.05). This feeding 
protocol however did initiate the translocation of both mTOR and Vps34 to the cell 
periphery 1h following feeding. These proteins’ colocalisation was also noted to 
increase at this time point, and these processes occurred in parallel to elevations in 
mTORC1 activity (S6K1 kinase activity). This data therefore suggests that it may be 
changes in Vps34 cellular location, rather than kinase activity, that contributes to 
Vps34s purported role as a nutrient sensor in skeletal muscle.  
149 
 
5.2 – Introduction 
Amino acids (AAs) are critical to skeletal muscle plasticity, acting as substrates to 
stimulate muscle protein synthesis (MPS). In parallel, these nutrients can also initiate 
signalling pathways which stimulate MPS(1), and inhibit muscle protein breakdown 
(MPB)(2). Net protein balance (NPB) can only become positive following resistance 
exercise if AAs are also ingested, as acute resistance exercise alone elevates MPS and 
MPB in parallel(2). As AA ingestion and resistance exercise exhibit synergistic effects 
on MPS, it is hypothesised that each of these anabolic stimuli activate MPS via divergent 
signalling pathways. In skeletal muscle, it is believed that increases in MPS are governed 
primarily by the activation of the mechanistic target of rapamycin complex 1 
(mTORC1)(3, 4), an evolutionarily conserved serine/threonine kinase complex which 
stimulates translation initiation and elongation(5-7).  
AAs are thought to stimulate mTORC1 activation by increasing the localisation of Rag 
proteins with lysosomes (8) where they can recruit mTORC1 to the surface of this 
organelle (8, 9). We (10, 11), and others (12), have recently challenged this paradigm in 
human skeletal muscle finding no change in mTOR-lysosome association following 
resistance exercise and/or protein-carbohydrate feeding, events which both potently 
stimulate mTORC1 signalling. What is currently unknown is to how AA stimulate 
mTORC1 in skeletal muscle and whether this process results in mTORC1 translocation 
to the cell periphery. A potential candidate for AA action on mTORC1 is the vacuolar 
protein sorting 34 (Vps34), a class III PI3Kinase, whose action is to produce 
phosphatidylinositol 3-phosphate (PI(3)P) through the phosphorylation of 
phosphatidylinositol (13). This product is then able to recruit various proteins to 
phospholipid bilayers i.e. plasma and lysosomal membranes (14). 
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Vps34 implication in nutrient sensing was first proposed by Byfield et al.(15), who 
reported that overexpression of Vps34 in HEK293 cells elicited a 2-fold increase in S6K1 
activity, a similar elevation to that induced by insulin. Furthermore, in the presence of 
siRNA targeting Vps34, insulin-stimulated S6K1Thr389 phosphorylation was abolished 
and the removal of AAs reduced endogenous Vps34 activity even in the presence of 
insulin(15). A similar study by Nobukuni et al.(16) reiterated these findings, displaying 
that siRNA-mediated reductions in Vps34 expression, in HEK293 cells, dramatically 
attenuated mTORC1 activation in response to both AA and insulin stimulation. 
Interestingly, recent evidence has suggested that activated Vps34 colocalises with mTOR, 
close to cell membranes, following insulin stimulation(17). Moreover, when Vps34 
kinase activity was inhibited, mTOR recruitment to the plasma membrane and the 
subsequent phosphorylation of S6K1Thr389 was significantly attenuated (17). This data 
implicates Vps34 in the recruitment of mTOR toward the cell periphery, a process we 
have recently identified in human skeletal muscle (10). 
In human primary myotubes, evidence for the involvement of Vps34 in nutrient-sensing 
pathways has also been reported. In response to leucine (5mM) and insulin (100nM) 
stimulation, Vps34 protein abundance was elevated by 20-50% at 0.5h, 3h, and 24h (18). 
This increase in Vps34 was mirrored by rises in mTORSer2448 and S6K1Thr389 
phosphorylation (18), however, it was not clear from this data as to whether there was an 
interaction between Vps34 and mTORC1 activation, or whether the co-ordinated 
induction was coincidental. In addition to AA/insulin stimulation, contractile loading is 
also known to increase Vps34 kinase activity in rodent skeletal muscle (19). In an attempt 
to elucidate a mechanism behind this elevation of Vps34 activity, the level of 
intramuscular leucine noted following contraction was then added to C2C12 muscle cells 
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for 3h. This resulted in a ~5-fold increase Vps34 kinase activity, yet incubation with 
physiological levels of all AAs did not affect kinase activity (19). Overall, such data 
implicates a possible role for Vps34 in AA sensing within skeletal muscle; however a 
more detailed investigation of Vps34 in human tissue is still required to understand the 
mechanism by which Vps34 may ‘sense’ nutrient levels particularly in response to 
anabolic stimuli other than mechanical loading i.e. feeding. 
To further elucidate a role for Vps34 in human skeletal muscle nutrient sensing, this 
chapter examined cell responses to the Vps34 inhibitor, SAR405(20, 21), determining the 
importance of Vps34 kinase activity for mTORC1 activation in C2C12 and human 
primary skeletal muscle myotubes. Following this, we then aimed to investigate how 
AA/carbohydrate feeding affected Vps34 activity and cellular localisation in human 
skeletal muscle. We hypothesised that inhibition of Vps34 would impair serum/leucine 
activation of mTORC1. In addition, we hypothesised Vps34 activity would increase in 
response to AA/carbohydrate feeding in human skeletal muscle in parallel to increases in 
mTORC1 signaling. 
5.3 – Methods 
5.3.1 In vitro experimental design 
C2C12 and human primary myoblasts were cultured and subsequently differentiated into 
myotubes as described in Chapter 2 (Sections 2.8.1 and 2.8.2). When full myotubes had 
formed, cells were nutrient deprived for ~14h in Earl’s Balanced Salt Solution (EBSS), 
supplemented with PenStrep (1%). For human primary samples (characteristics described 
in Section 2.8.2 of this thesis), a subset of myotubes from each individual was placed in 
F-10 Hams media (supplemented with 20% FBS and 1% Pencillin-Streptomycin) for this 
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period and used as a baseline condition. For C2C12 cells, a subset of myotubes were 
cultured in normal differentiation media for ~14h to use as a baseline condition. Another 
set of cells were collected following this deprivation to determine the effects of this 
protocol on mTORC1 signalling. The remaining myotubes were split into 2 conditions; 
serum recovery, and serum recovery + Vps34 inhibition. In human primary cells, the 
serum recovery condition consisted of 30 minutes of incubation in F-10 Hams media 
(supplemented with 20% FBS and 1% Pencillin-Streptomycin) following the nutrient 
deprivation protocol.  In C2C12 myotubes, serum recovery consisted of incubation in 
normal differentiation media, for 30 minutes, following nutrient deprivation. Vps34 
inhibition conditions were identical to the corresponding serum recovery conditions apart 
from a 60 minute pre-incubation with 10µM SAR405. Following each treatment, cells 
were washed twice in PBS (Fisher Scientific, Loughborough, UK) and scraped into ice-
cold sucrose lysis buffer (see Chapter 2 - 2.5.1). Lysates were frozen in liquid nitrogen 
and stored at -80ºC until further analysis. To initiate analysis, samples were thawed, 
sonicated for 3 x 15 seconds at 50% maximum wattage, centrifuged at 8000g, for 10 
minutes at 4ºC and the supernatant used for analysis. Protein concentration was 
determined using the DC protein assay as described in Chapter 2 (Section 2.5.1). 
Experiments in human primary myotubes were run in triplicate for each donor and 
experiments in C2C12 myotubes were run in triplicate and repeated on 3 separate days to 
enhance the reliability of our measurements. 
5.3.2 Immunoblotting 
Identical amounts of protein were separated on 8-12.5% polyacrylamide gels by SDS-
PAGE as described in Chapter 2 (Section 2.5.2). Proteins were then transferred to 
BioTrace NT nitro-cellulose membranes (Pall Life Sciences, UK) at 100V for 1h, blocked 
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in 3% milk/TBST and incubated overnight in the desirable primary antibodies (all 1:1000 
dilution in TBST). The following day, membranes were washed in TBST and incubated 
in corresponding secondary antibodies (diluted 1:10000 in TBST) at room temperature 
for 1h. Chemiluminescence horseradish peroxidase reagent kit (Merck-Millipore) was 
used to quantify protein content following IgG binding. Images were captured with a 
G:Box Chemi-XR5 (Syngene (A Division of Synoptics Ltd.), Cambridge, UK) imaging 
system and blot bands were quantified using GeneTools software (Syngene). Each protein 
target was expressed in relation to a loading control (Ponceau) and each phosphorylation 
site is presented in relation to its corresponding total protein abundance. 
5.3.3 Antibodies 
For immunoblotting analysis all primary antibodies were purchased from Cell Signaling 
Technologies (CST) and diluted at 1:1000 in TBST unless stated otherwise. Antibodies 
utilised were: p70 ribosomal S6 kinase 1 (S6K1, #2708), p-S6K1Thr389 (#9205), ribosomal 
protein S6 (S6, #2217), p-S6Ser235/236 (#4858), p-S6Ser240/244 (#5364), eukaryotic 
translation initiation factor 4E-binding protein 1 (4EBP1, #9452, 1:500), p-4EBP1Thr37/46 
(#9459), AKT (#4697), p-AKTThr308 (#2965), p-AKTSer473 (#4060) and eukaryotic 
elongation factor 2(eEF2, #2332). All primary antibodies were produced in rabbits and 
as such anti-rabbit IgG HRP-linked secondary antibody (CST#7074) was utilised. 
Antibody binding was detected via the use of enhanced chemiluminescence horseradish 
peroxidase substrate detection kit (Millipore, Watford, UK). 
For enzyme kinase activity assays, antibodies utilised were as follows: S6K1 (sc-2708, 
Santa Cruz Biotech., Dallas, TX, USA), AKT (sc-4691, Santa Cruz Biotech.) and Vps34 
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(anti-sheep antibody produced by Dr. James Murray, Trinity Biomedical Science 
Institute, Trinity College, Dublin, IE). 
For immunohistochemical analysis, antibodies utilised were as follows: anti-mTOR (#05-
1592, Merck Chemical Ltd., Nottingham, UK), anti-LAMP2 (#AP1824d, Abgent, USA), 
anti-Vps34 (CST#3358) and Wheat Germ Agglutinin (WGA-350, #11263, 
ThermoFisher, UK). Corresponding secondary antibodies were goat anti-mouse IgGγ1 
Alexa®594 (#R37121, ThermoFisher, UK, targeting mTOR) and goat anti-rabbit 
IgG(H+L) Alexa®488 secondary antibodies (#A11008, ThermoFisher, UK, targeting 
LAMP2/Vps34). 
5.3.4 Human Trial Experimental Design 
Eight young, healthy men (age – 21.1±0.5yrs, Mean±SEM) volunteered to partake in the 
study. Participants were healthy (as assessed by a general health questionnaire), 
recreationally active and non-smokers. All participants provided written informed 
consent prior to partaking in the study.  
On the day of the trial, participants reported to the laboratory  at the School of Sport, 
Exercise and Rehabilitation Sciences building at 08.00h, following an overnight fast 
(~10h) and having refrained from strenuous exercise and alcohol or caffeine consumption 
for 48h prior to the trial. Participants were placed in a supine position for ~20 minutes to 
allow for reliable resting samples to be taken. A 21G cannula was then inserted into the 
antecubital vein of one arm of the participant and a resting blood sample (10mL) was 
drawn. Subsequent blood samples were obtained every 20 minutes throughout the 
experimental trial. Each blood sample was split (5mL) between serum separator and 
EDTA-coated (plasma) vacutainers (BD Biosciences, Oxford, UK.). EDTA-coated 
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vacutainers were placed immediately on ice and serum separator tubes remained at room 
temperature for 30 minutes to coagulate before being placed on ice. Following the trial 
blood samples were centrifuged for 10 mins at 3000g at 4℃ and plasma and serum were 
transferred to eppendorfs at stored at -80℃ until further analysis. A muscle biopsy sample 
was then taken from the vastus lateralis using the bergstrom percutaneous needle 
technique, modified for suction. Participants then consumed a commercially available 
protein-carbohydrate beverage (Gatorade Recover®, Chicago, IL, USA.) providing 
20/44/1g of protein, carbohydrate and fat respectively. Subsequent muscle biopsies were 
taken 1h and 3h post-consumption of this beverage. Muscle samples were blotted free of 
blood and dissected free of any excess adipose or connective tissue. A piece of each 
muscle samples was immediately frozen in liquid nitrogen and kept at -80ºC until 
analysed. A separate piece was placed in OCT compound (VWR, Lutterworth, UK.) and 
frozen in liquid nitrogen-cooled isopentane before storage at -80ºC. The experimental 
design is depicted in Figure 5.1. 
5.3.5 Blood analyses 
Serum insulin and plasma AA concentrations were determined by ELISA and GC-MS 
respectively as described in sections 2.7.1 ad 2.7.2 of this thesis. 
5.3.6 Kinase Activity Assays 
Kinase activity assays were conducted targeting S6K1, AKT and Vps34 as described in 
Chapter 2 (Section 2.6.1 for S6K1 and AKT, section 2.6.2 for Vps34) utilising 32γ-ATP 




5.3.7 Skeletal Muscle Immunohistochemistry  
Skeletal muscle samples were processed for immunohistochemical analysis as described 
in Chapter 2 (Sections 2.3 and 2.4). In this chapter, protein targets of interest were 
mTOR(594nm)-LAMP2(488nm)-WGA(350nm) and mTOR(594nm)-Vps34(488nm)-
WGA(350nm), each combination visualised as described in section 2.4.5 of this thesis. 
Image analysis for colocalisation of these targets was conducted using ImagePro software 
as described in section 2.4.6.2. 
5.3.8 Statistics 
Changes in phosphorylation status of proteins in human primary myotubes were analysed 
using a repeated measures ANOVA with one within-subject factor (treatment). Changes 
in phosphorylation status of proteins in C2C12 myotubes were analysed using a one-way 
ANOVA with one between-subject factor (treatment). Kinase activity and protein-protein 
colocalisation were analysed using a repeated measures analysis of variance (ANOVA) 
with one within-subject factor (time). When a significant main effect was found, post-hoc 
tests were completed with the Holm-Bonferroni correction for multiple comparisons. 
Significance for all variables analysed was set at p≤.05. Data are presented as mean±SEM 
unless otherwise stated. 
 
Figure 5.1. Human trial experimental design. 
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5.4 – Results 
5.4.1 In Vitro Study  
5.4.1.1 Effects of SAR405 on serum-induced mTORC1 activation in C2C12 myotubes 
A significant treatment effect was noted for the phosphorylation of S6K1Thr389 following 
serum withdrawal and recovery in C2C12 myotubes (p<0.0001, Fig. 5.2a). Serum 
withdrawal decreased S6K1Thr389 phosphorylation (~35% reduction, p<0.001) and 
subsequent serum recovery for 30mins, irrespective of SAR405 administration, elevated 
S6K1Thr389 phosphorylation above both baseline and serum withdrawal levels (SR – 65% 
above baseline, SR+SAR405 – 50% above baseline, p<0.0001, Fig. 5.2a). No difference 
in S6K1Thr389 phosphorylation was observed between SR or SR+SAR405 treatments 
(p=0.26). A treatment effect was also observed for 4EBP1Thr37/46 phosphorylation 
(p<0.0001, Fig. 5.2b). Serum withdrawal elicited a 32% reduction in 4EBP1Thr37/46 
phosphorylation (p<0.001, Fig. 5.2b). Subsequent serum recovery, both in the presence 
and absence of SAR405, significantly elevated phosphorylation above serum withdrawal 
levels (62% and 65% elevation respectively, p<0.0001, Fig. 5.2b) with no difference 
between SR and SR+SAR405 apparent (p=0.80).  
A treatment effect was noted for S6Ser235/236 phosphorylation (p<0.0001, Fig. 5.2c). 
Similarly, serum withdrawal reduced S6 phosphorylation at this site (35% reduction, 
p<0.001) compared to baseline. Serum stimulation elevated S6Ser235/236 phosphorylation 
above baseline and serum withdrawal values (33% above baseline, p=0.038 vs. baseline, 
p<0.001 vs. SW, Fig. 5.2c). Again, SAR405 had no effect on these responses (30% above 
baseline, p=0.05 vs. baseline, p<0.001 vs. SW, Fig. 5.2c) nor was there any difference 
between SR and SR+SAR405 treatments (p=0.83, Fig. 5.2c). A treatment effect was also 
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noted for S6 phosphorylation at Ser240/244 (p<0.0001, Fig. 5.2d). Here, serum 
withdrawal elicited an 18% reduction in S6Ser240/244 phosphorylation (p<0.001), with 
subsequent serum recovery elevating phosphorylation above serum withdrawal levels 
irrespective of SAR405 (SR – 27.7% above SW, p<0.001; SR+SAR405 – 26.1% above 
SW, p<0.001, Fig. 5.2d). No difference between the responses in SR and SR+SAR405 
were observed (p=0.80). 
Figure 5.2. The effects of overnight serum withdrawal and subsequent serum recovery (30 minutes), 
with or without SAR405), on anabolic signalling in C2C12 myotubes (n=9/group). p-S6K1Thr389 (A), 
p-4EBP1Thr37/46 (B), p-S6Ser235/236 (C), p-S6Ser240/244 (D), p-AKTThr308 (E) and p-AKTSer473 (F) phosphorylation 
was quantified in relation to their total proteins and ponceau staining was used as a loading control. 
Representative images are also provided (G). Data is presented as Mean±SEM. *Significantly different to 
B (p<0.05). #Significantly different to SW (p<0.05). 
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A treatment effect was also observed for AKT Thr308 and AKTSer473 phosphorylation (both 
p<0.0001). Serum withdrawal elevated AKTThr308 phosphorylation by 22% (p=0.007), 
and subsequent serum recovery increased phosphorylation at this site above both baseline 
and serum withdrawal levels (88.2% above baseline, p<0.001, Fig. 5.2e). Serum recovery 
in the presence of SAR405 also elevated AKTThr308 phosphorylation above both baseline 
and serum withdrawal levels (95.7% above baseline, p<0.0001, Fig. 5.2e), with no 
difference when compared to SR (p=0.69). AKTSer473 was affected in a similar manner, 
with serum recovery causing a significant rise in phosphorylation above baseline 
(p<0.0001) and serum withdrawal (p<0.001) values irrespective of inhibition treatment 
(SRvs.SR+SAR405 p=0.76, Fig. 5.2f). Representative images for all immunoblots 
described are displayed in Fig. 5.2g. 
5.4.1.2 Effects of SAR405 on serum-induced mTORC1 activation in Human Primary 
myotubes 
A significant treatment effect was noted for S6K1Thr389 phosphorylation following serum 
withdrawal and recovery in Human primary myotubes (p<0.0001). Here, serum 
withdrawal significantly reduced S6K1Thr389 phosphorylation by ~70% (p=0.02, Fig. 
5.3a). Serum recovery, with or without SAR405 administration, elevated S6K1Thr389 
phosphorylation above both baseline and SW (SR – 92% above baseline, SR+SAR405 – 
54% above baseline, all p<0.05, Fig. 5.3a), with no difference between SR and 
SR+SAR405 conditions (p=0.069, Fig. 5.3a) A treatment effect was also noted for 
4EBP1Thr37/46 phosphorylation (p=0.004). Here, serum withdrawal elicited a 63% 
reduction in 4EBP1Thr37/46 phosphorylation (Fig. 5.3b). Further serum recovery, with or 
without SAR405, elevated phosphorylation 40% and 26% above baseline respectively. 
160 
 
However, no comparisons were significant following post-hoc tests and no difference was 
observed between the effects of SR and SR+SAR405 (p=0.20, Fig. 3b).  
Figure 5.3. The effects of overnight serum withdrawal and subsequent serum recovery (30 minutes), 
with or without SAR405), on anabolic signalling in Human Primary Myotubes (n=4/group). p-
S6K1Thr389 (A), p-4EBP1Thr37/46 (B), p-S6Ser235/236 (C), p-S6Ser240/244 (D) and p-AKTThr308  (E) phosphorylation 
was quantified in relation to their total proteins and ponceau staining was used as a loading control. 
Representative images are also provided (F). Data is presented as Mean±SEM. *Significantly different to 
B (p<0.05). #Significantly different to SW (p<0.05). γTrend toward different to SR+SAR405 (p<05). 
¥Significant Treatment effect (p<0.05). 
 
S6Ser235/236 phosphorylation displayed a significant treatment effect (p=0.01, Fig. 5.3c). 
Serum withdrawal elicited a 64% reduction in S6Ser235/236 phosphorylation, whereas serum 
recovery elevated S6Ser235/236 phosphorylation 3.8 fold above SW levels. No difference 
was observed between SR and SR+SAR405 groups (p=0.45). A significant treatment 
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effect was also noted for S6Ser240/244 phosphorylation at (p=0.003), where serum recovery 
elevated S6Ser235/236 phosphorylation ~3 fold above SW levels. No difference was 
observed between SR and SR+SAR405 groups. A trend toward a treatment effect was 
apparent for AKTThr308 phosphorylation (p=0.083, Fig. 5.3e). Here, no comparisons were 
significant following post-hoc analysis, most likely due to the large variability in 
individual responses noted in this measure. Representative images for all immunoblots 
described are displayed in Fig. 5.3f. 
5.4.2 Human Study 
5.4.2.1 Serum Insulin Concentrations 
Serum insulin concentrations were significantly elevated above baseline levels at 40 and 
80 minutes post-drink ingestion (5- and 2.9-fold increase respectively, p<0.005, overall 
time effect – p<0.0001, Fig. 5.4a). Trends toward elevated serum insulin concentrations 
were also noted at 20 (7.1-fold), 60 (4.2-fold), 100 (2.75-fold) and 120 (2.59-fold) 
minutes post-feeding (all p<0.081, Fig. 5.4a). Serum insulin returned to basal values at 
140 minutes post-ingestion (p=0.12, Fig. 5.4a). 
5.4.2.2 Plasma AA Concentrations 
A significant time effect was noted for the fold change, from baseline, in plasma leucine 
concentrations (p=0.0001, Fig. 5.4b). Here, plasma leucine concentrations rose above 
baseline at 20 minutes post-drink ingestion (1.7 fold increase, p<0.03) and remained 
elevated (all time points p<0.01) before returning to basal values at 160 min (p=0.40, Fig. 
5.5.4b). The plasma concentrations of threonine and phenylalanine followed a similar 
pattern to this, rising above baseline at 20 minutes post-ingestion (22% and 34.8% 
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elevation respectively, p<0.01) and remaining above baseline until 140mins following 
ingestion (p<0.05, Fig. 5.5.4c & d). 
5.4.2.3 Kinase Activity Assays 
A significant time effect was noted for S6K1 kinase activity (p=0.001). There was a ~9 
fold increase in S6K1 kinase activity 1 hour following ingestion of the protein-
carbohydrate beverage (10.8±1.02fmol/min/mg vs. 92.57±13.8fmol/min/mg, p=0.002, 
Fig. 3a), before returning to baseline at 3 hours post-ingestion (10.8±1.02fmol/min/mg 
vs. 15.06±2.08fmol/min/mg, p=0.11, Fig. 5.5a). S6K1 kinase activity at 1h post-ingestion 
was also significantly greater than that noted at 3h post-ingestion (p=0.001). A significant 
time effect was also noted for AKT kinase activity (p=0.004). AKT kinase activity was 
significantly elevated above baseline at 1 hour post-ingestion (28.04±5.37fmol/min/mg 
vs. 44.01±2.14fmol/min/mg, p=0.03, Fig. 5.5b) and returned to baseline values by 3 hours 
post-ingestion (28.04±5.37fmol/min/mg vs. 28.56±3.57fmol/min/mg, p=0.89, Fig. 5.5b). 
Similarly, AKT kinase activity at 1 hour following consumption was significantly greater 
than 3 hours post-ingestion (p=0.02). Finally, no significant differences at any time point 
were noted in VPS34 kinase activity (p>0.05, Fig. 5.5c). 
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Figure 5.4. The effects protein-carbohydrate ingestion on serum insulin (A) and plasma leucine (B), 
threonine (C) and phenylalanine (D) concentrations (n=8). All values are in relation to individual 
baseline values. Data presented as Mean±SEM. *Significantly different from baseline (p<0.05). γTrend 
toward different to baseline (p<0.081). 
5.4.2.4 mTOR colocalisation with LAMP2 and WGA 
No significant differences were noted at any time points in the colocalisation of mTOR 
and LAMP2 (lysosomal marker) suggesting these two proteins are constantly localised 
(p=0.347, Fig. 5.6b). However, a significant time effect for the colocalisation of mTOR 
and WGA was observed (p=0.026). mTOR-WGA colocalisation increased from baseline 
values by ~17% 1h post-feeding, before returning close to baseline values at 3 hours 





Figure 5.5. The effects of protein-carbohydrate 
ingestion on S6K1 (A), AKT (B) and Vps34 (C) 
kinase activity (n=8). Data presented as 
Mean±SEM. *Significantly different to Pre values 








5.4.2.5 VPS34 colocalisation with mTOR and WGA 
A significant time effect was noted for mTOR-VPS34 colocalisation (p=0.045), with 
mTOR-VPS34 colocalisation increased by ~11% 1 hour post-ingestion before returning 
to baseline 3 hours post-ingestion (Fig. 5.7b). A trend toward a greater mTOR-VPS34 
colocalisation was apparent at 1 hour post-ingestion compared to 3 hours post-ingestion 
(p=0.067, Fig. 5.7b). A trend toward a significant time effect was also found when 
studying VPS34 colocalisation with WGA (p=0.053). Here, VPS34-WGA colocalization 
rose at 1 hour following drink consumption (~27% increase from baseline, Fig. 5.7c), 




Figure 5.6. The effects of protein-carbohydrate ingestion on mTOR-LAMP2 and mTOR-WGA 
colocalisation (n=8). Representative images of mTOR, LAMP2 and WGA stains at each time point are 
provided (A). mTOR stain is shown in the first column of images (red), LAMP2 in the second (green) and 
WGA in the third (blue). Quantification of mTOR-LAMP2 (B) and mTOR-WGA (C) colocalisation was 







Figure 5.7. The effects of protein-carbohydrate ingestion on mTOR-VPS34 and mTOR-WGA 
colocalisation (n=8). Representative images of mTOR, VPS34 and WGA stains at each time point are 
provided (A). mTOR stain is shown in the first column of images (red), VPS34 in the second (green) and 
WGA in the third (blue). Quantification of mTOR-VPS34 (B) and VPS34-WGA (C) colocalisation was 
completed. Data in B and C are Mean±SEM. ¥Significant time effect (p<0.05).  
5.5 – Discussion 
Herein, we report that the Vps34 specific inhibitor SAR405 does not affect mTORC1 
activation following serum recovery in human primary or C2C12 myotubes. These 
findings suggest Vps34 kinase activity may not be essential for mTORC1 activity in vitro. 
Further to these findings, we show that Vps34 kinase activity is not affected by protein-
carbohydrate feeding in human skeletal muscle. The feeding protocol however, did alter 
Vps34’s cellular location, prompting a translocation toward the cell periphery and 
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inducing an increase in its colocalisation with mTOR. The alterations in the cellular 
locations of these proteins coincided with an augmentation of mTORC1 activity. 
Together, these observations suggest a change in Vps34 cellular location, rather than its 
kinase activity, may contribute to AA sensing in human skeletal muscle. 
The notion that Vps34 contributes to AA sensing is based on studies utilising non-muscle 
immortalised cell lines(15, 16, 22) which may not necessarily mimic a ‘normal’ 
physiological response of skeletal muscle. Furthermore, the importance of Vps34 kinase 
activity in skeletal muscle cells has not yet been directly tested. In an attempt to elucidate 
the importance of Vps34 kinase activity in muscle we utilised C2C12, an immortalised 
mouse myoblast cell line, and isolated human primary myotubes (23). The effect of the 
Vps34-specific inhibitor SAR405 on the activation of mTORC1 in response to serum 
recovery, following overnight withdrawal, was then tested to examine the importance of 
Vps34 kinase activity in this response. In C2C12 myotubes, SAR405 had no effect on the 
activation of mTORC1 (Fig. 5.2). This evidence suggests that Vps34 kinase activity does 
not contribute in to mTORC1 activation in this immortalised muscle cell line. This data 
contradicts other reports in vitro where SAR405 administration, at low concentrations 
(3µM), in HEK293 cells completely ablated S6K1 phosphorylation in response to AAs 
(22). Therefore, our finding that SAR405 had no effect on mTORC1 activation in C2C12 
myotubes is contrary to our working hypothesis. There are a number of potential reasons 
for this lack of effect. First our assumption is that Vps34 is activated in muscle cells in 
response to serum stimulation. Currently we do not have evidence to support this and so 
the model used needs further validation to its suitability to study vps34 activity in vitro. 
Second, the SAR405 dose incorporated in our studies may not be sufficient to inhibit 
Vps34 activity in myotubes. C2C12 myoblasts have a much higher metabolism than 
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HEK293, proliferating and differentiating at a greater rate (24). We assumed that the dose 
previously reported to inhibit vps34 in vitro would be sufficient to inhibit Vps34 in our 
experimental models, however without direct or surrogate readouts of Vps34 activity we 
are unable to confirm this point at this stage. Furthermore, it is possible that our serum 
recovery protocol exerted such a large effect on mTORC1 activation that the ‘threshold’ 
for maximal signalling effects was already reached irrespective of any possible effects of 
the Vps34 inhibitor. This suggests that even if SAR405 did cause some inhibition of 
mTORC1 activity it did not reduce this below the threshold level and therefore maximal 
S6K1 phosphorylation still occurred. Interestingly, one previous report suggests that 
Vps34 activity may actually be reduced in C2C12s in the presence of AAs(25) which may 
explain why no effect of SAR405 was apparent, however these findings have not been 
replicated in other cell lines(15, 16). In fact, the addition of leucine to C2C12 myotubes 
elevates Vps34 kinase activity to a similar extent as did eccentric contractions in rodent 
skeletal muscle (19). These contradictory findings, combined with our own, advocated 
the need to investigate the importance of Vps34 kinase activity in human primary 
myotubes.   
Subsequently, we also did not find an effect of SAR405 on mTORC1 activation in human 
primary myotubes. Here, however, the administration of this inhibitor reduced S6K1 
Thr389 phosphorylation, in relation to baseline levels, by ~42%, yet this attenuation did 
not reach significance (p=0.069). This effect did not extend downstream of S6K1 or to 
any other mTORC1 target. This is the first study to directly investigate the effects of 
Vps34 activity on mTORC1 signalling in primary myoblasts. Previous in vitro data 
reported a complete ablation of mTORC1 activity in the presence of Vps34 inhibitors 
(22) or siRNA targeting this kinase(15, 16, 26-28), suggesting Vps34 may completely 
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govern mTORC1 activation in response to AAs or insulin. The data gathered in the 
current study contradicts these findings however, as we did not directly measure Vps34 
kinase activity we cannot fully conclude its importance in this scenario. Interestingly, 
several other candidates for nutrient sensors to mTORC1 have been purported including 
Sestrins(26-28), MAP4K3(29) and leucyl-tRNA synthetase (LRS)(30, 31). Of note, when 
each of these other ‘nutrient sensors’ were inhibited in HEK293 or HeLa cells, a complete 
ablation of the S6K1Thr389 response was also reported(28-30), suggesting all these proteins 
coordinate into one signal pathway to activate mTORC1. A second, more plausible, 
explanation is that simple nature of these cellular monolayers allows the knockdown of a 
single protein to have a drastic effect on cellular signalling, whereas in a more ‘complex’ 
in vitro system, such as human primary myotubes, these proteins may display smaller 
contributory roles. Though the importance of Vps34 kinase activity has not been 
previously investigated in human primary myotubes, the effect of leucine and insulin 
administration on Vps34 protein content has been reported. Gran and Cameron-Smith(18) 
reported that leucine and/or insulin exposure for 0.5, 3 or 24h all elevated Vps34 protein 
content, an effect that occurred alongside mTORC1 activation. The significance of this 
increase in Vps34 protein is difficult to deduce as it is impossible to know whether it 
occurred upstream or downstream of the altered mTORC1 signalling. Nevertheless, this 
data does suggest Vps34 content is regulated somewhat by nutrient provision, however 
Vps34 kinase activity was not measured and as such conclusions regarding this aspect of 
its regulation cannot be drawn. Together, our findings show that the use of the Vps34 
specific inhibitor SAR405 has no significant effect on mTORC1-related signalling 
following serum recovery in C2C12 or human primary myotubes. As such future research 
regarding the potential importance of Vps34 kinase activity in specific tissues is required.  
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We next investigated whether Vps34 kinase activity was altered by protein-carbohydrate 
feeding in vivo in human skeletal muscle. Contrary to our hypothesis, Vps34 kinase 
activity did not change across the postprandial time course. Previously, it has been shown 
that eccentric contractions elevated Vps34 kinase activity in rodent skeletal muscle, and 
this was believed to be due to the elevation in intracellular leucine that occurred here(19). 
Based on the elevations in plasma leucine, our feeding protocol would have likely 
increased intramuscular leucine, therefore stimulating Vps34 kinase activity however, 
this was not apparent. In human skeletal muscle, there is only one previous study which 
assessed Vps34 kinase activity(32). Here, sprint exercise combined with protein-
carbohydrate ingestion did not alter kinase activity whereas exercise in the fasted state 
elicited a trend toward elevated activity ~1.5h following the final exercise bout. This 
implies that protein-carbohydrate feeding itself may attenuate Vps34 kinase activity, a 
notion we did not find in the current study. A potential explanation for these contradictory 
findings is the large number of complexes in which Vps34 is comprised(13). As the only 
class III PI3 Kinase in mammalian cells, Vps34 resides in many complexes of varying 
functions. For example, when associated with Beclin-1 and Atg14, Vps34 will regulate 
phagophore nucleation and aid the induction of autophagy(33), whereas an association 
Rab5/7 will allow Vps34 to regulate endocytic sorting(34). Further to this, and as 
described earlier, Vps34 seems to regulate anabolic responses nutrient provision (15, 16). 
Importantly, these processes, in particular mTORC1 activation and autophagosome 
nucleation, are oppositely regulated by nutrient provision. This could result in protein-
carbohydrate feeding eliciting opposing effects on certain Vps34 complexes and, as our 
method of measuring Vps34 kinase activity does not distinguish between these 
complexes, may explain the absence of a change in this measure. It may also explain the 
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differing results from previous analysis where eccentric contractions in rodents could 
have simultaneously activated both anabolic and catabolic Vps34 complexes(19), whilst 
the addition of protein-carbohydrate feeding following sprint exercise(32) may inhibit 
catabolic and activate anabolic Vps34 complexes resulting in similar findings to those we 
report. As our understanding of the in vivo regulation of Vps34 kinase activity is in its 
infancy, further research is imperative to fully elucidate this kinase’s role in skeletal 
muscle.  
The current most widely accepted model of AA-induced mTORC1 activation is based on 
recruitment of mTORC1 to the lysosome where it can bind with its direct activators Rheb 
and PA(8, 35-38). However recent evidence from our laboratory  (10, 11), and others (12) 
suggests that mTORC1 activation in skeletal muscle seems to involve the translocation 
of mTORC1-lysosome complexes to peripheral regions of the cell, an event which 
coincides with elevated mTORC1 activity(10, 11) and elevated interaction between 
mTORC1 and Rheb(10). Recently, Vps34 has been implicated in this process in vitro, 
where Vps34 is required for the recruitment of mTOR to cellular projections in response 
to insulin stimulation and in fact colocalises with mTOR in these regions (17). We 
investigated this paradigm in human skeletal muscle through the use of 
immunofluorescence microscopy partnered with colocalisation analysis. Firstly, we 
found no change in mTOR-LAMP2 colocalisation following protein-carbohydrate 
feeding, in agreement with our previous data displaying mTOR to be constantly 
associated with the lysosome(10, 11). Interestingly, these findings have been contradicted 
recently by other groups(39, 40), reporting an increase in mTOR-LAMP2 localisation 
following resistance exercise or essential AA feeding. The discrepancy in findings is 
difficult to explain however, could be due to differences in antibodies utilised and 
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quantification methods (Pearson’s vs. Mander’s correlation coefficients). In the current 
study we next observed mTOR-positive structures move toward the cell periphery, 
inferred by the time effect noted for mTOR-WGA (marker of the cell membrane) 
localisation. This time effect was most likely driven by the 17% increase noted at 1 hour 
following feeding; an alteration which occurred in concurrence with an increase in 
mTORC1 activation, reinforcing our hypothesis that mTORC1 translocation is a key 
event in this kinase’s activation(10, 11). Notably, this change in mTOR-WGA 
localisation following protein-carbohydrate feeding is similar to an effect we have 
previously observed (11), showing a reproducibility in our measurements. The 
colocalisation of Vps34 with WGA exhibited a similar pattern as that of mTOR-WGA, 
with a trend toward a time effect noted (p=0.053). Here, Vps34-WGA colocalisation 
increased significantly above baseline 1 hour post-feeding before returning to baseline 3 
hours after drink consumption. This investigation is the first to our knowledge which has 
examined Vps34 cellular location in skeletal muscle, however a translocation toward the 
cell periphery has been previously observed in vitro in response to insulin 
administration(17). Moreover, the product of Vps34 kinase activity (PI(3)P) is also 
visualised in these areas and the translocation of mTORC1 to peripheral regions is 
believed to be PI(3)P dependent(17, 41, 42).  Our finding that Vps34 translocation also 
occurs in human skeletal muscle suggests that this may direct Vps34 kinase activity 
toward these regions in order to recruit mTORC1. Specifically, this may further clarify 
why global Vps34 kinase activity remained unchanged in the current study, as an 
alteration in the location at which PI(3)P production occurs rather than an increase in total 
PI(3)P presents a more efficient mechanism of mTORC1 peripheral recruitment.  
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Notably, we also report an effect of protein-carbohydrate feeding on mTOR-Vps34 
colocalisation where an overall time effect was observed. Again an increase in this 
variable 1 hour following feeding (11%) most likely drove this effect and a trend toward 
a greater colocalisation at this time point, compared to 3 hours post-feeding (p=0.067. 
This data implies that protein-carbohydrate feeding elicits both mTORC1 and Vps34 
translocation toward the cell periphery where these proteins associate. This association 
has been reported in NIH3T3 cells following insulin exposure (17) and our similar 
observations in human skeletal muscle further reinforces the notion that Vps34 could 
regulate nutrient-induced mTORC1 trafficking and activation(15, 16). A recent study in 
HeLa cells suggests that PI(3)P may regulate lysosomal positioning via its receptors 
Protrudin and FYCO1(42). Specifically, AAs induce an increased association of FYCO1 
with lysosomes and the ablation of this protein, or Protrudin, caused the clustering of 
mTOR-positive lysosomes to perinuclear regions and attenuated mTORC1 activity, 
irrespective of nutrient availability(42). This intricate control mechanism of lysosomal 
positioning by the product of Vps34 activity may extend to human skeletal muscle and 
explain the results we present here, and previously (10, 11), regarding both mTORC1 and 
Vps34 translocation. With this current in vivo study design we are unable to conclude 
whether Vps34 translocation occurs before, or in fact causes, mTORC1 translocation. 
Intriguingly, several other mechanisms by which Vps34 may regulate mTORC1 have 
been presented. Mohan et al.(41) utilised a Vps34 mutant, which exhibited elevated 
kinase activity, in NIH3T3 cells finding an increased amount of PI(3)P in peripheral 
regions. This active form of Vps34 was found to co-immunoprecipitate with TSC1, most 
likely via both protein’s association with phosphatidylinositol 3-phosphate 5-kinase 
(PIKFYVE). The formation of this complex removed TSC1 from its association with 
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TSC2 and led to ubiquitination and breakdown of this protein(41). The consequential 
removal of TSC2-induced inhibition of Rheb would then allow for a greater activation of 
mTORC1 through direct binding of Rheb to the catalytic domain, as described previously 
(43-46). Yoon et al.(22) reported a differing mechanism whereby Vps34 may exhibit its 
AA sensing role through leucyl t-RNA synthetase (LRS). Here it was suggested that, 
during times of high AA availability, leucine will bind to LRS and activate this enzyme. 
LRS will then bind to and activate Vps34 which will subsequently cause the translocation 
of phospholipase D1 (PLD1) to lysosomal membranes(22). Here this enzyme will 
produce PA, another direct mTORC1 activator, which can bind to the FKB domain of 
mTOR and enhance its kinase capabilities(37, 38, 47, 48). This mechanism seems to rely 
on an increase in Vps34 activity, a finding we failed to report here and as such this 
mechanism may be unlikely in the present study. Furthermore, it was recently purported 
that PLD1 may not regulate PA production in skeletal muscle as once believed(49). 
Nevertheless, as each of these potential mechanisms have only been studied in vitro, 
further investigations are warranted to fully understand their contribution to human 
skeletal muscle protein synthetic response in vivo.  
5.6 – Conclusions 
In conclusion, we present evidence that treatment of C2C12 and primary human 
myoblasts with the Vps34 kinase inhibitor SAR405 does not alter serum-induced 
activation of mTORC1. Further, in human skeletal muscle in vivo, we show that a change 
in Vps34 cellular location, rather than activity, occurs in response to protein/carbohydrate 
ingestion in the basal state. Specifically, in response to feeding, Vps34 and mTOR 
translocate toward the cell periphery, an event coinciding with elevated mTORC1 
activity. Previous in vitro evidence suggests mTORC1/lysosomal translocation may be a 
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result of increased Vps34 kinase activity in peripheral regions and as such future research 
should focus on elucidating this mechanism in skeletal muscle. Additionally the effects 
of resistance exercise, a paradigm previously shown to activate Vps34 in vivo in rodents, 
on the measures described herein should be investigated to fully understand Vps34’s role 
in AA sensing. 
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6.1 – Abstract 
The mechanistic target of rapamycin is believed to be the central regulator of protein 
synthesis in human skeletal muscle. Due to this much research has focussed on 
identifying the upstream mechanism by which mTORC1 is regulated in response to 
anabolic stimuli. Recent evidence has suggested that vacuolar protein sorting 34 
(Vps34) is implicated in sensing variations in nutrient levels and signalling these to 
mTORC1. Furthermore, amino acid transport, particularly through the primary leucine 
transporter LAT1, has been purported to contribute to skeletal muscle anabolism. 
Therefore the aim of the current study was to investigate the effect of unilateral 
resistance exercise and/or protein carbohydrate feeding on the regulation of these two 
proteins in relation to mTORC1 signalling. 8 young, healthy males (age – 21.3±3.6yrs, 
BMI – 22.5±2.1kg/m2, Body fat % - 11.1±3.3%) completed a trial whereby unilateral 
knee extensions were completed followed by consumption of a protein carbohydrate 
beverage (20g PRO, 40g CHO, 0.6g FAT). Muscle biopsies were taken at rest and then 
bilaterally at 1h and 3h post exercise/feeding in order to create distinct feeding alone 
(FED) and exercise + feeding (EXFED) conditions. The regulation of mTORC1 and 
Vps34 was then analysed via immunoblots for related targets and LAT1 regulation was 
analysed via immunohistochemistry and immunoblot. Following exercise/feeding 
mTORC1 related signalling (S6K1Thr389, S6Ser235/236, S6Ser240/244) was elevated in both 
conditions but to a greater extent, and for a more prolonged period, in EXFED, 
suggestive of greater mTORC1 activation. Vps34 protein content and a surrogate 
marker of its activity (SGK3Thr320) were unchanged in either group (p>0.05), suggesting 
mTORC1 can be activated without changes in these parameters. Interestingly a negative 
association between Vps34Ser249 and S6K1Thr389 phosphorylation was found (r=-0.43, 
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p=0.009) indicative of a link between mTORC1 activity and the regulation of this post-
translational modification which is purported to regulate autophagy induction. 
Interestingly, this finding add further complexity to Vps34s purported association to 
mTOR signalling as it may lie both upstream and downstream of this kinase. Finally, 
LAT1 fibre type differences were maintained across the post-exercise/feeding period 
and large amounts of positive intracellular LAT1 staining was also apparent at each 
time point in type II fibres (55-67% greater, all p<0.0001). This identifies a need for 
further research regarding the role of this intracellular LAT1 expression. Overall, these 
data suggest mTORC1 activity can be stimulated without alterations in Vps34 kinase 
activity and protein content or LAT1 fibre type differences. Further the identification of 
a potential relationship between mTORC1 activity and Vps34Ser249 phosphorylation 
provides a potential mechanism by which Vps34 complexes of differing roles may be 




6.2 – Introduction 
The protein synthetic response in skeletal muscle can be activated via nutritional, 
mechanical and hormonal stimuli (1, 2). Under normal physiological conditions, the two 
principal stimuli thought to increase muscle protein synthesis (MPS) are amino acid 
(AA) feeding (3-5) and resistance-type exercise (6). These stimuli both act initiate 
signalling pathways which elevate MPS (7), whilst AAs can simultaneously inhibit 
MPB (2). In fact, both AA feeding and resistance exercise exhibit synergistic effects on 
muscle protein turnover whereby net protein balance (NPB), the difference between 
MPS and MPB, can only become positive following resistance exercise if AAs are also 
ingested (5). Interestingly, these two anabolic stimuli exert their positive effects on 
MPS via the same protein kinase, the mechanistic target of rapamycin (mTOR), 
specifically mTOR complex 1 (mTORC1) (7-9). In fact, if this serine/threonine kinase 
is inhibited both AA feeding and resistance exercise are no longer able to stimulate 
MPS (10, 11). Accordingly, recent research has focussed on understanding the 
mechanisms by which AA feeding and resistance exercise activate mTORC1 in human 
skeletal muscle. 
Byfield et al (12) first identified vacuolar protein sorting 34 (Vps34), as a potential 
regulator of mTORC1 activation in human skeletal muscle, and hypothesised it to have 
a role in AA sensing. Vps34 converts phosphatidylinositol into phosphatidylinositol 3-
phosphate (PI(3)P) (13), a compound implicated in the translocation of several proteins 
to cellular and/organelle membrane (14), and is essential for maximal mTORC1 
activation in response to insulin and AAs in vitro (12, 15, 16). Furthermore, inhibiting 
the kinase activity of Vps34 inhibits mTOR translocation to the cell periphery following 
insulin stimulation (17) whilst simultaneous reducing mTORC1 activity. We have 
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investigated the role of Vps34 in AA sensing in Chapter 5 of this thesis finding that its 
kinase activity does not seem to contribute to mTORC1 activation in C2C12 or human 
primary myotubes. Furthermore, in human skeletal muscle, protein-carbohydrate 
feeding initiated the translocation of Vps34 and mTOR toward the cell periphery where 
these two proteins colocalised. Interestingly Vps34 kinase activity was unaltered by 
protein-carbohydrate feeding in human skeletal muscle, suggesting that it may be the 
change in Vps34’s cellular location that may contribute to its role in AA sensing 
through the recruitment of mTORC1 to peripheral regions. Of note, Vps34 kinase 
activity has been shown to increase in response to eccentric contractions in rodent 
skeletal muscle (18), and this was purported to be a result of the change in intracellular 
leucine concentrations noted following these contractions. However it may also be that 
a contractile stimulus rather than AA alone is required to achieve full activation of 
Vps34 in skeletal muscle. The protein expression, post-translational regulation and 
kinase activity of Vps34 are yet to be investigated in response to resistance type 
exercise in human skeletal muscle. Recently, a new phosphorylation site on Vps34 
(ser249) has been identified which is specific to the serine/threonine kinase ULK1 (19). 
ULK1 is negatively regulated by mTORC1 through direct phosphorylation at ser757 
(20-22) and as such this novel Vps34 phosphorylation site is an intriguing avenue for 
investigation in human skeletal muscle. Moreover, the phosphorylation status of 
serine/threonine-protein kinase 3 (SGK3) at Thr320 is believed to be regulated by 
Vps34 kinase activity (23), however is yet to be studied in human skeletal muscle. 
Therefore elucidating how these two novel post-translational modifications are 
regulated following resistance exercise and/or protein-carbohydrate feeding could 
provide valuable insight into Vps34 action in human skeletal muscle. 
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The increase in intramuscular AAs following resistance exercise and/or AA feeding can 
occur via two processes, first an elevation in intramuscular protein breakdown (6, 24, 
25) or second through an increase in AA transport into the muscle (26). As mTORC1 
inhibits autophagy through phosphorylation of ULK1, Atg13 and Atg14 (22, 27-29), it 
seems plausible that an elevated AA transport may be a prominent contributor. In 
skeletal muscle, the major AAs implicated in skeletal muscle anabolism are transported 
into the cell by the permease L-Type amino acid transporter 1 (LAT1) (30), also known 
as the solute carrier family 7 member 5 (SLC7A5), via a bi-transport system which 
concomitantly exports glutamine from the cell (31). Studies of the global protein 
expression of this AA transporter, in skeletal muscle, following anabolic stimuli have 
yielded varying results (32-35), possibly due to the need of the transporter to be 
associated with the plasma membrane to be fully functional. To combat this, our 
laboratory has recently characterised this protein in resting skeletal muscle through the 
use of immunofluorescent microscopy (36). Here, we reported that LAT1 was more 
highly expressed in type II muscle fibres, and in these fibres it resided both in 
intracellular and peripheral regions (36). As LAT1 may be more active following 
anabolic stimuli we believe it is important to understand how the distribution of this 
protein may be altered by resistance exercise and/or protein-carbohydrate feeding. 
In this study, we utilised a unilateral exercise model combined with protein-
carbohydrate feeding to elicit both feeding alone and feeding + exercise conditions 
within the same individual. We then aimed to elucidate how increasing AA availability 
in either basal or post-exercise conditions altered Vps34, LAT1 and mTORC1 activity. 
We hypothesised that Vps34 phosphorylation/activity would be associated with an 
increase in mTORC1 activity. Further we hypothesised that LAT1 translocation to the 
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cell periphery would occur in type II fibres in response to feeding + exercise, but not 
feeding alone. 
6.3 – Methods 
6.3.1 Subjects 
Eight young, healthy males (age – 21.3±3.6yrs, BMI – 22.5±2.1kg/m2, Body fat % - 
11.1±3.3%) volunteered to partake in the study after being deemed healthy based on 
responses to a general health questionnaire. Participants were informed of all 
experimental procedures to be undertaken and any risks involved before written 
informed consent was obtained.  
6.3.2 Experimental Design 
Study participants visited the School of Sport, Exercise and Rehabilitation Sciences at 
the University of Birmingham on three separate occasions. The first visit consisted of 
anthropometric measurements followed by a 10 repetition maximum (10RM) unilateral 
strength test on a Knee extension machine (Gym Gear Elite Series, Lancashire, UK.). 
Participants reported to the laboratory in a fasted state where body mass was determined 
to the nearest 0.1kg on a digital scale and height was measured, without shoes, using a 
stadiometer. Body fat % was determined using bioelectrical impedance (BodyStat 
QuadScan 4000, Isle of Man, British Isles.) following a period of 5 minutes resting in 
the supine state. 10RM strength testing consisted of 10 repetitions of knee extensions at 
ascending loads until 10 repetitions could no longer be completed. Each set was 
separated by a period of 3 minutes rest. The final load at which the participant 
completed 10 successful repetitions was recorded as the 10RM for the participant. The 
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leg used for this test was randomised for each participant and this leg was used each 
exercise bout in the remaining visits. 
After a period of 5-7 days, subjects reported to the School of Sport, Exercise and 
Rehabilitation Sciences at 08:00h following a 10h overnight fast, having not consumed 
alcohol or caffeine for 24 hours and having not completed strenuous lower-body 
exercise for 48 hours. This visit consisted of an identical exercise bout to that which 
would be completed in the final experimental visit and was aimed at familiarising the 
participant with the exercise protocol. This was conducted in order to minimise 
potential effects of unaccustomed exercise, rather than the exercise protocol itself, on 
variables measured in the final trial. This session also allowed for verification of the 
10RM load determined in the initial laboratory visit. The exercise bout itself consisted 
of 10 sets of 10 repetitions of unilateral knee extensions at 10RM interspersed by 2 
minutes of rest, designed to elicit volitional failure on the 10th repetition of each set. If 
volitional failure occurred before the 10th repetition, load was adjusted such that 10 
repetitions were maintained in subsequent sets. Based on the loads lifted during this 
session, the starting load for the final experimental session was adjusted if required to 
allow for better load maintenance throughout the exercise session. Following 
completion of this exercise bout participants were free to leave the laboratory. 
The final visit took place 5-7 days following the familiarisation session and subjects 
arrived at the laboratory at 7.30am in an identical state to that of the previous session. 
Upon arrival 21G cannulas were inserted into the antecubital vein of each forearm. One 
cannula was used for repeated blood sampling throughout the trial and the other was 
used to administer a primed continuous infusion of L-[ring13C6]phenylalanine (prime 
dose 2 µmol·kg-1; continuous infusion 0.05µmol·kg-1·min-1; Cambridge Isotope 
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Laboratories, Andover, MA, USA). The infusion began after a basal, resting blood 
sample had been obtained. Further blood samples were obtained every 30 minutes for 
150 minutes prior to the exercise bout. Subsequent samples were then obtained 
immediately post-exercise and 15, 30, 45, 60, 90, 120, 150 and 180 minutes post 
exercise/beverage consumption. Unfortunately, analysis utilising these measures was 
not completed before submission of this thesis and therefore will not be further 
discussed. Subjects rested in a supine position before a skeletal muscle biopsy was 
obtained, under local anaesthesia (1% lidocaine), from the vastus lateralis of the 
subject’s non-exercising leg using the Bergstrom technique (37). Muscle samples were 
process for immunoblotting and immunohistochemical analysis as described previously 
(Chapter 2.3). Following this, subject’s completed an identical unilateral exercise bout 
to that undertaken in the familiarisation session, with loads again adjusted to ensure 10 
repetitions were completed in each set. The mean starting load for this bout was 
52±6.8kg and, on average, loads had decreased by ~24% by the final set. Immediately 
following the exercise bout, subjects consumed a protein-carbohydrate beverage 
(Optimum Nutrition 2:1:1 Recovery, Downers Grove, IL, USA.) containing 20/40/0.6g 
of protein carbohydrate and fat respectively. A small amount of L-
[ring13C6]phenylalanine was added to the beverage (enriched to 4%) to minimise 
changes in plasma 13C6  phenylalanine enrichment.  Subjects then remained in a supine, 
rested state for 3 hours, with bilateral skeletal muscle biopsies taken at 1 and 3 hours 
following exercise/feeding. This protocol allowed for divergent within-subject 
conditions of protein-carbohydrate feeding alone (FED) and resistance exercise 
combined with protein-carbohydrate feeding (EXFED) to be investigated within the 
same trial. Each skeletal muscle biopsy was processed for both immunoblotting and 
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immunohistochemical analysis and was stored at -80°C until needed. The experimental 
trial protocol is depicted in Figure 6.1. 
6.3.3 Antibodies 
For immunoblotting analysis all primary antibodies were purchased from Cell Signaling 
Technologies (CST) and diluted at 1:1000 in TBST unless stated otherwise. Antibodies 
utilised were: p-mTORSer2448 (#2971), mTOR (#2983), p-TSC2Thr1461 (#3611), p-
TSC2Ser939 (#3615), TSC2 (#3612), p-AKTThr308 (#2965), p-AKTSer473 (#4060), AKT 
(#4691), p-Vps34Ser249 (#13875), Vps34 (#3358), p-S6K1Thr389 (#9205, 1:500), S6K1 
(#2708), p-rpS6Ser235/236 (#4858), p-rpS6Ser240/244 (#5364), rpS6 (#2217), p-4EBP1Thr37/46 
(#9459, 1:500), 4EBP1 (#9452, 1:500), ULK1 (#8054, 1:500), p-ULK1Ser757 (#6888), p-
SGK3Thr320 (#5642), SGK3 (#8156), p-eEF2Thr56 (#2331), eEF2 (#2332), GAPDH 
(#5174) and LAT1 (Abcam, #Ab85226, 1:500). All primary antibodies were produced 
in rabbits and as such anti-rabbit IgG HRP-linked secondary antibody (CST #7074) was 
utilised. Antibody binding was detected via the use of enhanced chemiluminescence 
horseradish peroxidase substrate detection kit (Millipore, Watford, UK). 
For immunohistochemical analysis the antibodies utilised were as follows: LAT1 
(1:100, Abcam, #Ab85226), MHC1 (1:250, #A4.840, DSHB, Iowa, USA) and Wheat 
Germ Agglutinin (1:20, WGA-350, #11263, ThermoFisher, UK). Corresponding 
secondary antibodies were goat anti-mouse goat anti-mouse IgM Alexa®594 (#A21044, 
ThermoFisher, UK, targeting MHC1) and goat anti-rabbit IgG(H+L) Alexa®488 
secondary antibodies (#A11008, ThermoFisher, UK, targeting LAT1). WGA-350 was 





Identical amounts of protein were separated on 8-15% polyacrylamide gels by SDS-
PAGE as described in Chapter 2 (Section 2.5.2). Proteins were then transferred to 
BioTrace NT nitro-cellulose membranes (Pall Life Sciences, UK.) at 100V for 1h, 
blocked in 3% milk/TBST (5% Bovine Serum Albumin (BSA) for LAT1 and  p-
TSC2S939) and incubated overnight in the desirable primary antibodies. The following 
day, membranes were washed in TBST and incubated in corresponding secondary 
antibodies (diluted 1:10000 in TBST) at room temperature for 1h. Chemiluminescence 
horseradish peroxidase reagent kit (Merck-Millipore) was used to quantify protein 
content following IgG binding. Images were captured with a G:Box Chemi-XR5 
(Syngene (A Division of Synoptics Ltd.), Cambridge, UK) imaging system and blot 
bands were quantified using GeneTools software (Syngene, Cambridge, UK). Each 
protein target was expressed in relation to a gel control (combination of all samples) and 
a loading control (eEF2 or GAPDH dependent on weight of target protein) and each 
phosphorylation site is presented in relation to its corresponding total protein 
abundance. 
6.3.5 Immunohistochemistry  
Skeletal muscle samples were processed for immunohistochemical analysis as described 
in Chapter 2 (Section 2.3). Following this, skeletal muscle sections were fixed, blocked 
and stained as described previously (Section 2.4). MHC1(594nm)-LAT1(488nm)-
WGA(350nm) stains were visualised as described in section 2.4.5 of this thesis. Image 
analysis for colocalisation and fibre-type specific fluorescence intensity of these targets 
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was conducted using ImagePro or Fiji (ImageJ) software respectively, as described in 
section 2.4.6.2. 
6.3.6 Statistics 
Changes in intramuscular signalling and fibre type-specific LAT1 fluorescence intensity 
were examined using a repeated measures ANOVA with two within-subject factors 
(time and condition). Differences in LAT1 fluorescence intensity between fibre types 
were analysed using independent t-tests at each time point. When a significant main or 
interaction effect was found, post-hoc tests were completed with the Holm-Bonferroni 
correction for multiple comparisons. Significance for all variables analysed was set at 
p≤.05. Data are presented as means±SEM unless otherwise stated.  
 
Figure 6.1. Experimental trial design 
6.4 – Results 
6.4.1 Intramuscular signalling upstream of mTORC1 
A significant interaction effect was observed for AKT phosphorylation at Thr308 
(p=0.011). Phosphorylation at this site was significantly greater, in both conditions, 1h 
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following exercise/feeding compared to PRE and 3h time points (EXFED – 7.6±1.2 fold 
above PRE, FED – 4.4±0.7 fold above PRE, all p<.05, Fig 6.2a). A time effect was 
noted for AKTSer473 phosphorylation (p<.001) suggesting that, when both conditions are 
combined, phosphorylation at this site was greater at the 1h time point compared to both 
PRE and 3h (p<0.01, Fig 6.2b). TSC2Thr1462 phosphorylation remained unchanged in 
either condition at any time point (p>0.05, Fig 6.2c). A significant interaction effect was 
noted for TSC2Ser939 phosphorylation (p=0.023), however following post hoc tests no 
differences between time points/conditions were significant (p>0.05, Fig 6.2d). In 
addition, significant condition (p=0.011) and time (p=0.028) effects were observed for 
this variable. This suggests that when time points are combined, greater TSC2Ser939 
phosphorylation is apparent following EXFED compared to FED. Furthermore, when 
conditions were combined, the extent of TSC2Ser939 phosphorylation at the 1h time point 
was significantly greater than 3h (p=0.027, Fig 6.2d). 
6.4.2 Intramuscular signalling downstream of mTORC1 
A significant time effect was observed for mTORSer2448 phosphorylation (p<.0.001). 
Pairwise comparisons displayed that protein-carbohydrate feeding, irrespective of 
accompanying resistance exercise, elicited an increase in mTORSer2448 phosphorylation 
ay 1h post feeding (p=0.003, Fig 6.3a) which remained above PRE values at 3h post-
feeding (p=0.012, Fig 6.3a). Furthermore the extent of mTORS2448 phosphorylation at 
the 1h time point was greater than 3h, when condition were combined (p=0.027, Fig 
6.3a). A significant interaction effect was observed for S6K1Thr389 phosphorylation 
(p=0.004). Here, both feeding alone, and combined with resistance exercise, elicited 
significant elevations in S6K1Thr389 phosphorylation above PRE and 3h values at 1h 
(EXFED – 43.3±4.4 fold, p<0.001, FED – 27.9±5.4 fold, p<0.01, Fig 6.3b). These 
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elevations remained above PRE at 3h in both conditions (EXFED – 13.5±3.0 fold, FED 
– 3.8±0.8 fold, both p=0.012, Fig 6.3b). Furthermore, at both 1h and 3h, the extent of 
S6K1Thr389 phosphorylation was greater in the EXFED condition compared to FED 
(p<0.05, Fig 6.3b).  
Figure 6.2. The effect of resistance exercise and/or protein-carbohydrate feeding on AKT/TSC2 
signalling (n=8). AKTThr308 (A), AKTSer473(B), TSC2Thr1462 (C) & TSC2Ser939 (D) phosphorylation at rest 
(PRE) and following protein-carbohydrate feeding with (EXFED – open bars) or without (FED – black 
bars) prior resistance exercise. Each phosphorylation site is displayed in relation to its corresponding total 
protein. Representative images are also displayed (E). *significantly different to corresponding PRE 
(p<0.05). #significantly different to corresponding 3h (p<0.05). Black lines denote time effect. Data 
presented as Mean±SEM. 
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A significant interaction effect was also observed for S6Ser240/244  phosphorylation 
(p=0.007). Here, both FED and EXFED increased S6Ser240/244 phosphorylation above 
PRE values at 1h (EXFED – 19.2±4.1 fold, p=0.016, FED – 17.4±4.3 fold, p=0.028, Fig 
6.3c). S6Ser240/244 phosphorylation remained above PRE values at 3h in both conditions, 
however was only lower than 1h in the FED condition (p=0.042, Fig 6.3c), suggesting a 
maintenance of phosphorylation at this site with resistance exercise. Furthermore, at 3h, 
S6Ser240/244 phosphorylation was greater the EXFED condition compared to FED 
(p=0.027, Fig 6.3c). S6Ser235/236 phosphorylation also exhibited a significant interaction 
effect (p=0.014), where both conditions elicited significant elevations above PRE at 1h 
(EXFED – 53.3±8.1 fold, p=0.003, FED – 35±8.9 fold, p=0.041, Fig 6.3d). 
Phosphorylation at this time point was also greater in the EXFED condition compared 
to FED (p=0.043, Fig 6.3d). S6Ser235/236 phosphorylation returned to PRE values in the 
FED condition at 3h, however there was a trend toward  greater phosphorylation, 
compared to PRE, at this time point in the EXFED condition (39.6±13.1 fold, p=0.067), 
again suggesting a possible synergistic effect of feeding combined with resistance 
exercise. 
An interaction effect was noted for eEF2Thr56 phosphorylation (p=0.006), showing a 
reduction in phosphorylation at this site, in both conditions at 1h compared to PRE 
(EXFED – 0.58±0.03 fold of PRE, p=0.006, FED – 0.73±0.05 fold of PRE, p=0.035, 
Fig 6.3e). In addition eEF2Thr56 phosphorylation was lower at this time point in the 
EXFED condition compared to FED (p=0.038, Fig 6.3e). Phosphorylation at this site 
returned to PRE values in the FED condition at 3h (p=0.289), however a trend toward 
lower phosphorylation, compared to PRE, in the EXFED condition was noted at this 
time point (0.66±0.05 fold of PRE, p=0.064). Further trends were also apparent when 
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comparing between 1h and 3h in the FED condition (p=0.06) and between conditions at 
3h (p=0.057). Finally, there were no alterations in 4EBP1Thr37/46 phosphorylation at any 
time point or between conditions (p>0.05, Fig 6.3f). 
Figure 6.3. The effect of resistance exercise and/or protein-carbohydrate feeding on mTORC1-
related signalling (n=8). mTORSer2448 (A), S6K1Thr389 (B),S6Ser240/244 (C),  S6Ser235/236 (D), eEF2Thr56 (E) & 
4EBP1Thr37/46 (F) phosphorylation at rest (PRE) and following protein-carbohydrate feeding with (EXFED 
– open bars) or without (FED – black bars) prior resistance exercise. Each phosphorylation site is 
displayed in relation to its corresponding total protein. Representative images are also displayed (G). 
*significantly different to corresponding PRE (p<0.05). #significantly different to corresponding 3h 
(p<0.05). δsignificantly different to corresponding FED (p<0.05). Black lines denote time effect. Data 




6.4.3 Vps34-related intramuscular signalling 
Vps34Ser249 phosphorylation was reduced at 1h in both conditions (EXFED – 0.29±0.05 
fold of PRE, FED – 0.55±0.15 fold of PRE) before increasing back toward baseline at 
3h but did not achieve significance (time effect - p=0.084, Fig 6.4a). Both total Vps34 
protein content and SGK3Thr320 phosphorylation remained unaltered across the time 
course in both conditions (p>0.05, Fig 6.4b & c). A significant time effect was observed 
for ULK1Ser757 phosphorylation (p=0.001). Here, protein-carbohydrate feeding, 
irrespective of prior resistance exercise, elevated ULK1Ser757 phosphorylation above 
PRE and 3h values at 1h (EXFED – 3.4±0.8 fold, FED – 3.1±0.6 fold, p<0.05, Fig 
6.4d). Correlation analysis displayed that the extent of Vps34Ser249 phosphorylation at all 
time points was significantly correlated to that of S6K1Thr389 (r = -0.43, p=0.009, Fig 
6.4e) but not that of ULK1Ser757 (r = -0.01, p=0.95, Fig 6.4f). 
6.4.4 LAT1 fibre type distribution and protein content 
LAT1 fluorescence intensity was greater in type II fibres (MHC1-negative), compared 
to type I fibres (MHC1-positive), at each time point (on average 1.6±0.02 fold greater, 
all p<0.001, Fig 6.5b). In type I fibres, LAT1 fluorescence intensity did not change at 
any time point in either condition (p>0.05). However, in type II fibres, a significant time 
effect was observed (p=0.004, Fig 6.5b) whereby LAT1 fluorescence intensity was 
reduced at both 1h (p=0.03) and 3h (p=0.028), irrespective of condition. Total LAT1 
protein content, measured by immunoblot, remained unchanged across the time course 





Figure 6.4 The effect of resistance exercise and/or protein-carbohydrate feeding on Vps34-related 
signalling (n=8). Vps34Ser249 (A), Vps34 (B), SGK3Thr320 (C) & ULK1Ser757(D) phosphorylation at rest 
(PRE) and following protein-carbohydrate feeding with (EXFED – open bars) or without (FED – black 
bars) prior resistance exercise. Each phosphorylation site is displayed in relation to its corresponding total 
protein. Vps34Ser249 phosphorylation is also correlated to S6K1Thr389 (E) and ULK1Ser757 (F). 
Representative images are also displayed (G). *significantly different to corresponding PRE (p<0.05). 
#significantly different to corresponding 3h (p<0.05).  Black lines denote time effect. Data presented as 
Mean±SEM. 
6.5 – Discussion 
In the present study, we report that the phosphorylation of SGK3Thr320, a marker of 
Vps34 kinase activity, and total Vps34 protein content are unaffected by protein-
carbohydrate feeding either when consumed alone or after a unilateral bout of resistance 
198 
 
exercise. Furthermore, the phosphorylation of Vps34Ser249, decreased across the trial and 
this reduction was negatively associated with mTORC1 activity. In addition we also 
investigated whether LAT1 fibre-type distribution and protein content were affected by 
resistance exercise and/or protein-carbohydrate feeding. Here we show that the greater 
LAT1 content in type II fibres, previously reported in basal skeletal muscle, is 
maintained in both conditions across the trial. Interestingly however, we also find that 
type II-specific LAT1 expression decreases following protein carbohydrate feeding, 
irrespective of prior resistance exercise completion, though total LAT1 protein content, 













Figure 6.5 The effect of resistance exercise and/or protein-carbohydrate feeding on LAT1 total and 
fibre-type expression (n=7). LAT1 fibre type specific intensity (B) was quantified in type I (black bars) 
and type II (open bars) across the timecourse. Representative images of each stain are displayed (A). 
Total LAT1 protein expression was measured via immunoblot (C) and representative images are 
provided. *Significantly different from corresponding type I (p<0.001). #Significantly different to PRE 
(p<0.05). Data presented as Mean±SEM. 
mTORC1 signalling is known to be essential for MPS stimulation following anabolic 
stimuli i.e. mechanical loading and AA feeding (10, 11). These particular anabolic 
stimuli have been consistently reported to have synergistic effects both on mTORC1-
related signalling and MPS (4, 5, 38-41). Here we provide further confirmation of this 
synergism, observing elevated phosphorylation of several downstream mTORC1 
targets, in the EXFED condition compared to FED. Specifically the phosphorylation of 
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S6K1Thr389, S6Ser235/236 and S6Ser240/244 was propagated above FED levels, at varying time 
points, following EXFED. Furthermore the extent of eEF2Thr56 phosphorylation was 
significantly lower at 1h following EXFED, again indicative of increased mTORC1 
activity (42). These findings suggest that the processes of translation initiation and 
elongation would most likely be greater in this condition (42-44), therefore stimulating 
greater levels of MPS as described previously (45). In contrast, one direct downstream 
target of mTORC1, 4EBP1Thr37/46, did not exhibit this synergistic pattern, or in fact any 
alteration in phosphorylation status. Although somewhat counterintuitive due to the 
high elevation in mTORC1 activation we note on other targets, this finding has been 
previously described on several occasions (46, 47). 4EBP1 contains 4 sites of 
mTORC1-dependent phosphorylation (Thr37/46, Ser65 & Ser70) which are 
phosphorylated in a hierarchical manner before this protein is removed from its 
interaction with eIF4E (48). 4EBP1Thr37/46 are the initial sites of phosphorylation on this 
target, essentially priming this protein for further phosphorylation (48). It is therefore 
possible that the time points utilised in this study may have missed this initial ‘priming’ 
phosphorylation which may have been subsequently removed when the other sites were 
phosphorylated. This suggestion can be reinforced through the visual examination of the 
immunoblot images for 4EBP1 (Fig 6.3g), where this protein consistently exhibited an 
upward gel shift at every time point other than PRE. This suggests that this protein is 
hyper-phosphorylated at these time points, most likely at the subsequent mTORC1-
dependent phosphorylation sites (Ser65 & Ser70). 4EBP1Ser65 phosphorylation has been 
previously noted to increase both 90 and 180 minutes following resistance exercise and 
protein feeding, time points where alterations 4EBP1Thr37/46 were less apparent (46). 
These data suggest it may be these secondary phosphorylation sites which may be a 
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better readout of mTORC1 activity at these time points and therefore further research 
should aim to elucidate their full regulation in response to anabolic stimuli.  
Upstream of mTORC1, we report that AKT phosphorylation at its two major regulatory 
sites (Thr308 & Ser473) is elevated above baseline and 3h values at 1h, irrespective of 
prior exercise. These findings suggest this response was predominantly driven by 
protein-carbohydrate feeding with no propagation of the response by resistance 
exercise. This notion has been previously described as AKT is predominantly regulated 
by insulin/growth factors (49). Downstream of AKT lies TSC2 (50) which is believed to 
be regulated in an AKT-dependent fashion at two sites, Thr1462 and Ser939 (50). Here, 
no alteration in either phosphorylation site, from PRE values, was apparent although the 
extent of TSC2Ser939 phosphorylation was greater at 1h, compared to 3h, when 
conditions were combined. These findings were unexpected, particularly due to the 
large stimulation of AKT phosphorylation observed. Again, this absence of 
phosphorylation may be due to timings of samples, especially as AKT/TSC2 signalling 
lies upstream of mTORC1 and a large activation of mTORC1 is already apparent at our 
first post-intervention time point. Moreover, it is important to note here that it has been 
proposed that mTORC1 is activated in an AKT-independent manner following 
resistance exercise in skeletal muscle (51, 52), and therefore alterations in TSC2 
phosphorylation at these sites may not actually be relevant in this context. Jacobs et al. 
(53) describe a mechanism whereby TSC2 is phosphorylated at multiple sites on its 
RxRxxS∗/T∗ consensus motif following eccentric contractions in rodent skeletal 
muscle. This phosphorylation then elicits the removal of TSC2 from Rheb and 
subsequent activation of mTORC1 (54). Further recent work by the same group (55) has 
identified several new phosphorylation sites on TSC2 that seem to be regulated by 
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mechanical contraction (Ser664, Ser1155, Ser1254, Ser1364 & Ser1499/52). These sites 
therefore offer a more appropriate avenue for research regarding upstream mechanisms 
of mTORC1 activation following muscular contraction and warrant future research in 
human skeletal muscle. 
It is currently unknown how nutrients directly activate mTORC1 in human skeletal 
muscle. Recently, Vps34, has been reported to contribute to nutrient-induced mTORC1 
activation in vitro (12, 15), however little research has been conducted on this topic in 
skeletal muscle. In the previous chapter of this thesis (chapter 5) we reported that the 
use of a Vps34-specific inhibitor (SAR405) did not affect nutrient-induced mTORC1 
activation in both C2C12 and human primary myotubes. In addition, we observed no 
change in Vps34 kinase activity, in human skeletal muscle, in response to protein-
carbohydrate feeding. In fact, instead of a change in kinase activity it seemed alterations 
in Vps34 cellular location, and subsequent colocalisation with mTOR, may be the 
mechanism by which Vps34 completes its purported nutrient-sensing role. In the current 
study, we utilised the phosphorylation of SGK3 at Thr320 as a proxy measure of Vps34 
kinase activity. Phosphorylation at this site is dependent on SGK3’s ability to associate 
with PI(3)P (56), the product of Vps34 kinase activity (13), and is significantly reduced 
in the presence of a Vps34 specific inhibitor (VPS34IN1) (23). The phosphorylation 
status of the site remained unaltered across the time course of the current study, in both 
conditions, suggesting these anabolic stimuli have no effect of Vps34 kinase activity. 
These date are in agreement with those reported in the previous chapter of this thesis, 
however contradict that reported in rodent skeletal muscle following eccentric 
contractions. Mackenzie et al. (18) reported that forced eccentric contractions of the 
tibialis anterior of rodents elicited a 70% increase in Vps34 kinase activity 3h following 
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said contractions. Furthermore, this alteration in Vps34 kinase activity was associated 
with the intracellular change in leucine apparent following these contractions, shown 
when this amount of leucine was added to C2C12 myotubes and a similar Vps34 
activation found (18). Importantly, however, the two concentrically contracting muscles 
analysed, the plantaris and soleus, exhibited much lower or no elevation in Vps34 
kinase activity respectively (18). This may explain the discrepancies in results between 
this study and that of Mackenzie et al. (18) as we sampled skeletal muscle tissue from 
the vastus lateralis of subjects, a muscle that would contract in a concentric manner to 
complete knee extension exercise. It is possible that eccentric contractions alone can 
produce a great enough stimulus to elevate Vps34 kinase activity and therefore our 
exercise protocol may have had no effect. Future research on the effect of contraction 
type on Vps34 kinase activity in human skeletal muscle is therefore required.  
To our knowledge, other than the study described in chapter 5, only one study has 
investigated the effect of exercise or protein feeding on Vps34 kinase activity in human 
skeletal muscle. Here, repeated sprint exercise followed by EAA feeding elicited no 
change in Vps34 kinase activity ~1.5h following the final sprint interval (57). 
Interestingly however, sprint exercise alone, with no feeding, elicited a trend toward an 
increase in Vps34 kinase activity. The authors here hypothesise that this may be due to 
the varying of roles of Vps34 complexes in mammalian cells (12, 13, 17, 58-60). Vps34 
complexes are known to contribute both to autophagy induction (58, 61) and mTORC1 
activation (12, 15, 59) in vitro and therefore EAA ingestion would have opposing 
effects on the kinase activity of Vps34 in these complexes (13). As a beverage 
containing fairly high (20g) amounts of protein was consumed by subjects in the current 
study this may provide further evidence as to why an absence of Vps34 activation is 
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apparent here. One final potential mechanism as to why Vps34 activity was unchanged 
here is similar to that hypothesised in the previous chapter of this thesis. It is possible 
that a change is Vps34 kinase activity is not required to exert an effect upon mTORC1, 
but that an alteration in its cellular location is sufficient to recruit mTORC1 to 
peripheral regions and permit its activation, as previously described in vitro (17, 62). 
Specifically, this mechanism occurs through the recruitment of the PI(3)P binding 
protein FYCO1 to lysosomes, which initiates the translocation of mTORC1-positive 
lysosomes to the cell periphery (62). These particular mechanisms were not investigated 
in the current study and therefore require further investigation to fully understand 
whether they extend in vivo in human skeletal muscle.  
A second mechanism by which Vps34 may contribute to mTORC1 activation is through 
a potential increase in its overall protein content. However, similarly to the readout of 
its activity, there was no change in the total protein expression of Vps34 in the current 
study.  Previous studies in human skeletal muscle, following a combination of sprint 
exercise and protein feeding have echoed these findings (57) . In vitro data in human 
primary myotubes however, contradicts this notion (63). Leucine or insulin exposure 
induces a 30-50% increase in Vps34 protein content following 0.5, 3 or 24h of 
incubation. However, concentrations of insulin and leucine utilised were 
supraphysiological (100nM and 5mM respectively) (63) and therefore may have driven 
a greater stimulation of Vps34 protein translation than can be noted in human skeletal 
muscle following exercise and feeding. Therefore, due to these contradictory findings 
further research is required into the regulation of Vps34 expression and activity in 
human skeletal muscle. Nevertheless it can be concluded that overall in this current 
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study, resistance exercise and/or protein-carbohydrate feeding does not seem to elevate 
either Vps34 protein content or activity.  
Recently, a novel phosphorylation site on Vps34 has been identified, serine residue 249 
(19). Further analysis utilising ULK1 knockout (KO) HEK293 cells revealed this to be a 
ULK1-regulated site (19). As ULK1 is negatively regulated by mTORC1 activity, a 
potential phosphorylation site on Vps34 which could be regulated by mTORC1 activity 
is an intriguing notion, especially due to Vps34 purported upstream role of mTORC1. 
Here, despite a numerical reduction in Vps34Ser249 phosphorylation post exercise, there 
were no significant changes in Vps34Ser249 observed. There was however a significant, 
negative correlation apparent between S6K1Thr389 and Vps34Ser249 phosphorylation (r=-
0.43, p=0.009, Fig 6.4e), suggesting a downstream link between mTORC1 activity and 
Vps34 post-translational regulation. The complete role of this post-translational 
modification has not yet been fully elucidated, however it is believed to contribute to 
autophagy regulation via Vps34’s complex with Beclin-1 and Ambra-1 (19). Therefore, 
the reduction in phosphorylation at this site, and its association with S6K1Thr389 
phosphorylation, may provide a further mechanism as to how mTORC1 can inhibit 
autophagy induction, in addition to its direct inhibitory effect on ULK1, Atg13, Atg14 
and TFEB (20, 28, 29, 64, 65). In addition, a reduction in phosphorylation here could 
conceivably negatively affect the kinase activity of this autophagy-related Vps34 
complex and provide further credence to the notion that anabolic and catabolic Vps34 
complexes may be oppositely regulated by resistance exercise and protein-carbohydrate 
feeding. 
Further we report that Vps34Ser249 phosphorylation is not correlated with ULK1Ser757 
phosphorylation (r=-0.01, p=0.95, Fig 6.4f), its direct upstream kinase and a target of 
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mTORC1 (19, 21). Although this seems counterintuitive, this may be explained by the 
numerous mechanisms by which ULK1 itself may be regulated. ULK1, in addition to 
being inhibited by mTORC1, can also be phosphorylated by AMP-activated protein 
kinase (AMPK) at serine residues 317, 555 and 777 (20, 21, 66) which elicits an 
increase in ULK1’s kinase activity (20, 21). Upon nutrient provision, phosphorylation at 
these sites is reduced (67) and therefore ULK1 kinase activity would also decrease. 
Importantly, mTORC1-dependent phosphorylation of ULK1Ser757 disturbs the 
association of AMPK and ULK1 removing its ability to phosphorylate ULK1 at these 
sites (20). In addition, mTORC1 also regulates ULK1 activity via the phosphorylation 
of another component in the ULK1-autophagy complex, Atg13 (28). mTORC1 is able 
to directly phosphorylate Atg13 at serine residue 258 thereby preventing the ULK1 
complex from translocating to areas of need (28). It is likely that is an amalgamation of 
these mTORC1-dependent effects that contribute to a reduction in Vps34Ser249 
phosphorylation and as such a direct correlation with ULK1Ser757 would not be apparent. 
Nevertheless a significant correlation with S6K1Thr389, considered a reliable readout of 
mTORC1 activity, suggests an interaction between mTORC1 and Vps34 complexes and 
as such warrants further investigation.  
AA transport is a further mechanism which has been purported to affect mTORC1 
activation and therefore MPS (68, 69). Of the myriad of AA transporters which are 
expressed in human tissue, LAT1 has received the greatest attention due to its role in 
the transport of leucine, the major anabolic EAA (30, 70). Early research regarding how 
anabolic stimuli affected this transporter studied total LAT1 protein content in whole 
muscle lysates. Findings here were variable, with LAT1 protein content increasing at 
varying time points between 3h-24h post-exercise/feeding in young individuals (32, 33). 
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Furthermore, the addition of EAA feeding post-exercise seemed to reduce LAT1 protein 
content in young individuals yet elevate protein content in the skeletal muscle of elderly 
individuals (33, 34). Here, we report no change in total LAT1 protein content in 
response to resistance exercise and/or protein-carbohydrate feeding (Fig 6.5c). These 
differing results, and the notion that LAT1 must be in a specific cellular location 
(associated with a membrane) in order for its permease activity to be active (71-73), 
prompted us to examine LAT1 cellular distribution using immunofluorescent techniques 
(36). We utilised this method in the current study, finding that the elevation in LAT1 
protein content in type II fibres was apparent at every time point measured. Interestingly 
however, when studying the intensity of LAT1 staining in type II fibres, across the trial, 
a time effect was apparent (Fig 6.5b), suggesting LAT1 staining intensity was reduced 
at both 1h and 3h post-feeding in this fibre type irrespective of prior resistance exercise. 
This reduction in staining intensity may be due to a catabolism of LAT1 in type II 
fibres, however this may not be the case as no reduction in overall LAT1 protein 
content (immunoblot) was observed. It is possible that LAT1 may have translocated to 
the plasma membrane in this fibre type and that the nature of our analysis method may 
not have been sensitive enough to detect this i.e. the identification of fibre borders using 
WGA may have discounted positive staining within positive WGA staining. 
Furthermore, due to the large intracellular amounts of LAT1 in type II fibres, and the 
inability to distinguish between type I and type II plasma membranes, we were unable 
to measure the localisation of LAT1 proteins with WGA. In the future, it would be 
beneficial to utilise either immuno-electron microscopy or plasma membrane 
fractionation to determine the translocation of this AA transporter. A recent study did 
indeed utilise plasma membrane fractionation to this end and reported an increase in 
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LAT1 protein content following low-load resistance exercise and protein feeding in a 
pulse, but not bolus fashion (35). These findings are intriguing and seem to suggest that 
small frequent protein doses may increase AA transporter translocation compared to 
bolus feeding. However as this research avenue is still in its infancy, much more 
research combining a variety of these measures is needed before full conclusions can be 
drawn.  
The current finding that the majority of basal intracellular LAT1 remains intracellular 
following resistance exercise and/or protein-carbohydrate feeding was somewhat 
unexpected. As LAT1 must be associated with a membrane to be active, this suggests 
there may be large amounts of ‘inactive’ LAT1 within type II fibres which is not 
associated with a membrane. However, it is possible that this LAT1 may actually be 
associated with other, intracellular membranes. Recent in vitro evidence proposes that 
LAT1 can associate with the membrane of lysosomes, permitting the influx of leucine 
into the lysosomes themselves (74). Furthermore, this association of LAT1 with the 
lysosomal membrane seems to be required for mTORC1 activation, via the inside-out 
mechanism proposed by the Sabatini laboratory (75), in response to EAAs and/leucine 
alone (74). This mechanism provides a functional justification for the presence of large 
amounts of intracellular LAT1, and why this remained following anabolic stimuli. A 
second possibility is that this intracellular LAT1 may not be able to associate with a 
membrane due to a lack of its associated glycoprotein CD98. In order for LAT1 to 
associate with a membrane, it must form a heterodimer with CD98 (71, 73), and 
therefore if there is a dearth of this protein intracellular LAT1 would not be able to 
associate with any membranes and remain intracellular. Indeed, it has been previously 
reported that CD98 protein expression in human skeletal muscle remains unchanged 
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following EAA consumption (32), and is not elevated until 24h following resistance 
exercise (33), and as such any change in LAT1 expression may be have no effect AA 
transport. CD98 expression was not studied in the current study, so conclusions on this 
cannot be made. As such, future research regarding the intricate regulation of these 
proteins is warranted. 
6.6 – Conclusions 
In summary, the data presented herein display that neither the ingestion of protein-
carbohydrate alone or following fatiguing resistance exercise affects Vps34 protein 
content or kinase activity, in spite of a strong induction of mTORC1 signalling in both 
conditions. In addition, we report a negative association between Vps34Ser249 and 
S6K1Thr389 suggestive of a downstream inhibitory effect of mTORC1 on autophagy-
related Vps34 complexes. This provides an intriguing paradox whereby certain Vps34 
complexes may contribute to mTORC1 activation following anabolic stimuli while 
others are inhibited by this activation, a phenomena which warrants more in-depth 
investigation. Finally, we observed higher protein abundance of LAT1 in type II 
compared to type I muscle fibres, however neither AA ingestion or resistance exercise 
altered the cellular localisation of LAT1.In conclusion, our data indicates that activation 
of Vps34 or cellular trafficking of LAT1 is not required for mTORC1 activation 
following AA ingestion or resistance exercise in human skeletal muscle. As such, this 
study provides new insight into the regulation of potential AA/nutrient sensors in 
human skeletal muscle following anabolic stimuli and suggests that the mechanism(s) 
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7.1 – Introduction 
Skeletal muscle is an essential organ to the human body contributing mechanically to 
posture maintenance and locomotion as well as metabolically to lipid oxidation and 
glucose disposal. Therefore maintaining skeletal muscle mass throughout life will 
positively affect both health and independence (1). Skeletal muscle mass is governed by 
the balance of two processes, muscle protein synthesis (MPS) and muscle protein 
breakdown (MPB) both of which vary greatly throughout a day in response to nutrition 
and physical activity (2, 3). Recent research has suggested that it is MPS which has the 
greatest effect on Net Protein Balance (NPB), as it seems to be the more plastic process 
(4) and changes in this variable can account for the majority of muscle loss noted during 
atrophy (5). Therefore, how this intricate process is regulated at the molecular level is an 
important area of research.  
Central to the regulation of MPS is the mechanistic target of rapamycin (mTOR), a 
serine/threonine kinase which forms two distinct complexes in skeletal muscle, mTORC1 
and mTORC2 (6). Of the two complexes, mTORC1 is the most relevant in the regulation 
of MPS as its substrates stimulate translation initiation and elongation, in addition to 
inhibiting catabolic processes (7, 8). Both mechanical loading and protein ingestion are 
known to increase mTORC1 activity in human skeletal muscle (9-14), whilst inhibition 
of mTORC1 using the specific inhibitor rapamycin (15, 16) blocks resistance exercise or 
amino acid-mediated increases in MPS (15, 16). As such it seems that mTORC1 is the 
main regulatory protein governing MPS in human skeletal muscle. Whilst the requirement 
of mTORC1 activity for the MPS response in human skeletal muscle is well established, 
how this process is co-ordinated at the cellular level is less well understood. Therefore 
the aims of this thesis were: 
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1. To investigate how resistance exercise and/or protein-carbohydrate feeding 
affects mTOR localisation and protein-protein interactions in human skeletal 
muscle. 
2. To characterise the cellular location and distribution of the leucine transporter 
LAT1 in human skeletal muscle in basal and anabolic scenarios. 
3. To investigate the regulation of a novel AA sensor, Vps34, in human skeletal 
muscle in vitro and in vivo. 
This chapter will provide a brief summary of the results presented in this thesis and how 
they relate to the current knowledge surrounding the regulation of mTORC1 in human 
skeletal muscle. Furthermore the limitations of the current research will be discussed and 
recommendations for future research provided. 
7.2 – mTORC1-lysosome translocation as a mechanism of mTORC1 activation 
The current, most widely accepted model of mTORC1 activation in response to AA 
availability revolves around the recruitment of mTOR, via Rag proteins, to the lysosomal 
membrane (17). Here mTOR is in close proximity both to its direct activators (Rheb and 
PA) as well as an abundant supply of AAs. Recently, Korolchuk et al. (18) provided 
evidence that in conditions of less extreme nutrient deprivation, which may be similar to 
that observed in postabsorptive human skeletal muscle, mTOR does not disassociate from 
lysosomal membranes yet becomes less active (27). Furthermore, upon AA stimulation, 
mTOR-lysosomal complexes were observed to translocate to the cell periphery, a process 
coinciding with elevated mTORC1 activity (18). The inhibition of this translocation was 
shown to completely ablate the effect of AA provision on mTORC1 activation, thereby 
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suggesting that the translocation of these complexes to the cell periphery is a central 
mechanism for mTORC1 activation (18).  
Previous work from our laboratory  has observed a similar phenomena in human skeletal 
muscle in response to resistance exercise and protein/carbohydrate feeding (14). 
However, as the immunohistochemical approach used in our previous work could not 
distinguish between mTOR complexes, we were unable to conclude whether the 
responses we observed were specific to mTORC1. Consequently, the study described in 
Chapter 3, aimed to answer the questions by utilising a unilateral exercise protocol, 
combined with protein-carbohydrate feeding, allowing the separation of FED vs. EXFED 
responses simultaneously in subjects and co-staining mTOR with Raptor and Rictor 
antibodies to distinguish mTORC1 and mTORC2 complexes. 
Our data supported previous work in that resistance exercise combined with protein-
carbohydrate feeding induced a translocation of mTOR-lysosomal complexes towards the 
cell membrane (identified with WGA), which was greater across the time course in this 
condition compared with feeding alone. Furthermore, mTOR-WGA colocalisation was 
elevated above baseline at 3h post exercise and protein-carbohydrate feeding, whilst 
returning to baseline levels with feeding alone. These elevations coincided with 
elevations in S6K1 kinase activity, a readout of mTORC1 activity. These findings display 
a synergistic effect of the combination of resistance exercise and protein feeding on 
mTOR translocation and may provide a mechanism as to why greater mTORC1 activation 
(S6K1 phosphorylation or kinase activity) is consistently reported in response to these 
anabolic stimuli (9, 10, 14, 19). Furthermore, the maintenance of elevated mTOR 
complexes at the cell membrane (identified via mTOR-WGA colocalisation) in the 
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EXFED condition could contribute to the purported sensitisation of skeletal muscle to 
subsequent protein feeding (20, 21).   
In addition to these findings, we next validated antibodies to probe for the mTOR complex 
specific proteins Raptor (mTORC1) and Rictor (mTORC2) using mKO tissue for each 
target protein. These antibodies were then utilised on human tissue sections to investigate 
mTOR complex-specific translocation following anabolic stimuli. Rictor-WGA 
localisation remained unchanged in both conditions across the timecourse suggesting 
mTORC2 localisation does not alter in response to anabolic stimuli. In contrast, Raptor-
WGA colocalisation increased to a similar extent to that of mTOR-WGA at 1h post-
exercise/feeding before decreasing below baseline values only in the FED condition at 
the 3h time point, where a difference between conditions was noted. These data therefore 
suggest that mTORC1, the complex which contributes most to MPS, translocates in 
response to anabolic stimuli. 
mTOR-lysosome translocation was also investigated in Chapter 5 of this thesis, in 
response to protein-carbohydrate feeding alone. Data here corroborated that reported in 
Chapter 3, where mTOR-WGA colocalisation was elevated 1h post-feeding before 
returning to basal levels at 3h post-feeding. This temporal alteration in mTOR-WGA 
localisation again occurred in parallel to elevations is S6K1 kinase activity, reiterating 
the potential link between mTOR cellular location and mTORC1 activation (14, 18). 
Overall, these data regarding mTOR-lysosome translocation display how the observations 
of Korolchuk et al. (18) transfer to human skeletal muscle and extend the knowledge of 




7.3 – Immunofluorescent Characterisation of LAT1 
The process of AA transport is known to be essential for optimal cell function as it allows 
for the influx of substrates needed to synthesise new proteins (22, 23). In skeletal muscle, 
this process is particularly critical as AAs are needed to maintain NPB and prevent the 
loss of muscle mass (24). The most potently anabolic AA is believed to be leucine, which 
has been shown to activate mTORC1 both in vitro (25) and in vivo (9, 10). As LAT1 is 
the main AA transporter responsible for transporting leucine, and other BCAAs, from the 
bloodstream into muscle, its specific role in AA transport has garnered recent focus (26-
28). The majority of previous research has focussed on investigating how anabolic stimuli 
affect mRNA and protein expression of LAT1 in whole muscle lysates (26-28). These 
investigations have produced varying results (27, 28), and this is likely in part due to the 
need for LAT1 to be in a specific cellular location (associated with a membrane) to be 
active (29). Therefore, by measuring LAT1 protein content in whole muscle lysates it is 
impossible to deduce whether any change actually affects AA transport. In Chapter 4 of 
this thesis we attempted to circumvent this issue by developing an immunofluorescent 
staining protocol whereby LAT1 could visualised in human skeletal muscle. 
To achieve this, we first successfully validated a LAT1 antibody through the use of LAT1 
mKO tissue. Staining for LAT1 in human tissue then displayed a strong reactivity close 
to the periphery in most fibres and a strong intracellular reactivity only in type II fibres. 
The peripheral location of LAT1 was in agreement with evidence from other tissues 
including human placenta (30) and several tumour types (31, 32), and is congruent with 
LAT1s role as an AA transporter. Conversely, the pronounced fibre type difference in 
intracellular LAT1 expression was surprising and contrary to our hypothesis. We 
speculated that elevated LAT1 content in type II fibres may contribute to the greater 
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cross-sectional area observed in these fibres (33). Furthermore, following exercise, AA 
influx into type II fibres is greater than that of type I fibres (34), a discrepancy that this 
fibre type difference in LAT1 content may contribute to. It is possible however, that this 
‘intracellular’ LAT1 is actually associated with organelle membranes i.e. lysosomes or 
endoplasmic reticulum which may require AA transport (35). We also hypothesised that 
a portion of this intracellular LAT1 may translocate to the cell periphery in response to 
anabolic stimuli in order to allow this greater post-exercise AA influx in type II fibres 
(34). We investigated this hypothesis further in Chapter 6, finding a feeding–driven 
reduction in type II fibre LAT1 content, however a fibre-type difference remained. This 
data suggests that intracellular LAT1 may be reduced following feeding in type II fibres, 
however total LAT1 protein content measured via immunoblot remained unchanged. We 
suggest further research is therefore required in order to fully understand the effects of 
anabolic stimuli on LAT1 protein content. Nevertheless, these data provide a valid 
method whereby LAT1 can be visualised in human skeletal muscle and can be used in 
combination with other methods in order to determine the effects of anabolic stimuli on 
LAT1 regulation (expression and subcellular location).  
7.4 – Vps34 regulation in response to anabolic stimuli 
Much mTORC1 centered research has focused on identifying upstream ‘nutrient sensors’ 
which recognise alterations in the nutrient availability within cells to initiate signalling 
cascades resulting in elevated mTORC1 activity (36). One purported nutrient sensor is 
Vps34, which was first implicated in the regulation of autophagy (37), but has since been 
observed to regulate many other cellular processes including cytokinesis and 
phagocytosis (38). The notion that Vps34 may regulate mTORC1 response to nutrients 
was first proposed by Byfield et al. (39) who reported that the siRNA-mediated silencing 
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of Vps34 completely ablated AA and insulin stimulation of mTORC1 activity in HEK293 
cells. Vps34 is a class III PI3Kinase which phosphorylates phosphatidylinositol to form 
PI(3)P, a compound which can regulate protein trafficking (38). This importance of 
Vps34 activity to mTORC1 signalling has been corroborated by other groups (40, 41), 
again finding its a role in mTORC1’s response to nutrients. In addition, it has been 
recently reported that Vps34 could regulate mTORC1-lysosome translocation through the 
production of PI(3)P (42, 43). This occurs through the recruitment of the PI(3)P binding 
protein FYCO1 to lysosomal membranes (43). Vps34 kinase activity has also been found 
to be responsive to forced contractions in rodent skeletal muscle, a response believed to 
be driven by changes in intracellular leucine (44). Due to the potential of Vps34 to be a 
nutrient sensor to mTORC1, we studied the effect of protein-carbohydrate feeding on 
Vps34 kinase activity, translocation and protein-protein interactions in Chapter 5 of this 
thesis. In addition, we utilised the Vps34-specific inhibitor SAR405 (45) in both C2C12 
and human primary myotubes to ascertain the importance of Vps34 to serum-induced 
mTORC1 signalling.  
The use of SAR405 did not significantly reduce the serum-induced activation of 
mTORC1 signalling pathways in either cell type investigated. These data suggested that 
Vps34 kinase activity may not contribute to mTORC1 activation in this cell type. 
Furthermore, we found Vps34 kinase activity to be unresponsive to protein-carbohydrate 
feeding, which could be a result of the many different Vps34-complexes apparent in 
mammalian cells, many of which have opposing functions (38). Nonetheless, we did 
observe a translocation of Vps34 toward the cell periphery where it associated with 
mTOR at a time when mTORC1 activity was high. This supports previous in vitro data 
implicating Vps34 in the translocation of mTORC1 to peripheral regions of the cells (42). 
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Therefore, from this data it seems that it may be the location of Vps34 rather than a change 
in its activity that contributes to nutrient sensing in skeletal muscle. 
We further investigated Vps34 regulation in Chapter 6 of this thesis, where the effect of 
resistance exercise and/or protein-carbohydrate feeding on Vps34 phosphorylation and 
content was studied. Here, using a surrogate measure of Vps34 activity, SGK3Thr320, we 
again found no effect of these anabolic stimuli on Vps34 kinase activity. These findings 
corroborated the only other study to investigate Vps34 kinase activity in human skeletal 
muscle when no change was found following sprint intervals and EAA consumption (46). 
Vps34 protein content was also unchanged in both conditions across the time course, 
again in agreement with previous human data (46). As mTORC1-related signalling was 
elevated in both conditions across this trial, and in response to feeding alone in Chapter 
5, this indicates that a change in overall Vps34 kinase activity or content is not required 
for the induction of mTORC1-related signalling following anabolic stimuli, questioning 
its role as a leucine sensor in skeletal muscle. However, we did observe a negative 
correlation between S6K1Thr389 and Vps34Ser249 phosphorylation indicating a possible 
negative regulation of this site by mTORC1. This post-translational modification of 
Vps34 is believed to lie downstream of ULK1, and is suggested to contribute to autophagy 
induction (47). This finding is therefore intriguing as it adds a further layer of complexity 
to the role Vps34 could exhibit in mTORC1 regulation. Specifically, it seems anabolic 
Vps34 complexes may regulate mTORC1 activation by contributing to its translocation 
toward the cell membrane, which in turn causes mTORC1 to have a inhibitory effect on 
autophagy-related Vps34 complexes. In all, this thesis provides further evidence that 
Vps34 may contribute to nutrient sensing in human skeletal muscle, most likely through 
altering the translocation of mTOR-lysosome complex to the cell periphery.  
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7.5 – Limitations 
As with any studies in the field of muscle physiology, the studies described in this thesis 
were conducted in a small number of participants (~8 per study) which could impact the 
statistical power of our analysis. Nevertheless, power calculations were conducted on the 
primary measure for each of the studies and the number of participants required were 
based on this calculation in an attempt to maintain statistical power. Nonetheless, these 
power calculations suggest enough statistical power for ANOVA testing, not post-hoc 
analysis and therefore the interpretation of such tests may be unreliable. Ethical 
obligations and time/equipment constraints would also have prevented the recruitment of 
more participants. Furthermore, a small n number (n=4) of human primary myotubes 
donors were utilised in Chapter 5 of this thesis, which may have impacted results gleaned 
in these experiments, especially as a trend toward an effect of the Vps34 inhibitor was 
noted here. Unfortunately, at the time when the experiments were conducted, our 
laboratory did not possess ethical approval to isolate primary myoblasts from subjects 
and therefore could only utilise what was made available to us by collaborators. 
Nevertheless, the statistical power of the experiments would improve greatly from the 
addition of further primary myoblast donors. The characteristics of these donors (age – 
60.8±6.4yrs, BMI – 28.7±0.65kg/m2) were also different from the participants who 
completed the in vivo aspect of this study (age – 21.1±0.5yrs), and therefore it is possible 
that results may have differed if similar populations were investigated. Again, as our 
laboratory did not hold ethical approval at the time of testing for human primary myoblast 
isolations this was not possible. Therefore, future research should aim to elucidate the 
effect of SAR405 on mTORC1 signalling in human primary myotubes isolated from 
young, lean donors. 
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Another limitation of this thesis is the absence of direct MPS measurements, meaning we 
can only infer the induction of MPS based on the activation of mTORC1. With the current 
data it is impossible to elucidate how our measures relate to MPS, however we do expect 
to complete this analysis in the near future. We did utilise stable isotope methods in the 
study described in Chapter 6 of this thesis however, time constraints and equipment 
malfunctions resulted in the inability for this to be completed. Chapter 6 of this thesis 
included a surrogate measure of Vps34 activity, SGK3Thr320, which is utilised in vitro as 
a read out of Vps34 kinase activity (48). A direct comparison with Vps34 kinase activity 
has not yet been completed in human skeletal muscle and as such there is a risk that this 
measure may not be valid. Kinase activity assays targeting Vps34 are expected to be 
completed for this study in the near future, however, again time constraints due to the 
need for this analysis to be completed at a different institution did not allow completion 
of this analysis in the thesis timeframe.  
Finally, it is important to acknowledge that the use of widefield epifluorescence 
microscopy is not the optimal method for investigating protein-protein interactions. 
Although this technique is widely used to measure colocalisation/protein-protein 
interactions, both confocal and immune-electron microscopy techniques produce greater 
spatial resolution, therefore allowing more accurate analysis of colocalisation. 
Unfortunately, equipment, costing and time restraints meant this analysis could not be 
completed. In addition, the marker of the cell membrane utilised in this thesis, WGA, can 
also bind to sarcoglycans which may be present in intracellular regions of muscle fibres, 
which could have resulted in unreliable colocalisation values. Each image analysed was 
observed to be free of any intracellular WGA staining before analysis in order to combat 
this. Furthermore, as we are only inferring movement toward the cell membrane rather 
227 
 
than an actual association, we believe the use of this marker is valid. Future analysis could 
utilise a ‘cleaner’ marker of the cell membrane i.e. dystrophin to understand if results may 
differ. 
7.6 – Future Research 
We hypothesise that the process of mTOR-lysosomal translocation toward the cell 
periphery, in human skeletal muscle, following anabolic stimuli is an important event in 
the activation of mTORC1 following such stimuli. As such, it is important to investigate 
this mechanism in populations who exhibit an inability to fully activate mTORC1 in 
response to anabolic stimuli i.e. elderly (49) and obese (50) individuals. Future research 
should therefore focus on these populations and determine whether mTOR-lysosome 
translocation is impaired. This could provide a novel therapeutic target for future 
interventions aiming to minimize muscle loss and maximize muscle mass gains in these 
populations. In addition to investigating this mechanism in diverse populations it is also 
vital to further elucidate why mTOR-lysosome translocation occurs. Evidence does 
suggest that direct mTOR activators, translation initiation factors and blood vessels are 
located in the regions to which mTORC1-lysosome complexes translocate (14). 
Furthermore, MPS itself is believed to occur in these regions, however further 
investigations are warranted in order to identify where other regulators of mTORC1 
signalling are located and whether mTOR associates with them following anabolic 
stimuli.  
Due to the large amounts of intracellular LAT1 staining apparent in type II fibres, it was 
impossible to determine whether resistance exercise and/or protein-carbohydrate feeding 
elicited a translocation of this transporter to the cell membrane. It is therefore important 
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that a combination of methods are utilised to understand the effects of anabolic stimuli 
on LAT1. This could be achieved through the use of membrane/large sarcolemmal vesicle 
fractions, a method recently utilised to find an increase in membrane-associated LAT1 
following low-load resistance exercise and pulse protein feeding (51). Recent studies 
have also utilised immunoblotting techniques on individual fibres to study fibre-type 
differences in target protein content (52). This method could be utilised to further confirm 
fibre type differences in LAT1 content and how anabolic stimuli may affect this. Further 
investigations in young, healthy individuals following a variety of anabolic stimuli should 
be completed using this method to elucidate if LAT1 does translocate in these scenarios. 
Fractionations of other organelle membranes should also be completed in an attempt to 
clarify the reasons behind the large amount of intracellular LAT1 in type II fibres. For 
example, recent in vitro evidence suggests LAT1 can associate with lysosomal 
membranes and these observations should be attempted in human skeletal muscle. 
Finally, utilising this immunofluorescent staining method, LAT1 expression in diverse 
population i.e. elderly and diseased should be investigated to better understand the 
potential mechanisms behind type II fibre atrophy in these populations. 
Finally, investigations regarding the contribution of Vps34 to ‘nutrient sensing’ in human 
skeletal muscle is still in its infancy; to our knowledge, only 3 studies having investigated 
this purported sensor. Therefore, future research must continue to investigate the 
mechanisms by which Vps34 may contribute to nutrient sensing. One potential avenue 
for such research would be whether anabolic stimuli affects the recruitment of the PI(3)P 
binding protein FYCO1 to lysosomal membranes, as this is purported to stimulate mTOR-
lysosome translocation to the periphery (43). Furthermore as in Chapter 6  of this thesis 
a surrogate measure of Vps34 kinase activity was utilised, a comparison between this and 
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direct Vps34 kinase activity measurements should be conducted to ensure this measure is 
valid in vivo. 
7.7 – Reflections  
Completing my Ph.D. studies at the University of Birmingham has been an invaluable 
learning experience which has greatly benefitted myself in my progression into a 
successful researcher. The knowledge and skilled I have gained, and the contacts I have 
made, will no doubt prove vital in my ongoing career in research. I have learnt that 
research can be frustrating at times, yet these occasions are outweighed by those times 
where research proves to be extremely gratifying. Nevertheless, there are some aspects 
of the Ph.D. process which I would have done differently if beginning this process again. 
Firstly, I would have liked to have a greater involvement in human testing and sample 
collection for the studies presented in this thesis. As human testing and sample collection 
for the studies presented in chapters 3-5 were conducted at other institutions or prior to 
my arrival this was not possible. The opportunity to be more involved with this aspect of 
research would certainly have improved my research profile and is something I plan to 
have more involvement with as I proceed in my research career.  
Secondly, several parts of my analysis were conducted by ‘experts’ in that technique at 
other institutions. Although this resulted in the analysis being conducted efficiently and 
reliably it meant that I wasn’t able to be exposed to these techniques. If beginning this 
process again I would attempt to visit these laboratories in order to learn these techniques 
so I could take them forward in my research career. Finally, a major limitation of this 
thesis is that some analysis planned for the final experimental chapter (Chapter 6) was 
not completed in time for the submission of this thesis. I believe that if testing for this 
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study had been completed at an earlier date, this analysis may have been undertaken in 
time. To achieve this, a greater collaborative effort could have been undertaken, however 
this was not possible particularly as several members of my primary supervisor’s 
laboratory left the university during this time. Nonetheless, if starting this process again, 
this is an aspect which could have been improved upon. 
7.8 – Conclusions 
In this thesis we provided evidence that mTOR translocation following resistance 
exercise and/or protein-carbohydrate feeding is specific to mTORC1. Furthermore, this 
translocation is greater when exercise and feeding are combined compared to feeding 
alone and is associated with an increase in S6K1 activity. In addition, we show that 
following protein-carbohydrate feeding Vps34 also translocates toward the cell periphery 
and associates with mTOR, and again this is associated with elevated S6K1 activity. 
Contrary to in vitro and rodent data we find no effect of anabolic stimuli on Vps34 kinase 
activity, or protein content. Moreover, the Vps34-specific inhibitor SAR405 had no effect 
on serum-stimulated mTORC1 activation, suggesting Vps34’s role in nutrient sensing 
may involve an alteration in its cellular location rather than kinase activity. Intriguingly, 
we identify a phosphorylation site on Vps34 which may be negatively regulated by 
mTORC1 and warrants further investigation, adding further complexity to the intricate 
mechanism of nutrient sensing. We also provide a protocol by which LAT1 can be 
visualised in skeletal muscle, and observe a greater expression of this transporter in type 
II fibres, compared to type I, which is maintained throughout the post-exercise/prandial 
period. Overall these data extend the knowledge base regarding the regulation of 
mTORC1 in human skeletal muscle, in response to anabolic stimuli, and identify new 
potential mechanisms by which mTORC1 may be regulated under these conditions. 
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